

e424b3

<http://www.oblible.com>

424B3 1 g26997b3e424b3.htm 424B3

<http://www.sec.gov/Archives/edgar/data/1044942/000095012311055783/g26997b3e424b3.htm>

PROSPECTUS

**Offer to Exchange Registered 6.625% Senior Notes due 2020
For All of Outstanding
Unregistered 6.625% Senior Notes due 2020**

We are offering to exchange up to \$400,000,000 of our new 6.625% Senior Notes due 2020, which are jointly and severally guaranteed on a basis by certain of our current and future domestic subsidiaries (the “exchange notes”), which will be registered under the Securities Act, for any and all of our outstanding 6.625% Senior Notes due 2020, which are jointly and severally guaranteed by certain of our current and future domestic subsidiaries (the “outstanding notes”). We are offering to exchange the exchange notes to satisfy our obligations contained in the registration rights agreement that we entered into when the outstanding notes were sold in Regulation S under the Securities Act. We sometimes refer to the exchange notes and the outstanding notes collectively as the “

The Exchange Offer

- We will exchange all outstanding notes that are validly tendered and not validly withdrawn for an equal principal amount of exchange notes, except in limited circumstances described below.
- You may withdraw tenders of outstanding notes at any time prior to the expiration date of the exchange offer.
- The exchange offer expires at 11:59 p.m., New York City time, on June 28, 2011, unless extended. We do not currently intend to extend the offer.
- The exchange of the outstanding notes for exchange notes in the exchange offer will not be a taxable event for U.S. federal income tax purposes.
- We will not receive any cash proceeds from the exchange offer.

The Exchange Notes

- We are offering exchange notes to satisfy certain obligations under the registration rights agreement entered into in connection with the outstanding notes.
- The terms of the exchange notes to be issued in the exchange offer are identical in all material respects to the outstanding notes, except that the exchange notes will be freely tradable, except in limited circumstances described below.
- We do not plan to list the exchange notes on a national securities exchange or automated quotation system.

All untendered outstanding notes will continue to be subject to the restrictions on transfer set forth in the outstanding notes and in the registration rights agreement. Outstanding notes may not be offered or sold, unless

e424b3

e424b3

[Table of Contents](#)

registered under the Securities Act, except pursuant to an exemption from, or in a transaction not subject to, the Securities Act and applicable state securities laws. Other than in connection with the exchange offer, we currently do not anticipate that we will register the outstanding notes under the Securities Act.

See “Risk Factors” beginning on page 13 for a discussion of certain risks that you should consider before participating in the exchange offer.

Each broker-dealer that receives exchange notes for its own account pursuant to the exchange offer must acknowledge that it will deliver a prospectus to any person purchasing exchange notes from it, and that it will not effect any resale of such exchange notes as required by applicable securities laws and regulations. The letter of transmittal states that by so acknowledging, a broker-dealer will not be deemed to admit that it is an “underwriter” within the meaning of the Securities Act.

This prospectus, as it may be amended or supplemented from time to time, may be used by a broker-dealer in connection with resale of exchange notes on the exchange for outstanding notes where such outstanding notes were acquired by such broker-dealer as a result of market-making activities. In addition, all dealers effecting transactions in the exchange notes may be required to deliver a prospectus. We have agreed that, for a period of 90 days after the date of this prospectus, we will make this prospectus available to any broker-dealer for use in connection with such resale. See “Plan of Distribution” for more information.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these exchange notes, nor the accuracy of this prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus is June 1, 2011.

e424b3

TABLE OF CONTENTS

Market and Industry Data

Trademarks, Trade Names and Service Marks

Forward-Looking Statements

Summary

Use of Proceeds

Ratio of Earnings to Fixed Charges

Capitalization

Description of Other Indebtedness

The Exchange Offer

Description of the Exchange Notes

Certain U.S. Federal Income Tax Considerations

Plan of Distribution

Legal Matters

Experts

Where You Can Find More Information; Incorporation By Reference

You should rely only on the information contained or incorporated by reference in this prospectus or in any additional written communication authorized by us. We have not authorized anyone to provide you with any information or represent anything about us, our financial condition, our business, our performance, our prospects, our strategy, our plans, our operations, our management, our financial results, or any other information that is not contained in or incorporated by reference into this prospectus or in any additional written communication prepared or to be prepared by us. Any such other information or representation should not be relied upon as having been authorized by us. We are not making an offer of securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information in this prospectus and any written communication prepared by or on behalf of us is accurate only as of the date on its cover page and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference.

e424b3

[Table of Contents](#)

MARKET AND INDUSTRY DATA

This prospectus and the documents incorporated by reference herein include market share and industry data and forecasts that we obtained from third-party surveys and internal company surveys. Although we believe that the third-party sources are reliable, we have not independently verified the data provided by third parties or by industry or general publications, and we do not take any further responsibility for this data. Similarly, while the data with respect to our industry are reliable, our estimates have not been verified by any independent sources, and we cannot assure you that our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the sections entitled “Risk Factors” below.

TRADEMARKS, TRADE NAMES AND SERVICE MARKS

We own or have rights to use the trademarks, trade names and service marks that we use in conjunction with the operation of our business, including Making Communities Healthier®, LifePoint Hospitals® and LifePoint®. We do not own any trademark, trade names or service mark of any other entity.

FORWARD-LOOKING STATEMENTS

We make forward-looking statements in this prospectus and in reports and proxy statements we file with the SEC. In addition, our management may make forward-looking statements orally to analysts, investors, the media and others. Broadly speaking, forward-looking statements include:

- projections of our revenues, net income, earnings per share, capital expenditures, cash flows, debt repayments, interest rates, and other financial items;
- descriptions of plans or objectives of our management for future operations, services or growth plans including acquisitions, divestitures, and other initiatives;
- interpretations of Medicare and Medicaid laws and regulations and their effect on our business; and
- descriptions of assumptions underlying or relating to any of the foregoing.

In this prospectus and the documents incorporated by reference herein, for example, we make forward-looking statements, including statements about our expectations about:

- this offering, including the use of proceeds, stabilizing transactions and the issuance and delivery of the notes;
- future financial performance and condition;
- future liquidity and capital resources;
- future cash flows;
- existing and future debt and equity structure;
- our strategic goals;
- future acquisitions;
- our business strategy and operating philosophy, including an evaluation of growth strategies for existing markets and for potential markets.

e424b3

- costs of providing care to our patients;
-

e424b3

Table of Contents

- changes in interest rates;
- our compliance with new and existing laws and regulations;
- the impact of national healthcare reform;
- the performance of counterparties to our agreements;
- effect of credit ratings;
- professional fees;
- increased costs of salaries and benefits;
- industry and general economic trends;
- reimbursement changes;
- patient volumes and related revenues;
- future capital expenditures, including capital expenditures related to information systems;
- the impact of changes in our critical accounting estimates;
- claims and legal actions relating to professional liabilities, governmental investigations and other matters; and
- physician recruiting and retention, including trends in physician employment.

Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking words such as “can,” “could,” “may,” “should,” “believe,” “will,” “would,” “expect,” “project,” “estimate,” “seek,” “anticipate,” “intend” and similar expressions. You should not unduly rely on forward-looking statements, which give our expectations about the future and are not guaranteed to occur. We speak only as of the date they are made. We operate in a continually changing business environment, and new risk factors emerge from time to time. Such new risk factors nor can we assess the impact, if any, of such new risk factors on our business or to the extent to which any factor discussed herein may cause actual results to differ materially from those expressed or implied by any forward-looking statement. We do not undertake any obligation to update our forward-looking statements to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events.

There are several factors, including some beyond our control, that could cause results to differ significantly from our expectations. See more detail in the section captioned “Risk Factors.” Other factors, such as market, operational, liquidity, interest rate, regulatory and other factors, may also affect our results. You should read this prospectus and the documents incorporated by reference in this prospectus. Any factor described in this prospectus or the documents incorporated by reference herein, or any combination of them, or any other factor, or factors not known to us, or together with one or more factors, adversely affect our business, results of operations and/or financial condition. There may be other factors that could cause results to differ from our expectations.

[Table of Contents](#)**SUMMARY**

This summary highlights selected information contained elsewhere or incorporated by reference in this prospectus and does not constitute an offer of securities. You should read carefully this entire prospectus and the documents incorporated by reference in this prospectus, including the "Risk Factors," beginning on page 13 of this prospectus for more information about important risks that you should consider before making an investment decision. Unless the context otherwise requires, LifePoint Hospitals, Inc. and its subsidiaries are referred to herein as "LifePoint," the "Company," "we," "us," or "our."

Our Company

We operate general acute care hospitals in non-urban communities in the United States. At March 31, 2011, we operated 52 hospitals with a total of 5,798 licensed beds. We generate revenue primarily through hospital services offered at our facilities. We generated \$3,263.1 million in continuing operations for the year ended December 31, 2010 and \$888.6 million for the three months ended March 31, 2011.

Our hospitals typically provide the range of medical and surgical services commonly available in hospitals in non-urban markets, including surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, rehabilitation services, and some of our hospitals, specialized services such as open-heart surgery, skilled nursing, psychiatric care and neuro-surgery. In many markets, we provide outpatient services such as same-day surgery, laboratory, x-ray, respiratory therapy, imaging, sports medicine and lithotripsy. Like non-urban markets, our hospitals do not engage in extensive medical research and medical education programs. However, three of our hospitals are affiliated with medical schools, including the clinical rotation of medical students, and one of our hospitals owns and operates a school of health professions and a radiologic technology program.

We derived 42.8% of our revenues from continuing operations from the Medicare and Medicaid programs, collectively for the year ended December 31, 2010 and 42.9% for the three months ended March 31, 2011. Payments made to our hospitals pursuant to the Medicare and Medicaid programs generally exceed our costs for such services. The hospital industry is also enduring a period where the costs of providing care are rising faster than the reimbursement rates. As a result, we rely largely on payments made by private or commercial payors, together with certain limited services provided to Medicare and Medicaid patients, to operate at an operating profit.

Industry Overview

We believe that non-urban communities present opportunities for us because of the following factors:

- **Less Competition than Urban Markets.** Because non-urban communities have smaller populations, they generally have fewer service providers. Because non-urban hospitals are generally the sole providers of inpatient services in their markets, there is less competition. However, we are experiencing an increase in competition from other specialized care providers, including outpatient surgery, oncology, diagnostic centers, as well as competing services rendered in physician offices.
- **Community Focus.** We believe that the local hospital generally is viewed as an integral part of the community. In addition, non-urban communities can have a higher level of patient and physician loyalty that fosters cooperative relationships among the local community, employees, patients and local government authorities.
- **Acquisition Opportunities.** Currently, not-for-profit and governmental entities own most non-urban hospitals. These entities

e424b3

<http://www.oblible.com>

capital needed to keep pace with advances in medical technology. In addition, these entities sometimes lack the resources in the manner necessary to control hospital expenses, recruit and retain physicians, expand healthcare services and comply with reimbursement and managed care requirements. As a result, patients may migrate, be referred by local physicians, or be encouraged to travel to hospitals in larger, urban markets. We believe that, as a result of these pressures, many not-for-profit and government hospitals who wish to maximize the value of their

e424b3

[Table of Contents](#)

community assets and preserve the local availability of quality healthcare services are interested in selling or leasing these that is committed to the local delivery of healthcare and that has greater access to capital and management resources. Of the 28 hospitals that were previously operated by either not-for-profit or governmental entities as of March 31, 2011, 28 were previously operated by either not-for-profit or governmental entities.

Operating Philosophy

Since inception, our primary mission has been to acquire, develop and operate strong community-based hospitals in non-urban markets. We have adopted an operating philosophy that is focused on the unique patient and provider needs and opportunities in these communities. We seek to make Communities Healthier® by striving to:

- improve the quality and types of healthcare services available in our communities;
- provide physicians with a positive environment in which to practice medicine, with access to necessary equipment and resources;
- develop and provide a positive work environment for employees;
- expand each hospital's role as a community asset; and
- improve each hospital's financial performance.

We expect our hospitals to be the place where patients choose to come for care, where physicians want to practice medicine and where employees want to work.

Business Strategy

We manage our hospitals in accordance with our operating philosophy and have developed the following strategies as part of our overall business strategy for our existing markets and for new markets.

- *Provide a Positive Environment.* We seek to fulfill our mission of Making Communities Healthier® by striving to improve the quality and types of healthcare services available in our communities, provide physicians with a positive environment in which to practice medicine, with access to necessary equipment and resources, develop and provide a positive work environment for employees, expand each hospital's role as a community asset, and improve each hospital's financial performance.
- *Focus on Improving Quality.* The quality of healthcare services provided at our hospitals (and the perceived quality of such services) is an important factor to patients when deciding where to seek care and to physicians when deciding where to practice. Because the quality of care for Medicare and Medicaid Services ("CMS") core measure scores ascribed to our hospitals are impacted by the practice of our medical staffs, we have implemented new strategies to work with medical staff members to improve scores at all of our hospitals that are below our average or below management's expectations. Recently, we have seen improvements in our CMS core measure scores, an important measure of patients' perspectives of hospital care. We will continue to improve our scores at our hospitals through targeted strategies, including increased education, when necessary, awareness campaigns, and action plans.
- *Expand the Breadth of Our Services.* We believe that growth can also be achieved by adding new service lines in our existing facilities, adopting new technologies desired by physicians and patients, and demonstrating the quality of care provided in our facilities. For the past several years, we have been successful in expanding our service lines and demonstrating the quality of care provided in our facilities.

e424b3

redesigned operating reviews of our hospitals to pinpoint new service lines or technologies that could reduce the outmigration of patients to other markets to receive healthcare services. Where needed service lines have been identified, we have focused on recruiting the physicians to operate such service lines. For example, our hospitals have responded to physician interest in requests for hospitalists by initiating hospitalist programs where appropriate. Our hospitals have

e424b3

[Table of Contents](#)

taken other steps, such as structured efforts to solicit input from medical staff members and to promptly respond to legitimate unmet needs, to offset the impact of outmigration and to grow.

- *Invest in New Technology and Facilities.* While responsibly managing our operating expenses, we have also made significant, targeted investments in our hospitals to add new technologies, modernize facilities and expand the services available. These investments should assist in our recruitment of physicians, to offset outmigration of patients and to make our hospitals more desirable to our employees and potential patients.
- *Increase Efficiency.* We also continue to strive to improve our operating performance by improving our revenue cycle processes, reducing operating expenses through purchases through our group purchasing organization, operating more efficiently and effectively, and working to appropriately streamline procedures and practices across all of our affiliated hospitals. We also believe that our position as the sole acute care hospital in the region has allowed us, and will continue to allow us, in many cases to negotiate preferred reimbursement rates with commercial insurance companies.

Additional Information

We are a Delaware corporation. Our principal executive offices are located at 103 Powell Court Brentwood, Tennessee 37027 and our telephone address is (615) 372-8500. Our corporate website address is www.lifepointhospitals.com. Information contained on our website or that is accessible through our website is not incorporated by reference in this prospectus and does not constitute a part of this prospectus and you should not rely on it.

e424b3

[Table of Contents](#)

The Exchange Offer

The summary below describes the principal terms of the exchange offer. See also the section of this prospectus titled “The Exchange Offer” for a detailed description of the terms and conditions of the exchange offer.

General

In connection with the private placement, we entered into a registration rights agreement in which we agreed, among other things, to deliver this prospectus to you and the registration statement on Form S-4 of which this prospectus is a part with the original issuance of the outstanding notes. You are entitled to exchange in the future outstanding notes for exchange notes, which are identical in all material respects to the original notes, except:

- the exchange notes will have been registered under the Securities Act;
- the exchange notes are not entitled to any registration rights that are applicable under the registration rights agreement; and
- the provisions of the registration rights agreement that provide for payment in the event of a registration default are no longer applicable.

The Exchange Offer

We are offering to exchange up to \$400,000,000 aggregate principal amount of our 2020 and the related guarantees, which have been registered under the Securities Act, for outstanding 6.625% Senior Notes due 2020 and the related guarantees.

Outstanding notes may be exchanged only in denominations of \$2,000 and in multiples in excess thereof; provided that the untendered portion of any outstanding note has a remaining denomination of \$2,000.

Subject to the satisfaction or waiver of specified conditions, we will exchange outstanding notes that are validly tendered and not validly withdrawn prior to the expiration of the offer. We will cause the exchange to be effected promptly after the expiration of the offer.

Resale

Based on interpretations by the staff of the SEC set forth in no-action letters, we believe that the exchange notes issued pursuant to the exchange offer in exchange for the original notes may be offered for resale, resold and otherwise transferred by you (unless you are an affiliate of the issuer, in which case the meaning of Rule 405 under the Securities Act) without compliance with the resale or delivery provisions of the Securities Act, provided that:

- you are acquiring the exchange notes in the ordinary course of your business;

e424b3

e424b3

[Table of Contents](#)

	• you have not engaged in, do not intend to engage in, and have no arrangement with any person to participate in, a distribution of the exchange notes. If you are a broker-dealer and receive exchange notes for your own account or for the account of a client, you must acknowledge that you have not entered into any arrangement or understanding with any affiliate of the Company to distribute such exchange notes and that you will not do so in connection with any resale of the exchange notes. See “Plan of Distribution” for more information. Any broker-dealer that distributes outstanding securities acquired for its own account as a result of market-making activities and who receives exchange notes in exchange for such outstanding securities, may be considered an underwriter; however, by so acknowledging an underwriting role, a broker-dealer will not be deemed to admit that it is an “underwriter” within the meaning of the Securities Act.
Expiration Date	The exchange offer expires at 11:59 p.m., New York City time, on June 28, 2011. We do not currently intend to extend the expiration date.
Withdrawal	You may withdraw any tender of your outstanding notes at any time prior to the expiration date of the offer. We will return to you any of your outstanding notes that are not accepted for exchange without expense to you, promptly after the expiration or termination of the offer.
Interest on the Exchange Notes and the Outstanding Notes	No interest will be paid on either the exchange notes or the outstanding notes. The exchange notes will accrue interest from and including the last interest payment date that has been paid on the outstanding notes. Accordingly, the holders of outstanding notes that are accepted for exchange will not receive unpaid interest on such outstanding notes at the time of tender. Rather, that interest will be paid on exchange notes delivered in exchange for the outstanding notes on the first day after the expiration date of the exchange offer, which will be October 1, 2011.
Conditions to the Exchange Offer	The exchange offer is subject to customary conditions, which we may assert at any time. See “Offer—Conditions to the Exchange Offer.”
Procedures for Tendering Outstanding Notes	If you wish to participate in the exchange offer, you must complete, sign and deliver to the exchange agent, a transmittal, or a facsimile of the letter of transmittal, according to the instructions set forth in the letter of transmittal. You must then mail or otherwise deliver the letter of transmittal, together with the outstanding notes and any other required documents, to the exchange agent at the address set forth on the cover page of the letter of transmittal.

e424b3

If you hold outstanding notes through The Depository Trust Company (“DT”) exchange offer, you must comply with the procedures under DTC’s Autom which you will agree to be bound by the letter of transmittal.

By signing, or agreeing to be bound by, the letter of transmittal, you will rep things:

e424b3

[Table of Contents](#)

- you do not have an arrangement or understanding with any person or entity of the exchange notes;
- you are not our “affiliate” within the meaning of Rule 405 under the Securities Act;
- you are not engaged in, and do not intend to engage in, a distribution of the exchange notes;
- you are acquiring the exchange notes in the ordinary course of your business;
- if you are a broker-dealer that receives exchange notes for your own account, you are not acquiring exchange notes that were acquired as a result of market-making activities, that you do not have an arrangement or understanding with the Company or an affiliate of the Company to acquire exchange notes and you will deliver a prospectus, as required by law, in connection with the acquisition of such exchange notes.

Any broker-dealer who holds outstanding securities acquired for its own account for market-making activities or other trading activities and who receives exchange notes in connection with the exchange offer, may be considered an underwriter of the exchange notes. If, in connection with acknowledging and delivering a prospectus, such broker-dealer will not be considered an “underwriter” within the meaning of the Securities Act.

Special Procedures for Beneficial Owners

If you are a beneficial owner of outstanding notes that are registered in the name of a commercial bank, trust company or other nominee, and you wish to tender those outstanding notes pursuant to the exchange offer, you should contact the registered holder promptly and instruct it to tender those outstanding notes on your behalf. If you wish to tender on your own behalf, you should complete and execute the letter of transmittal and delivering your outstanding notes to the registered holder. If you wish to complete and execute the letter of transmittal and delivering your outstanding notes to the registered holder, you should complete and execute the letter of transmittal and delivering your outstanding notes to the registered holder. The transfer of registered ownership of the outstanding notes may require a considerable time and may not be able to be completed prior to the expiration of the exchange offer.

Guaranteed Delivery Procedures

If you wish to tender your outstanding notes and your outstanding notes are not delivered to the registered holder, the letter of transmittal or any other instrument required to complete the tender of your outstanding notes, you must comply with the procedures under DTC’s Automated Tender Offer Program. If you wish to tender your outstanding notes, prior to the expiration date, you must tender your outstanding notes to the registered holder in accordance with the delivery procedures described under “The Exchange Offer—Guaranteed Delivery Procedures.”

Effect on Holders of Outstanding Notes

As a result of the making of, and upon acceptance for exchange of all validly tendered outstanding notes pursuant to the terms of, the exchange offer, we will have fulfilled a covenant under the indenture. Accordingly, there will be no increase in the interest rate on the outstanding notes.

e424b3

circumstances described in the registration rights agreement. If you do not tender your shares in the exchange offer, you will continue to be entitled to all the rights and limitations of the outstanding notes as set forth in the indenture under which the outstanding notes were issued. We do not have any further obligation to you to provide for the exchange and registration of your shares and related guarantees under the registration rights agreement. To the extent your shares are tendered and accepted in the exchange offer, the trading market for outstanding shares will not be affected.

e424b3

[Table of Contents](#)

Consequences of Failure to Exchange	All untendered outstanding notes will continue to be subject to the restrictions on the exchange of outstanding notes and in the indenture under which the outstanding notes were issued. Outstanding notes may not be offered or sold, unless registered under the Securities Act or an exemption from, or in a transaction not subject to, the Securities Act and the Securities Act. Other than in connection with the exchange offer, we do not anticipate that we will exchange notes under the Securities Act.
U.S. Federal Income Tax Consequences of the Exchange Offer	The exchange of outstanding notes for exchange notes in the exchange offer may have United States federal income tax purposes. See “Certain Material U.S. Federal Income Tax Consequences of The Exchange Offer.”
Use of Proceeds	We will not receive any cash proceeds from the issuance of exchange notes in the exchange offer of Proceeds.”
Exchange Agent	The Bank of New York Mellon Trust Company, N.A. is the exchange agent for the exchange offer. The addresses and telephone numbers of the exchange agent are set forth under “Exchange Agent.”

e424b3

[Table of Contents](#)

The Exchange Notes

The summary below describes the principal terms of the notes. Some of the terms and conditions described below are subject to exceptions. You should carefully read the “Description of Notes” section of this prospectus for a more detailed description of the notes.

Issuer	LifePoint Hospitals, Inc.
Securities Offered	\$400,000,000 aggregate principal amount of senior notes due 2020.
Maturity Date	October 1, 2020.
Interest	Interest on the notes will accrue at the rate of 6.625% per annum, payable semi-annually.
Interest Payment Dates	We will pay interest on the notes semi-annually on April 1 and October 1 of each year, beginning on April 1, 2011.
Ranking	The notes will be our senior unsecured obligations. Accordingly, they will rank: • equal in right of payment to our existing and future senior indebtedness; • senior in right of payment to our existing and future subordinated indebtedness; • effectively subordinated in right of payment to our secured debt to the extent of the assets securing such debt; and • structurally subordinated in right of payment to all existing and future indebtedness of any of our existing or future non-guarantor subsidiaries.
Guarantees	The notes will be jointly and severally guaranteed on an unsecured senior basis by our existing and future domestic subsidiaries. Each subsidiary guarantee will rank: • equal in right of payment to the guarantor’s existing and future senior indebtedness; • senior in right of payment to the guarantors’ existing and future subordinated indebtedness; • effectively subordinated in right of payment to the secured debt of the guarantor to the extent of the assets securing such debt. Our non-guarantor subsidiaries accounted for \$80.3 million, or 9.0%, of our total assets as of December 31, 2010.

e424b3

Optional Redemption

months ended March 31, 2011 and \$358.8 million, or 8.4%, of our assets (excluding receivables) and \$45.0 million, or 2.0%, of our liabilities (excluding intercompany payables) as of March 31, 2011.

We may redeem the notes, in whole or in part, at any time prior to October 1, 2011, at a redemption price of 100% of the principal amount of the notes redeemed plus an applicable “make-whole” premium (as defined in the “Description of Notes—Optional Redemption”), plus accrued and

e424b3

[Table of Contents](#)

unpaid interest, if any, to the date of redemption. We may redeem the notes, on or after October 1, 2015, at the redemption prices listed under “Description of Notes—Optional Redemption” plus accrued and unpaid interest, if any, to the date of redemption.

At any time before October 1, 2013, we may redeem up to 35% of the aggregate principal amount of the notes issued under the indenture with the net cash proceeds of one or more offerings of equity securities at a redemption price equal to 106.625% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest; provided that:

- at least 65% of the aggregate principal amount of the notes remains outstanding after the redemption; and
- such redemption occurs within 180 days of the date of the closing of any such offering.

See “Description of Notes—Optional Redemption.”

Change of Control

If we experience a change of control under certain circumstances, we must repurchase the notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest to the date. See “Description of Notes—Repurchase at the Option of Holders—Change of Control.”

Covenants

The indenture will contain covenants that, among other things, will limit our and our subsidiaries to:

- incur additional indebtedness;
- pay dividends or repurchase or redeem capital stock;
- make certain investments;
- create liens;
- enter into certain types of transactions with our affiliates; and
- sell assets or consolidate or merge with or into other companies.

These and other covenants that will be contained in the indenture are subject to certain exceptions and qualifications, which are described under “Description of Notes.”

If, on any date following the issuance date, certain conditions are met, including

e424b3

Risk Factors

notes maintain an investment grade rating, the application to the notes of ce will be suspended during such period that the notes maintain an investment above are also subject to a number of other important limitations and except Notes—Certain Covenants.”

See “Risk Factors” beginning on page 13 of this prospectus for important in investment in the notes.

No Prior Market

The exchange notes will be freely transferable but will be new securities for which there will not initially be a market. Accordingly,

e424b3

[Table of Contents](#)

we cannot assure you whether a market for the exchange notes will develop
market that may develop. The initial purchasers in the private offering of the
informed us that they currently intend to make a market in the exchange notes
obligated to do so, and they may discontinue any such market-making activities

e424b3

[Table of Contents](#)

Summary Consolidated Historical Financial Data

The following summary consolidated historical financial data is derived from our audited consolidated financial statements for the years ended December 31, 2010, 2009, 2008, 2007 and 2006 and from our unaudited consolidated financial statements for the three months ended March 31, 2011. Our unaudited consolidated financial statements have been prepared on the same basis as our audited consolidated financial statements and include adjustments, consisting of normal recurring adjustments, that we consider necessary for a fair presentation of our results of operations. Our results for any historical period are not necessarily indicative of the results that may be expected for any future period.

This information is only a summary and should be read in conjunction with the more detailed information contained in our Consolidated Financial Statements and related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2010 and our Quarterly Report on Form 10-Q for the period ended March 31, 2011, which are incorporated by reference into this prospectus.

(Dollars in millions)	Year Ended December 31,				
	2010	2009	2008	2007	2006
Revenues	\$ 3,262.4	\$ 2,962.7	\$ 2,700.8	\$ 2,568.4	\$ 2,336.5
Salaries and benefits	1,270.3	1,170.9	1,065.4	1,006.1	918.0
Supplies	443.0	409.1	372.6	352.2	326.1
Other operating expenses	605.2	538.0	499.8	464.0	397.4
Provision for doubtful accounts	443.8	375.4	313.2	307.0	250.0
Depreciation and amortization	148.5	143.0	132.1	129.4	105.4
Interest expense, net	108.1	103.2	107.7	107.4	105.5
Debt extinguishment costs	2.4	—	—	—	—
Impairment charges	—	1.1	1.2	—	—
	<u>3,021.3</u>	<u>2,740.7</u>	<u>2,492.0</u>	<u>2,366.1</u>	<u>2,102.4</u>
Income from continuing operations before income taxes	241.1	222.0	208.8	202.3	234.1
Provision for income taxes	<u>82.4</u>	<u>80.3</u>	<u>79.9</u>	<u>80.5</u>	<u>91.2</u>
Income from continuing operations	158.7	141.7	128.9	121.8	142.9
Less: Net income attributable to noncontrolling interests	<u>(3.1)</u>	<u>(2.5)</u>	<u>(2.2)</u>	<u>(1.7)</u>	<u>(1.4)</u>
Income from continuing operations attributable to LifePoint Hospitals, Inc.	<u>\$ 155.6</u>	<u>\$ 139.2</u>	<u>\$ 126.7</u>	<u>\$ 120.1</u>	<u>\$ 141.5</u>
	Year Ended December 31,				

e424b3

(Dollars in millions)	2010	2009	2008	2007	2006
Balance Sheet Data (as of end of period):					
Cash & cash equivalents	\$ 207.4	\$ 187.2	\$ 75.7	\$ 53.1	\$ 12.2
Working capital	\$ 498.8	\$ 485.9	\$ 376.2	\$ 373.6	\$ 377.7
Property & equipment, net	\$ 1,668.6	\$ 1,499.4	\$ 1,416.0	\$ 1,383.0	\$ 1,305.4
Total assets	\$ 4,162.9	\$ 3,873.3	\$ 3,680.3	\$ 3,635.9	\$ 3,638.3
Total debt, excluding unamortized discount of convertible debt instruments	\$ 1,651.7	\$ 1,502.2	\$ 1,516.7	\$ 1,517.1	\$ 1,668.5
Total LifePoint Hospitals, Inc stockholders' equity	\$ 1,887.5	\$ 1,827.7	\$ 1,652.0	\$ 1,629.1	\$ 1,471.5

e424b3

[Table of Contents](#)

(Dollars in millions)	Year Ended December 31,				
	2010	2009	2008	2007	2006
Additional Financial Data:					
Purchases of property and equipment	\$ 168.7	\$ 166.6	\$ 157.6	\$ 158.4	\$ 194.0
Net cash provided by operating activities—continuing operations	\$ 375.7	\$ 350.3	\$ 346.6	\$ 241.4	\$ 257.8
Net cash used in investing activities—continuing operations	\$ (353.6)	\$ (244.1)	\$ (185.3)	\$ (158.3)	\$ (475.8)
Net cash (used in) provided by financing activities—continuing operations	\$ (0.3)	\$ (13.9)	\$ (119.3)	\$ (165.6)	\$ (148.5)

e424b3

[Table of Contents](#)

RISK FACTORS

Before deciding to tender your notes in the exchange offer, you should carefully consider the risks described below, together with all other risks incorporated by reference in this prospectus. Any of the risks described herein could have a material adverse effect on our results of operations. In such case, you may lose all or part of your investment in the notes.

Risks relating to our business

We cannot predict the effect that healthcare reform and other changes in government programs may have on our business, financial condition and operations.

The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (collectively, the “ACA”) alters the United States healthcare system and is intended to decrease the number of uninsured Americans and reduce overall healthcare costs. We anticipate that the ACA will attempt to achieve these goals by, among other things, requiring most Americans to obtain health insurance, expanding Medicare and Medicaid payments, including disproportionate share hospital (“DSH”) payments to providers, expanding the Medicare program, creating new purchasing programs, tying hospital payments to the satisfaction of certain quality criteria, and bundling payments to hospitals and other providers. The ACA also contains a number of measures that are intended to reduce fraud and abuse in the Medicare and Medicaid programs, such as requiring the use of certified contractors (“RACs”) in the Medicaid program, expanding the scope of the federal False Claims Act and generally prohibiting physician self-referrals, physician owners or increasing the number of beds and operating rooms for which they are licensed. Because a majority of the measures in the ACA do not take effect until 2013, it is difficult to predict the impact the Affordable Care Act will have on our facilities. In addition, there is uncertainty as to the constitutionality of the Affordable Care Act, and some courts have ruled that the requirement for individuals to carry health insurance or the Affordable Care Act is unconstitutional. Several bills have been and will likely continue to be introduced in Congress to repeal or amend all or significant portions of the ACA. It is difficult to predict the full impact of the Affordable Care Act due to its complexity, lack of implementing regulations and interpretive guidance, delayed implementation, pending court challenges, and possible repeal and/or amendment, as well as our inability to foresee how individuals will exercise the choices afforded them by the Affordable Care Act. Depending on further legislative developments, how the pending court challenges are resolved, and how the Affordable Care Act is ultimately interpreted and implemented, it could have an adverse effect on our business, financial condition and operations.

Our revenues will decline if federal or state programs reduce our Medicare or Medicaid payments or if managed care companies limit our access to patients. In addition, the financial condition of payors and healthcare cost containment initiatives may limit our revenues and profitability.

For the first quarter of 2011, we derived 42.9% of our revenues from the Medicare and Medicaid programs, collectively. The Medicare and Medicaid programs are subject to statutory and regulatory changes, administrative rulings, interpretations and determinations concerning patient eligibility requirements, method of calculating payments or reimbursements, among other things; requirements for utilization review; and federal and state funding levels. Any change that materially increases or decreases payments from these government programs in the future, as well as affect the timing of payments to our facilities, could have an adverse effect on our business, financial condition and operations.

We are unable to predict the effect of future government healthcare funding policy changes on our operations. If the rates paid by government payors for the scope of services covered by governmental payors is limited or if we, or one or more of our subsidiaries’ hospitals, are excluded from the Medicare or Medicaid program or any other government healthcare program, there could be a material adverse effect on our business, financial condition and operations.

During the past several years, healthcare payors, such as federal and state governments, insurance companies and employers, have begun to change payment methodologies and monitor healthcare costs. As part of their efforts to contain healthcare costs, payors increasingly are demanding that healthcare providers assume the financial risk relating to paying for care provided, often

e424b3

e424b3

[Table of Contents](#)

in exchange for exclusive or preferred participation in their benefit plans. We expect efforts to impose greater discounts and more stringent terms on other payors to continue, thereby reducing the payments we receive for our services. In addition, these payors have instituted policies aimed at reducing or limit the use of inpatient services. For example, CMS has transitioned to full implementation of the MS-DRG system, which represents a move from the diagnosis-related group system. Future realignments in the MS-DRG system could impact the margins we receive for certain services. The Affordable Care Act provides for material reductions in the growth of Medicare program spending, including reductions in Medicare market basket updates. Medicare payments in federal fiscal year 2011 for inpatient hospital services are expected to be slightly lower than payments for the same services in 2010 because of reductions resulting from the Affordable Care Act and the MS-DRG implementation.

All of our hospitals are certified as providers of Medicaid services. Medicaid programs are jointly funded by federal and state governments. Some states under an approved plan that provides hospital and other healthcare benefits to qualifying individuals who are unable to afford care. States are experiencing budget problems and have adopted or are considering legislation designed to reduce their Medicaid expenditures, including implementing managed care programs and imposing additional taxes on hospitals to help finance or expand states' Medicaid systems. The American Recovery and Reinvestment Act of 2009 (the "ARRA") and the Education, Jobs, and Medicaid Assistance Act (the "Assistance Act") include increased federal funding for Medicaid. However, we are unable to predict at this time how this will impact states' ability to provide Medicaid coverage in the future, particularly with respect to eligibility requirements that become effective in 2014 as part of the Affordable Care Act. It is possible that, despite Congress's actions, states may be forced to resort to some of the cost saving measures mentioned above. These efforts could have a material adverse effect on our business, financial results, or cash flows.

For example, one of our hospitals, Memorial Medical Center of Las Cruces, New Mexico ("MMC"), received approximately \$38.5 million from the New Mexico Sole Community Provider Program (the "SCPP"). While the funds made available to MMC (and other New Mexico hospitals that participate in the SCPP) are tied directly to the cost of actual services provided, MMC is required to provide an annual report of its costs to Dona Ana County (the county in which MMC is located). Once desired funding levels were established by Dona Ana County for 2009, the county submitted funds to the New Mexico Human Services Department ("NMHSD"), which in turn were combined with funds sent by other New Mexico counties and then used by the NMHSD to request matching funds from the federal government. Once the federal matching dollars were made available to the state, the resulting sole community provider payment was made under the SCPP to the hospitals participating in the SCPP by the NMHSD. The payments made by the NMHSD to hospitals pursuant to the SCPP are based on the costs incurred by each participating hospital. The SCPP was created in 1993 and has resulted in significant payments to MMC in prior years. Like many other hospitals, we are concerned in New Mexico that the SCPP cannot be sustained at current funding levels as a result of budget concerns and other factors. It is possible that the SCPP will soon be reconstituted. We are not able to predict what changes may be made to the SCPP, but any change in the SCPP is likely to have a material impact on MMC.

We are subject to increasingly stringent governmental regulation, and may be subjected to allegations that we have failed to comply with such regulations, which could result in sanctions and even greater scrutiny that reduce our revenues and profitability.

All participants in the healthcare industry are required to comply with many laws and regulations at the federal, state and local government levels. Regulations require that hospitals meet various requirements, including those relating to hospitals' relationships with physicians and other healthcare providers, quality of medical care, equipment, personnel, operating policies and procedures, billing and cost reports, payment for services and supplies, medical records, privacy, compliance with building codes and environmental protection, among other matters. Many of the laws and regulations are complex, and, in public statements, governmental authorities have taken positions on issues for which little official interpretation was previously provided. These positions appear to be inconsistent with common practices within the industry but have not previously been challenged. In addition, the enforcing of penalties for violations of these laws and regulations is changing and increasing. For example, in 2010, CMS issued a rule requiring hospitals and other providers that wish to self-disclose potential

e424b3

e424b3

[Table of Contents](#)

violations of the provision of the Social Security Act commonly known as the “Stark law” and attempt to resolve those potential violations at levels below the maximum penalties and amounts set forth in the statute. In light of the provisions of the Affordable Care Act, the Claims Act liabilities for failing to report and repay known overpayments and return an overpayment within sixty (60) days of the identification date by which a corresponding cost report is due, whichever is later, hospitals and other healthcare providers are encouraged to disclose to CMS. It is likely that self-disclosure of Stark violations will continue in the future. Moreover, some government investigations that have been conducted under the civil provisions of federal law are now being conducted as criminal investigations under the Medicare fraud and abuse laws.

The healthcare industry has seen a number of ongoing investigations related to patient referrals, physician recruiting practices, cost reporting, laboratory and home healthcare services, physician ownership of hospitals and other healthcare providers, and joint ventures involving state government agencies have announced heightened and coordinated civil and criminal enforcement efforts. In addition, the Office of Inspector General, Department of Health and Human Services (the “OIG”) (which is responsible for investigating fraud and abuse activities in government programs) and the Department of Justice periodically establish targeted enforcement initiatives that focus on specific billing practices or other areas that are highly susceptible to fraud. The industry has reported savings and expected recoveries for federal healthcare programs of more than \$25.9 billion for federal fiscal year 2010 as a result of these efforts.

Hospitals continue to be one of the primary focal areas of the OIG and other governmental fraud and abuse programs. In January 2010, the OIG issued Compliance Program Guidance for Hospitals that focuses on hospital compliance risk areas. Some of the risk areas highlighted by the OIG include: proper procedure coding, revising admission and discharge policies to reflect current CMS rules, submitting appropriate claims for supplemental payments, managing costs and outlier payments and a general discussion of the fraud and abuse risks related to financial relationships with referral sources. In addition, the OIG publishes a General Work Plan that provides a brief description of the activities that the OIG plans to initiate or continue with respect to its oversight of the Department of Health and Human Services (“HHS”) and details the areas that the OIG believes are prone to fraud and abuse. In addition, the OIG’s audits by the RACs generally include a review of high dollar claims, including inpatient hospital claims. As a result, a large majority of the total Medicare claims come from hospitals. The Affordable Care Act expands the RAC program’s scope to include managed Medicare and to include Medicaid. The Affordable Care Act establishes programs to contract with RACs in 2011. In addition, CMS employs Medicaid Integrity Contractors (“MICs”) to perform post-payment audits and identify overpayments. The Affordable Care Act increases federal funding for the MIC program for federal fiscal year 2011 and later years. In addition, MICs, the state Medicaid agencies and other contractors have also increased their review activities.

The laws and regulations with which we must comply are complex and subject to change. In the future, different interpretations or enforcement of these laws and regulations could subject our practices to allegations of impropriety or illegality or could require us to make changes in our facilities, equipment, reimbursement programs and operating expenses. If we fail to comply with applicable laws and regulations, we could suffer civil or criminal penalties, lose our licenses to operate our hospitals and our ability to participate in the Medicare, Medicaid and other federal and state healthcare programs.

Finally, we are subject to various federal, state and local statutes and ordinances regulating the discharge of materials into the environment. Our operations generate medical waste, such as pharmaceuticals, biological materials and disposable medical instruments that must be disposed of in compliance with local environmental laws, rules and regulations. Our operations are also subject to various other environmental laws, rules and regulations that may apply when we renovate or refurbish hospitals, particularly older facilities.

We may continue to see the growth of uninsured and “patient due” accounts, and deterioration in the collectability of these accounts, which could result in lower collections of accounts receivable, results of operations and cash flows.

The primary collection risks associated with our accounts receivable relate to the uninsured patient accounts and patient accounts for which we have not yet received payment. We have not yet received payment from patients who have paid the amounts covered by the applicable agreement,

e424b3

[Table of Contents](#)

but patient responsibility amounts (deductibles and co-payments) remain outstanding. The provision for doubtful accounts relates primarily to patients. This risk has increased, and will likely continue to increase, as more individuals enroll in high deductible insurance plans or that have no insurance coverage. These trends will likely be exacerbated if general economic conditions remain challenging or if unemployment rates in which we operate rise. As unemployment rates increase, our business strategies to generate organic growth and to improve admissions at our hospitals could become more difficult to accomplish.

The amount of our provision for doubtful accounts is based on our assessments of historical collection trends, business and economic conditions, state governmental and private employer health coverage and other collection indicators. A continuation in trends that results in increased bad debt receivable being comprised of uninsured accounts and deterioration in the collectability of these accounts could adversely affect our operating results of operations and cash flows. As enacted, the Affordable Care Act seeks to decrease, over time, the number of uninsured individuals. The Affordable Care Act will, beginning in 2014, expand Medicaid and incentivize employers to offer, and require individuals to carry, health insurance with penalties. However, it is difficult to predict the full impact of the Affordable Care Act due to its complexity, lack of implementing regulations, gradual and potentially delayed implementation, pending court challenges, and possible repeal and/or amendment, as well as our inability to predict how businesses will respond to the choices afforded them by the Affordable Care Act. In addition, even after implementation of the Affordable Care Act, we may experience bad debts and be required to provide uninsured discounts and charity care for undocumented aliens who are not permitted to enroll in exchange or government healthcare programs.

Controls designed to reduce inpatient services may reduce our revenues.

Controls imposed by Medicare, Medicaid, and commercial third-party payors designed to reduce admissions and lengths of stay, commonly referred to as "utilization review," have affected and are expected to continue to affect our facilities. Federal law contains numerous provisions designed to ensure that services to Medicare and Medicaid patients meet professionally recognized standards and are medically necessary and that claims for reimbursement are properly submitted. These provisions include a requirement that a sampling of admissions of Medicare and Medicaid patients must be reviewed by quality improvement organizations to determine the appropriateness of Medicare and Medicaid patient admissions and discharges, the quality of care provided, the validity of MS-DRG assignments, and the appropriateness of cases of extraordinary length of stay or cost on a post-discharge basis. Quality improvement organizations may deny reimbursement and also have the authority to recommend to the HHS that a provider which is in substantial noncompliance with the standards of the program be excluded from participation in the Medicare program. The Affordable Care Act potentially expands the use of prepayment review by Medicare and Medicaid, statutory restrictions on their use, and, as a result, efforts to impose more stringent cost controls are expected to continue. Utilization review by non-governmental managed care organizations and other third-party payors. Inpatient utilization, average lengths of stay and occupancy rates are affected by payor-required preadmission authorization and utilization review and by third party payor pressure to maximize outpatient services for less acutely ill patients. Although we are unable to predict the effect these controls and changes will have on our operations, our services reimbursed and on reimbursement rates and fees could have a material, adverse effect on our business, financial position and results of operations.

The industry trend towards value-based purchasing may negatively impact our revenues.

There is a trend in the healthcare industry toward value-based purchasing of healthcare services. These value-based purchasing programs use quality data and preventable adverse events tied to the quality and efficiency of care provided by facilities. Governmental programs including Medicare and Medicaid currently require hospitals to report certain quality data to receive full reimbursement updates. In addition, Medicare does not reimburse for certain preventable adverse events. Many large commercial payors currently require hospitals to report quality data, and several commercial payors are beginning to tie reimbursement to certain preventable adverse events.

e424b3

[Table of Contents](#)

The Affordable Care Act contains a number of provisions intended to promote value-based purchasing. Effective July 1, 2011, the use of federal funds under the Medicaid program to reimburse providers for medical assistance provided to treat hospital acquired condition that is acquired by a patient while admitted as an inpatient at a hospital, such as a surgical site infection. Beginning in federal fiscal year 2013, hospitals in the top 25% of national risk-adjusted HAC rates for all hospitals in the previous year will receive a 1% reduction in their total Medicare payments. Hospitals with excessive readmissions for conditions designated by HHS will receive reduced payments for all inpatient discharges, not just discharges that exceed the excessive readmission standard.

The Affordable Care Act also requires HHS to implement a value-based purchasing program for inpatient hospital services. The Act requires HHS to reduce inpatient hospital payments for all discharges by a percentage beginning at 1% in federal fiscal year 2013 and increasing by 0.25% in federal fiscal year 2017 and subsequent years. HHS will pool the amount collected from these reductions to fund payments to reward hospitals that meet or exceed quality performance standards established by HHS. HHS will determine the amount each hospital that meets or exceeds the quality performance standards will receive from the pool of dollars created by these payment reductions.

We expect value-based purchasing programs, including programs that condition reimbursement on patient outcome measures, to become more prevalent. We are unable at this time to predict how this trend will affect our results of operations, but we believe it will reduce our revenues.

The lingering effects of the economic recession could materially adversely affect our financial position, results of operations or cash flows.

The United States economy recently emerged from an economic recession and unemployment levels remain high. While certain healthcare services are discretionary and may not be significantly impacted by economic downturns, other types of healthcare spending may be adversely impacted. If our patients are experiencing personal financial difficulties or have concerns about general economic conditions, they may choose:

- to defer or forego elective surgeries and other non-emergent procedures, which are generally more profitable lines of business for us;
- a high-deductible insurance plan or no insurance at all, which increases a hospital's dependence on self-pay revenue. Moreover, if our patients are unable to pay for care, they may seek care in our emergency rooms.

We are unable to determine the specific impact of these economic conditions on our business at this time, but we believe that the lingering effects of the economic recession could have an adverse impact on our operations and could impact not only the healthcare decisions of our patients, but also the decisions of our providers and other counterparties to transactions with us.

The failure of certain employers, or the closure of certain manufacturing and other facilities in our markets, can have a disproportionate impact on our revenues and results of operations.

The economies in the non-urban communities in which our hospitals operate are often dependant on a small number of large employers and other facilities. These employers often provide income and health insurance for a disproportionately large number of community residents who come to our hospitals for care. The failure of one or more large employers, or the closure or substantial reduction in the number of individuals employed at manufacturing or other facilities located in or near many of the non-urban communities in which our hospitals operate, could cause affected employees to move elsewhere, thereby reducing the health insurance coverage that was otherwise available to them. The occurrence of these events may cause a material reduction in our revenues and results of operations. Our business strategies intended to generate organic growth and improve operating results at our hospitals.

e424b3

[Table of Contents](#)

If we do not effectively attract, recruit and retain qualified physicians, our ability to deliver healthcare services efficiently will be

As a general matter, only physicians on our medical staffs may direct hospital admissions and the services ordered once a patient is admitted. The success of our hospitals depends in part on the number and quality of the physicians on the medical staffs of our hospitals, the admission of patients, and maintaining good relations with those physicians.

The success of our efforts to recruit and retain quality physicians depends on several factors, including the actual and perceived quality of our hospitals, our ability to meet demands for new technology and our ability to identify and communicate with physicians who want to practice in our communities. In particular, we face intense competition in the recruitment and retention of specialists because of the difficulty in convincing these individuals to remain in practice in non-urban communities. If the non-urban communities in which our hospitals operate are not seen as attractive, we will have difficulty attracting and retaining physicians to practice in our communities. We may not be able to recruit all of the physicians we target. In addition, we may incur malpractice expense if the quality of physicians we recruit does not meet our expectations.

Additionally, our ability to recruit physicians is closely regulated. For example, the types, amount and duration of assistance we can provide are limited by the Stark law, the anti-kickback provisions of the Social Security Act (the “Anti-kickback Statute”), state anti-kickback statutes, and other laws. For example, the Stark law requires, among other things, that recruitment assistance can only be provided to physicians who meet certain qualifications, that the amount of assistance cannot be changed during the term of the recruitment agreement, and that the recruitment payments cannot exceed the amount currently in practice in the community beyond recruitment costs actually incurred by them. In addition to these legal requirements, there is competition for physicians in our communities and facilities for these physicians, and this competition continues after the physician is practicing in one of our communities.

The profitability of our employed physicians will be affected by changes in the Medicare and Medicaid payment rates.

In recent years, physician payment amounts have been determined on a year by year basis. If the sustainable growth rate provision of the Affordable Care Act is implemented to the physician fee schedule in January 2012 as required by current legislation, Medicare payments will decrease by approximately 29%. As a result, employment by acute care hospitals has become more common as a result of actual and potential reductions in payment amounts for physicians. Our employment of physicians is consistent with industry trends. Employed physicians could present more direct risks to us than those presented by independent contractors on our hospitals’ medical staffs. The combination of increased salary cuts and potential liabilities are significant and if this trend continues, could have negative results of operations.

Our hospitals face competition for staffing, which may increase labor costs and reduce profitability.

In addition to our physicians, the operations of our hospitals are dependent on the efforts, abilities and experience of our management and support personnel, such as nurses, pharmacists and lab technicians. We compete with other healthcare providers in recruiting and retaining qualified management and support personnel responsible for the day-to-day operations of each of our hospitals, including nurses and other non-physician healthcare professionals. In addition, the availability of nurses and other medical support personnel presents a significant operating issue. This shortage may require us to enhance our efforts to recruit, retain nurses and other medical support personnel, recruit personnel from foreign countries, and hire more expensive temporary or contract personnel. In the jurisdictions in which we operate could adopt mandatory nurse-staffing ratios or could reduce mandatory nurse staffing ratios already in place. State legislation could significantly affect labor costs and have an adverse impact on revenues if we are required to limit admissions in order to meet the requirements of these laws. We may not be able to raise rates to offset these increased costs. We also depend on the available labor pool of semi-skilled and unskilled personnel in which we operate. Because a significant percentage of our revenue consists of fixed, prospective payments, our ability to pass along increased costs is limited. Our failure to recruit and retain qualified

e424b3

[Table of Contents](#)

management, nurses and other medical support personnel, or to control our labor costs could have a material adverse effect on our financial operations.

The loss of certain physicians can have a disproportionate impact on certain of our hospitals.

Generally, the top ten attending physicians within each of our facilities represent a large share of our inpatient revenues and admissions. The loss of these physicians — even if temporary — could cause a material reduction in our revenues, which could take significant time to replace given the time and expense involved with recruiting and retaining physicians.

We may be subjected to actions brought by the government under anti-fraud and abuse provisions or by individuals on the government's False Claims Act's "qui tam" or "whistleblower" provisions.

We are subject to the Anti-kickback Statute, which prohibits healthcare service providers from paying or receiving remuneration to induce or to reward the referral of patients or purchase of items or services covered by a federal or state healthcare program. We are also subject to the Stark law, which prohibits physicians from referring Medicare and Medicaid patients to selected types of healthcare entities in which they or any of their immediate family members have an ownership or financial relationship unless an exception applies. If regulatory authorities determine that any of our hospitals' arrangements violate the Anti-kickback Statute or the Stark law, we may be subject to a number of significant liabilities such as criminal penalties (for violations of the Anti-kickback Statute), civil monetary penalties, exclusion from participation in Medicare, Medicaid or other federal healthcare programs, any of which could impair our ability to operate one or more of our hospitals.

The federal False Claims Act prohibits providers from, among other things, knowingly submitting false claims for payment to the federal government. The "whistleblower" provisions of the False Claims Act allow private individuals to bring actions under the False Claims Act on behalf of the federal government. Whistleblowers are entitled to share in any amounts recovered by the government, and, as a result, the number of "whistleblower" lawsuits that have been filed under the False Claims Act has increased significantly in recent years. Defendants found to be liable under the federal False Claims Act may be required to pay three times the amount of the claim to the government, plus mandatory civil penalties ranging between \$5,500 and \$11,000 for each separate false claim.

There are many potential bases for liability under the False Claims Act. The government has used the False Claims Act to prosecute healthcare providers for healthcare program fraud such as coding errors, billing for services not provided, submitting false cost reports, and providing care that is not medically necessary or substandard in quality. The Affordable Care Act also provides that claims submitted in connection with patient referrals that result from a violation of the Anti-kickback Statute constitute false claims for the purposes of the federal False Claims Act, and some courts have held that a violation of the Stark law also constitutes a violation of the False Claims Act, as well. In addition, a number of states have adopted their own false claims and whistleblower provisions whereby a private party can bring a lawsuit against a provider. We are required to provide information to our employees and certain contractors about state and federal false claims laws and whistleblower protections.

Although we intend and will endeavor to conduct our business in compliance with all applicable federal and state fraud and abuse laws, we cannot assure you that our arrangements or business operations will not be subject to government scrutiny or be found to be in compliance with applicable fraud and abuse laws.

If our access to licensed information systems is interrupted or restricted, or if we are not able to integrate changes to our existing information systems of acquired hospitals, our operations could suffer.

Our business depends significantly on effective information systems to process clinical and financial information. Information systems are a critical component of our operations and we devote significant resources to maintain and enhance existing systems and develop new systems in order to keep pace with continuing changes in healthcare technology. We rely heavily on HCA-Information Technology and Services, Inc., ("HCA-IT"), for information systems. HCA-IT provides a variety of services, including patient accounting and network information services. HCA's

e424b3

e424b3

[Table of Contents](#)

primary business is to own and operate hospitals, not to provide information systems. We do not control HCA-IT's systems. If these systems are not available or access to these systems is limited in the future or if HCA-IT develops systems more appropriate for the urban healthcare market and not for our operations could suffer. Our existing contract with HCA-IT, expires on December 31, 2017 (including a wind-down period) unless extended.

System conversions are costly, time consuming and disruptive for physicians and employees. Some of our hospitals have recently converted from the system provided by HCA-IT to another third party information system. Implementation of such conversions are very costly and on a large scale, could have a material adverse effect on our business, financial condition, results of operations or cash flows.

In addition, as new information systems are developed in the future, we will need to integrate them into our existing systems. Evolving regulatory standards, such as the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") and meaningful use regulations, may require new systems in the future. We may not be able to integrate new systems or changes required to our existing systems or systems of acquired hospitals on a cost-efficient basis.

If we fail to effectively and timely implement electronic health record systems, our operations could be adversely affected.

As required by ARRA, the Secretary of HHS is in the process of developing and implementing an incentive payment program for eligible health care professionals that adopt and meaningfully use electronic health record ("EHR") technology. HHS intends to use the Provider Enrollment and Chain of Ownership System ("PECOS") to verify Medicare enrollment prior to making EHR incentive program payments. If our hospitals and employed professionals do not meet the requirements for participation in the incentive payment program, including having an enrollment record in PECOS, we will not be eligible for payments that could offset some of the costs of implementing EHR systems. Further, beginning in federal fiscal year 2015, eligible hospitals and health systems that do not demonstrate meaningful use of certified EHR technology will be subject to reduced payments from Medicare. System conversions to comply with EHR requirements are disruptive for physicians and employees. Failure to implement EHR systems effectively and in a timely manner could have a material adverse effect on our business, financial condition and results of operations.

We may have difficulty acquiring hospitals on favorable terms.

One element of our business strategy is expansion through the acquisition of acute care hospitals in non-urban markets. We face significant competition for attractive non-urban hospitals, and we may not find suitable acquisitions on favorable terms. Our primary competitors for acquisitions include other hospitals, exempt hospitals and hospital systems and privately capitalized start-up companies. Buyers with a strategic desire for any particular hospital, particularly those located near existing hospitals or those who will realize economic synergies — have demonstrated an ability and willingness to pay premium prices. Such buyers, as a result, can present a competitive barrier to our acquisition efforts.

Given the increasingly challenging regulatory and enforcement environment, our ability to acquire hospitals could be negatively impacted by unresolved material compliance issues, including obligations to self-report violations of law or outstanding obligations to pay amounts due under the protocol or other laws. We could experience delays in closing or fail to close transactions with targets that initially were attractive but become unattractive due to poor compliance program, material non-compliance with laws or failure to timely address compliance risks.

The cost of an acquisition could result in a dilutive effect on our results of operations, depending on various factors, including the amount of the acquired hospital's results of operations, allocation of purchase price, effects of subsequent legislation and limitations on rate increases. We have experienced temporary delays in improving the operating margins or effectively integrating the operations of our acquired hospitals. In order to improve the operating margins of acquired hospitals, operate them profitably or effectively integrate their operations, we may be unable to

e424b3

[Table of Contents](#)

Even if we are able to identify an attractive target, we may not be able to obtain financing, if necessary, for any acquisitions or joint ventures. We may be required to borrow at higher rates and on less favorable terms. We may incur or assume additional indebtedness as a result of acquisitions. Acquisitions of urban hospitals consistent with our growth plans could prevent us from increasing our revenues.

In recent years, the legislatures and attorneys general of several states have become more interested in sales of hospitals by tax-exempt organizations. This may increase the cost and difficulty, or prevent the completion, of transactions with tax-exempt organizations in the future.

We may encounter difficulty operating and integrating acquired hospitals.

We may be unable to timely and effectively integrate any hospitals that we acquire with our ongoing operations. We may experience difficulties with procedures and systems in newly acquired hospitals. Integrating an acquired hospital could be expensive and time consuming and could negatively affect cash flow and distract management and other key personnel. In addition, acquisition activity requires transitions from, and, usually, information systems that are used by acquired hospitals. We will rely heavily on HCA-IT and other third parties for information technology services under a contractual arrangement for information technology services. We may not be successful in causing HCA-IT and other third parties to integrate their hospitals' information systems in a timely manner.

If we acquire hospitals with unknown or contingent liabilities, we could become liable for material obligations.

Businesses we have acquired, or businesses we may acquire may have unknown or contingent liabilities for past activities of acquisition, including failure to comply with healthcare laws and regulations, medical and general professional liabilities, worker's compensation liabilities, product liability, and unacceptable business practices. Although we have historically obtained, and we intend to continue to obtain, contractual indemnification arrangements, matters, any indemnification obtained from sellers may be insufficient to cover material claims or liabilities for past activities of acquisition.

Other hospitals and outpatient facilities provide services similar to those which we offer. In addition, physicians provide services similar to those provided in our hospitals. These factors increase the level of competition we face and may therefore adversely affect our revenues.

Competition among hospitals and other healthcare service providers, including outpatient facilities, has intensified in recent years. We compete with, including larger tertiary care centers located in larger metropolitan areas, and with physicians who provide services in their offices which are closer to our hospitals. Although the hospitals with which we compete may be a significant distance away from our facilities, patients in our market may be referred by local physicians to, or may be encouraged by their health plan to travel to these hospitals. Furthermore, some of the hospitals we compete with may offer more or different services than those available at our hospitals, may have more advanced equipment or may have a medical staff more highly qualified. Also, some of the hospitals that compete with our facilities are owned by tax-supported governmental agencies or not-for-profit organizations and charitable contributions. These hospitals, in most instances, are also exempt from paying sales, property and income taxes.

We also face very significant and increasing competitions from services offered by physicians (including physicians on our medical staff) and specialized care providers, including outpatient surgery, oncology, physical therapy and diagnostic centers (including many in which physicians have a financial interest). Some of our hospitals have and will seek to develop outpatient facilities where necessary to compete effectively. However, to the extent we are not successful in developing outpatient facilities or physicians are able to offer additional, advanced services in their offices, our market share may decrease in the future.

Quality of care and value-based purchasing have also become significant trends and competitive factors in the healthcare industry. In addition, the release of performance data relating to ten quality measures that hospitals submit in connection with their Medicare reimbursement. Since that time,

e424b3

[Table of Contents](#)

increased the number of quality measures hospitals are required to report in order to receive the full Medicare inpatient prospective payment system ("OPPS") market basket updates. In addition, the Medicare program no longer reimburses hospitals for the preventable adverse events, and many private healthcare payors have adopted similar policies. If the public performance data become a choice to receive care, and if competing hospitals have better results than our hospitals on those measures, we would expect that our payor mix would change.

Our revenues are especially concentrated in a small number of states which will make us particularly sensitive to regulatory and economic changes in those states.

Our revenues are particularly sensitive to regulatory and economic changes in states in which we generate the majority of our revenues. New Mexico, Tennessee, West Virginia, Alabama, Arizona, Louisiana and Texas. The following table contains our revenues and revenue percentages by state for each of these states for the years presented (dollars in millions):

	Revenue Concentration by State			
	Amount		Percentage	
	2010	2009	2008	2010
Kentucky	\$ 544.8	\$ 485.5	\$ 465.0	16.7%
Virginia	404.7	384.1	381.6	12.4
New Mexico	295.4	288.0	245.7	9.1
Tennessee	293.9	225.5	223.2	9.0
West Virginia	273.7	250.7	243.4	8.4
Alabama	236.9	209.6	203.2	7.3
Arizona	216.7	195.2	173.8	6.6
Louisiana	212.3	204.2	194.6	6.5
Texas	148.2	139.9	142.3	4.5

Accordingly, any change in the current demographic, economic, competitive or regulatory conditions in the above-mentioned states could have a material adverse effect on our business, financial condition, results of operations and/or prospects. Medicaid changes in these states could also have a material adverse effect on our condition, results of operations or cash flows.

If we do not continually enhance our hospitals with the most recent technological advances in diagnostic and surgical equipment, our ability to attract patients and expand our markets may be adversely affected.

Technological advances, including with respect to computer-assisted tomography scanner (CTs), magnetic resonance imaging (MRI) scanner (PETs) equipment, continue to evolve. In addition, the manufacturers of such equipment often provide incentives to try to increase sales to hospitals. In an effort to compete, we must continually assess our equipment needs and update our equipment with technological improvements. We believe that the direction of the patient flow correlates directly to the level and intensity of such diagnostic and surgical services.

We have substantial indebtedness and we may incur significant amounts of additional indebtedness in the future which could affect our ability to obtain financing and capital expenditures, pursue desirable business opportunities or successfully operate our business in the future.

As of March 31, 2011, our consolidated debt, excluding the unamortized discount of convertible debt instruments, was approximately \$1.1 billion. Our ability to incur significant amounts of additional indebtedness, subject to the conditions imposed by the terms of our credit agreement and any other agreements governing any additional indebtedness that we incur in the future. As of December 31, 2010, revolving loans available for borrowing under our credit agreement were \$318.9 million, net of outstanding letters of credit of \$31.1 million. Additionally, our credit agreement contains uncommitted "accordion" features that allow us to increase at a later date additional aggregate principal amounts of up to \$650.0 million under the term A and the term B loan components and up to \$350.0 million under the revolving loan component, subject to obtaining additional lender commitments and the satisfaction of other conditions. Our ability to refinance our debt will depend on the credit markets and the satisfaction of other conditions.

e424b3

e424b3

Table of Contents

indebtedness will depend upon our ability to monetize our interests in our hospital assets and our operating performance, which may be affected by financial, competitive, regulatory, business and other factors beyond our control.

Although we believe that our future operating cash flow, together with available financing arrangements, will be sufficient to fund our obligations, our leverage and debt service obligations could have important consequences, including the following:

- Under our credit agreement, we are required to satisfy and maintain specified financial ratios and tests. Failure to comply with these covenants, or a default of default which, if not cured or waived, could require us to repay substantial indebtedness immediately. Moreover, if debt repayment is accelerated, we may be subject to higher interest rates on our debt obligations as a result of these covenants and our credit ratings may be adversely impacted.
- We may be vulnerable in the event of downturns and adverse changes in the general economy or our industry. Specific examples of events that may have an adverse impact on our cash flow include the implementation by the government of further limitations on reimbursement rates for services.
- We may have difficulty obtaining additional financing at favorable interest rates to meet our requirements for working capital, capital expenditures, general corporate or other purposes.
- We will be required to dedicate a substantial portion of our cash flow to the payment of principal and interest on indebtedness, leaving less funds available for operations, capital expenditures and future acquisitions.
- Any borrowings we incur at variable interest rates expose us to increases in interest rates generally.
- A breach of any of the restrictions or covenants in our debt agreements could cause a cross-default under other debt agreements. If we are unable to repay indebtedness immediately if we default on any of the numerous financial or other restrictive covenants contained in the debt agreements we will have, or will be able to obtain, sufficient funds to make these accelerated payments. If any senior debt is accelerated, we may be required to repay such indebtedness and our other indebtedness.
- In the event of a default, we may be forced to pursue one or more alternative strategies, such as restructuring or refinancing our debt, reducing or delaying capital expenditures or seeking additional equity capital. There can be no assurances that any of these strategies will result in satisfactory terms, if at all, or that sufficient funds could be obtained to make these accelerated payments.

Covenant restrictions under our senior secured credit facilities and our indenture will impose significant operating and financial covenants that may restrict our ability to operate our business and to make payments on the notes and other outstanding indebtedness. The exceptions to these covenants do not allow us to refinance subordinated indebtedness with senior indebtedness.

The credit agreement that governs our senior secured credit facilities and the indenture that will govern the notes contain covenants that may restrict our future operations or capital needs, to take advantage of other business opportunities that may be in our interest or to satisfy our obligations. These covenants restrict our ability to, among other things:

- incur or guarantee additional debt or extend credit;
- pay dividends or make distributions on, or redeem or repurchase, our capital stock or certain other securities;
- other debt;

e424b3

Table of Contents

- make other restricted payments, including investments;
- dispose of assets;
- engage in transactions with affiliates;
- enter into agreements restricting our subsidiaries' ability to pay dividends;
- create liens on our assets or engage in sale/leaseback transactions; and
- effect a consolidation or merger, or sell, transfer, lease all or substantially all of our assets.

The limitations in our credit agreement for our senior secured credit facilities, our indenture or other instruments governing indebtedness may restrict our ability to repay existing outstanding indebtedness. Subject to certain conditions, holders of the 3½% convertible senior 3¼% convertible senior subordinated debentures due 2025 may convert their securities for cash, and if applicable, shares in common stock or notes offered hereby. Failure to repay the 3½% convertible senior subordinated notes due 2014 or 3¼% convertible senior subordinated notes or upon conversion of the securities may result in a default.

Subject to certain conditions, the provisions of our indenture may also allow us to refinance indebtedness that is subordinated in right of payment to the notes with new indebtedness that would rank pari passu with the notes.

We may be subject to liabilities because of malpractice and related legal claims brought against our hospitals or our employed physicians. In the event of such claims, we could be required to pay significant damages, which may not be covered by insurance.

We may be subject to medical malpractice lawsuits and other legal actions arising out of the operations of our owned and leased hospitals and employed physicians. These actions may involve large claims and significant defense costs. In an effort to resolve one or more of these matters, we may enter into a settlement. Amounts we pay to settle any of these matters may be material. We maintain professional and general liability insurance with multiple carriers to provide for losses in excess of our SIR amount. As a result, one or more successful claims against us that are within our SIR amount could have a material effect on our results of operations, cash flows, financial condition or liquidity. Also, some of these claims could exceed the scope of the SIR coverage. No particular claims could be denied. In addition, we operate a wholly-owned captive insurance company under the name Point of Life Insurance Company. We maintain malpractice insurance policies to our employed physicians.

Insurance coverage in the future may not continue to be available at a cost allowing us to maintain adequate levels of insurance with multiple carriers. One or more of our insurance carriers may become insolvent and unable to fulfill its obligation to defend, pay or reimburse us when that obligation arises. Our employed physicians using our hospitals may be unable to obtain insurance on acceptable terms, which could result in these physicians not being able to meet the insurance requirements in the applicable hospital medical staff bylaws or necessitate a reduction in the level of insurance required to be carried under the bylaws.

Our revenues and volume trends may be adversely affected by certain factors over which we have no control.

Our revenues and volume trends are dependent on many factors, including physicians' clinical decisions and availability, payor programs, a competitive market-based environment, whether or not certain services are offered, seasonal and severe weather conditions, including the effects of extreme weather events such as tornadoes, earthquakes, current local economic and demographic changes, the intensity and timing of yearly flu outbreaks. In addition, technological advances and pharmaceutical improvements may reduce the demand for healthcare services or the profitability of the services we offer.

e424b3

[Table of Contents](#)

If our fair value declines, a material non-cash charge to earnings from impairment of our goodwill could result.

As of March 31, 2011, we had approximately \$1,551.2 million of goodwill. We expect to recover the carrying value of this goodwill and evaluate annually, based on our fair value, whether the carrying value of our goodwill is impaired. If the carrying value of our goodwill is impaired, we may record a non-cash charge to earnings.

Certificate of need laws and regulations regarding licenses, ownership and operation may impair our future expansion in some states.

Some states require prior approval for the purchase, construction and expansion of healthcare facilities, based on the state's determination of the need for expanded healthcare facilities or services. Ten states in which we operate hospitals require a certificate of need for capital expenditures, changes in bed capacity or services, and for certain other planned activities. We may not be able to obtain certificates of need required for certain activities. In addition, all of the states in which we operate facilities require hospitals and most healthcare providers to maintain one or more licenses. If we are unable to obtain a certificate of need or license, our ability to operate or expand operations in those states could be impaired.

In states without certificate of need laws, competing providers of healthcare services are able to expand and construct facilities without regulatory approval.

In the seven states in which we operate that do not require certificates of need for the purchase, construction and expansion of healthcare facilities, healthcare providers face low barriers to entry and expansion. If competing providers of healthcare services are able to purchase, construct and operate facilities without the need for regulatory approval, we may face decreased market share and revenues in those markets.

Different interpretations of accounting principles could have a material adverse effect on our results of operations or financial condition.

Generally accepted accounting principles are complex, continually evolving and may be subject to varied interpretation by us, our independent accounting firm and the SEC. Such varied interpretations could result from differing views related to specific facts and circumstances. If the SEC or the courts interpret generally accepted accounting principles differently than we do, our results of operations or financial condition could be materially adversely affected.

Our stock price has been and may continue to be volatile; any significant decline may result in litigation.

The trading price of our common stock has been and may continue to be subject to wide fluctuations. This may result in stockholder litigation and management's time away from operations and could result in higher legal fees and proxy costs.

- Our stock price may fluctuate in response to the results of our operations and to a number of events and factors, including:
- actual or anticipated quarterly variations in operating results, particularly if they differ from investors' expectations;
- changes in financial estimates and recommendations by securities analysts;
- changes in government regulations including those relating to reimbursement and operational policies and procedures;
- the operating and stock price performance of other companies that investors may deem comparable;
- changes in overall economic factors in our markets;

e424b3

[Table of Contents](#)

- news reports relating to trends or events in our markets; and
- issues associated with integration of the hospitals that we acquire.

Broad market and industry fluctuations may adversely affect the price of our common stock, regardless of our operating performance.

As a result of the above factors, we could be subjected to potential stockholder lawsuits. Such lawsuits are time consuming and expensive. Such lawsuits divert management's time and attention from operations. Such lawsuits also force us to incur substantial legal fees and proxy costs.

Risks relating to the notes

Your ability to enforce the guarantees of the notes may be limited.

Although the notes are our obligations, they will be unconditionally guaranteed on an unsecured senior basis by certain of our domestic subsidiaries. Each guarantor of its obligations with respect to its guarantee may be subject to review under relevant federal and state fraudulent conveyance, bankruptcy or reorganization case or lawsuit by or on behalf of unpaid creditors of such subsidiary guarantor. Under these statutes, if a federal or state fraudulent conveyance statute that a subsidiary guarantor did not receive fair consideration or reasonably equivalent value for the notes, and that, at the time of such incurrence, the subsidiary guarantor: (i) was insolvent; (ii) was rendered insolvent by reason of such incurrence; or (iii) engaged in a business or transaction for which the assets remaining with such subsidiary guarantor constituted unreasonably small capital, then the court, subject to applicable statutes of limitation, may, in order to enforce the guarantor's obligations under its guarantee, recover payments made under the guarantee, subordinate the guarantee to other indebtedness of the guarantor, or take any other action detrimental to the holders of the notes.

In the event of a finding that a fraudulent transfer or conveyance occurred, you may not receive any repayment on the notes. In addition, the provision intended to limit the guarantor's liability to the maximum amount that it could incur without causing the incurrence of obligations under the fraudulent conveyance. This provision may not be effective to protect the guarantees from being voided under fraudulent conveyance laws, which may void the obligations or reduce the guarantor's obligations to an amount that effectively makes the guarantee worthless. In a recent Florida bankruptcy case, a provision was found to be ineffective to protect the guarantees. Further, the voidance of the notes could result in an event of default with respect to the debt that could result in acceleration of such debt.

The measure of insolvency for these purposes will depend upon the governing law of the relevant jurisdiction. Generally, however, a company is insolvent for these purposes if the sum of that company's debts is greater than the fair value of all of that company's property or if the company's assets are less than the amount that will be required to pay its probable liability on its existing debts as they become absolute and payable as they become due. Moreover, regardless of solvency, a court could void an incurrence of indebtedness, including such transaction was made with the intent to hinder, delay or defraud creditors. In addition, a court could subordinate the indebtedness, claims of all existing and future creditors on similar grounds. The guarantees also could be subject to the claim that, since the guarantee was only indirectly for the benefit of the subsidiary guarantors, the obligations of the subsidiary guarantors under the guarantees were incurred for no equivalent value or fair consideration.

There can be no assurance as to what standard a court would apply in order to determine whether a subsidiary guarantor was "insolvent" at the time that, regardless of the method of valuation, a court would not determine that the subsidiary guarantor was insolvent upon consummation of the transaction. If a court concludes that a guarantee is voided or limited on fraudulent conveyance grounds, other senior creditors of ours may have priority over the assets of the relevant guarantor.

e424b3

e424b3

[Table of Contents](#)

The notes will be structurally subordinated to all obligations of our non-guarantor subsidiaries and effectively subordinated to our

We are a holding company and hold most of our assets at, and conduct most of our operations through, direct and indirect subsidiaries. Our results of operations depend on the results of operations of our subsidiaries. Moreover, we are dependent on dividends or other intercompany payments from our subsidiaries to meet our debt service and other obligations. The ability of our subsidiaries to pay dividends or make other payments or to generate operating results and will be subject to applicable laws and restrictions contained in agreements governing the debt of such subsidiaries.

The claims of creditors of our non-guarantor subsidiaries, including trade creditors, will generally have priority as to the assets of such subsidiaries, including the holders of notes. As of March 31, 2011, the aggregate amount of debt of our non-guarantor subsidiaries, including intercompany payables, was approximately \$45.0 million. Our non-guarantor subsidiaries accounted for \$80.3 million, or 9.0%, of our total assets as of March 31, 2011 and \$358.8 million, or 8.4%, of our assets (excluding intercompany receivables) and \$45.0 million, or 2.0%, of our intercompany liabilities as of March 31, 2011.

In addition, the notes are our general unsecured obligations. Therefore, the notes will be effectively subordinated to our and the guarantors' secured debt to the value of the collateral. As of March 31, 2011, we and the guarantors' had approximately \$451.2 million of secured debt.

We are permitted to create unrestricted subsidiaries, which generally will not be subject to any of the covenants in the indenture, and the cash flow or assets of those unrestricted subsidiaries to pay our indebtedness.

Unrestricted subsidiaries will generally not be subject to the covenants under the indenture. Unrestricted subsidiaries may enter into contracts that may impair their ability to make loans or other payments to fund payments in respect of the notes. Accordingly, we may not be able to rely on the cash flow of our subsidiaries to pay any of our indebtedness, including the notes. See "Description of Notes" for further information.

Our ability to repurchase the notes upon a change of control or in connection with an asset sale repurchase may be limited.

In the event of certain changes of control involving us, you will have the right, at your option, to require us to purchase all or a portion of your notes at a purchase price equal to 101% of the aggregate principal amount of your notes, plus accrued interest thereon to the repurchase date. In addition, we may be required by the terms of the indenture to make an offer to repurchase notes with proceeds from asset sales. Our ability to repurchase the notes upon a change of control or in connection with an asset sale repurchase will be dependent on the availability of sufficient funds and our ability to comply with applicable laws. Accordingly, there can be no assurance that we will be in a position to repurchase the notes upon a change of control or in connection with an asset sale repurchase.

Also, our ability to repurchase the notes upon a change of control is materially limited by covenants in our senior secured credit facilities. A change of control of our company upon the occurrence of a change in control will constitute an event of default under the indenture governing the notes. This default will also constitute an event of default under our senior secured credit facilities and may constitute an event of default under any future agreement governing our senior secured credit facilities. The related indebtedness to be accelerated after any applicable notice or cure periods. If such indebtedness were to be accelerated, we may not have sufficient funds to repurchase the Notes and repay the indebtedness.

The term "change of control" under the indenture is limited to certain specified transactions and may not include other events that may result in a downgrade of the credit rating (if any) of the notes, nor would the requirement that we offer to repurchase the notes necessarily afford holders of the notes protection in the event of a highly leveraged reorganization. See "Description of Notes—Repurchase Rights—Change of control."

e424b3

[Table of Contents](#)

We must rely on payments from our subsidiaries to make cash payments on the Notes, and our subsidiaries are subject to various payments.

We are a holding company and hold our assets at, and conduct our operations through, direct and indirect subsidiaries. In order to meet our other obligations, we depend upon receiving payments from our subsidiaries. In particular, we may be dependant on dividends and payments from indirect subsidiaries to service our obligations. You will not have any direct claim on the cash flow or assets of our non-guarantor operating subsidiaries. Our non-guarantor operating subsidiaries have no obligation, contingent or otherwise, to pay amounts due under the notes or the subsidiary guarantors for those payments. In addition, the payment of dividends and the making of loans and advances to us by our subsidiaries may be subject to the and future debt of certain of these subsidiaries may prohibit the payment of dividends or the making of loans or advances to us. In addition, our ability to make payments, loans or advances to us may be limited by the laws of the relevant jurisdictions in which such subsidiaries are organized. The events described above could make it more difficult for a guarantor to service its obligations and therefore adversely affect our ability to service the notes. If payments are not made to us by our subsidiaries, we may not have any other sources of funds available that would permit us to service the notes.

There is currently no public market for the notes, and an active trading market may not develop for the notes. The failure of a market to develop may adversely affect the liquidity and value of your notes.

The notes are a new issue of securities, and there is no existing market for the notes. We do not intend to apply for listing of the notes on any stock exchange or quotation of the notes on any automated dealer quotation system. We have been advised by the initial purchasers that following the completion of the offering, the initial purchasers currently intend to make a market in the notes. However, they are not obligated to do so and any market-making activity may be discontinued by them at any time without notice. In addition, any market-making activity will be subject to limits imposed by law. A market may not develop and there can be no assurance as to the liquidity of any market that may develop for the notes. If an active, liquid market does not develop, the liquidity and liquidity of the notes may be adversely affected. If any of the notes are traded after their initial issuance, they may trade at a discount to their face value.

The liquidity of the trading market, if any, and future trading prices of the notes will depend on many factors, including, among others, our operating results, financial performance and prospects, the market for similar securities and the overall securities market, and may be affected by changes in these factors.

A breach of a covenant in our debt instruments could cause acceleration of a significant portion of our outstanding indebtedness.

A breach of a covenant or other provision in any debt instrument governing our current or future indebtedness could result in a default under such instrument. Our ability to comply with these covenants and other provisions may be affected by events beyond our control, and we cannot assure you that we will be able to comply with these covenants and other provisions. Upon the occurrence of an event of default under any debt instrument, the lenders or holders of such debt instruments could declare all amounts outstanding to be immediately due and payable and terminate all commitments to extend further credit. If we were to default under such debt instruments, the lenders or holders of such debt instruments could proceed against collateral granted to them, if any, to secure the indebtedness. If our current or future assets or such debt instruments accelerate the payment of the indebtedness owed to them, we cannot assure you that our assets would be sufficient to pay the indebtedness.

If the notes are rated investment grade at any time by both Standard & Poor's Ratings Service and Moody's Investors Service, Inc., the ratings contained in the indenture governing the notes will be suspended.

If, at any time, the credit rating on the notes, as determined by both Standard & Poor's Ratings Service or Moody's Investors Service, Inc., is Baa3, respectively, or any equivalent replacement ratings, and no default has occurred and is continuing under the indenture then, we will not be in default under the indenture.

e424b3

[Table of Contents](#)

restrictive covenants contained in the indenture governing the notes. As a result, you may have less credit protection than you will at the event that one or both of the ratings later drops below investment grade, we will thereafter again be subject to such restrictive covenants.

Insurance coverage in the future may not continue to be available at a cost allowing us to maintain adequate levels of insurance with one or more of our insurance carriers may become insolvent and unable to fulfill its obligation to defend, pay or reimburse us when that obligation arises. Physicians using our hospitals may be unable to obtain insurance on acceptable terms, which could result in these physicians not being able to meet requirements in the applicable hospital medical staff bylaws or necessitate a reduction in the level of insurance required to be carried under the applicable hospital medical staff bylaws.

As a result of the above factors, we could be subjected to potential stockholder lawsuits. Such lawsuits are time consuming and expensive. Lawsuits divert management's time and attention from operations. Such lawsuits also force us to incur substantial legal fees and proxy costs.

Risks relating to the exchange offer

If you do not exchange your outstanding notes in the exchange offer, the transfer restrictions currently applicable to your outstanding notes and the market price of your outstanding notes could decline.

If you do not exchange your outstanding notes for exchange notes in the exchange offer, then you will continue to be subject to the transfer restrictions on your outstanding notes as set forth in the prospectus distributed in connection with the private offering of the outstanding notes. In general, the outstanding notes are not offered or sold unless they are registered, or exempt from registration, under the Securities Act (including pursuant to Rule 144 under the Securities Act, if available) and applicable state securities laws. Except as required by the registration rights agreement, we do not intend to register resale of the outstanding notes under the Securities Act. You should refer to "Prospectus Summary—The Exchange Offer" and "The Exchange Offer" for information on how to exchange your outstanding notes.

The tender of outstanding notes under the exchange offer will reduce the aggregate principal amount of the outstanding notes, which may increase the volatility of, the market prices of the outstanding notes due to reduction in liquidity. In addition, if you do not exchange your outstanding notes in the exchange offer, you will no longer be entitled to exchange your outstanding notes for exchange notes registered under the Securities Act. You will not be able to have your outstanding notes registered for resale under the Securities Act.

Your ability to transfer the exchange notes may be limited by the absence of an active trading market, and there is no assurance that an active market will develop for the exchange notes.

We do not intend to apply for listing of the exchange notes on a securities exchange or market. The exchange notes are a new issue of debt securities and do not have an established public market. The initial purchasers in the private offering of the outstanding notes have advised us that they intend to make a market in the exchange notes, as permitted by applicable laws and regulations; however, the initial purchasers are not obligated to make a market in any of the exchange notes, and their market-making activities at any time without notice. In addition, such market-making activity may be limited during the pendency of the exchange offer. An active market for any of the exchange notes may not develop or, if developed, it may not continue. In addition, subsequent to their initial offering, the market price of the exchange notes may trade at a discount from their initial offering price, depending upon prevailing interest rates, the market for similar notes, our performance, and other factors.

e424b3

[Table of Contents](#)

USE OF PROCEEDS

We will not receive any cash proceeds from the issuance of the exchange notes pursuant to the exchange offer. In consideration for the exchange offer contemplated in this prospectus, we will receive in exchange a like principal amount of outstanding notes, the terms of which are identical to the terms of the exchange notes, except that the exchange notes will not contain terms with respect to transfer restrictions, registration rights or special dividend payments in certain of our obligations under the registration rights agreement. The outstanding notes surrendered in exchange for the exchange notes cannot be reissued. Accordingly, the issuance of the exchange notes will not result in any change in our capitalization.

e424b3

Table of Contents

RATIO OF EARNINGS TO FIXED CHARGES

The following table sets forth our ratio of earnings to fixed charges for the years ended December 31, 2010, 2009, 2008, 2007 and 2006, and March 31, 2011 and 2010. For the purpose of determining the ratio of earnings to fixed charges, “earnings” consist of earnings (loss) before income taxes (benefit) plus fixed charges, and “fixed charges” consist of interest expense, including amortization of deferred financing costs, plus depreciation expense, which is representative of the interest factor.

	Year Ended December 31,				
	2010	2009	2008	2007	2006
Ratio of earnings to fixed charges	3.02x	2.93x	2.73x	2.59x	2.87x

e424b3

[Table of Contents](#)

CAPITALIZATION

The following table sets forth our consolidated cash and cash equivalents and our consolidated capitalization as of March 31, 2011. In connection with our consolidated financial statements and related notes incorporated by reference in this prospectus.

Cash and cash equivalents

Debt:

Senior Secured Credit Facilities:
 \$350.0 million Revolving Credit Facility due 2012(1)
 Term B Loans due 2011 and 2012
 Term B Loans due 2015
6.625% Senior Notes, due 2020
7.50% Province Senior Subordinated Notes due 2013
3.50% Convertible Senior Subordinated Notes due 2014
3.25% Convertible Senior Subordinated Debentures, due 2025
Capital lease obligations
Subtotal
Unamortized discount of convertible debt instruments
Total Debt

Equity:

LifePoint Hospitals, Inc. stockholders' equity:
Preferred stock, \$0.01 par value; 10,000,000 shares authorized; no shares issued
Common stock, \$0.01 par value; 90,000,000 shares authorized; 62,471,721 shares issued at March 31, 2011
Capital in excess of par value
Accumulated other comprehensive loss
Retained earnings
Common stock in treasury, at cost, 10,135,495 shares at March 31, 2011
Total LifePoint Hospitals, Inc. stockholders' equity:
Noncontrolling interests
Total equity
Total capitalization

(1) Excludes approximately \$31.1 million of outstanding letters of credit.

e424b3

e424b3

[Table of Contents](#)

SELECTED CONSOLIDATED FINANCIAL DATA

The following selected consolidated financial data is derived from our audited consolidated financial statements for the fiscal years ended December 31, 2010, 2009, 2008, 2007 and 2006 and from our unaudited consolidated financial statements for the three months ended March 31, 2011 and 2010. The statements have been prepared on the same basis as our audited consolidated financial statements and, in our opinion, include all adjustments, including recurring adjustments, that we consider necessary for a fair presentation of our results of operations for such periods. Operating results for any period are necessarily indicative of the results that may be expected for any future period.

This information is only a summary and should be read in conjunction with the more detailed information contained in our Consolidated Financial Statements and related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2010 and our Quarterly Report on Form 10-Q for the period ended March 31, 2011, which are incorporated by reference.

(Dollars in millions)	Year Ended December 31,				
	2010	2009	2008	2007	2006
Revenues	\$ 3,262.4	\$ 2,962.7	\$ 2,700.8	\$ 2,568.4	\$ 2,336.5
Salaries and benefits	1,270.3	1,170.9	1,065.4	1,006.1	918.0
Supplies	443.0	409.1	372.6	352.2	326.1
Other operating expenses	605.2	538.0	499.8	464.0	397.4
Provision for doubtful accounts	443.8	375.4	313.2	307.0	250.0
Depreciation and amortization	148.5	143.0	132.1	129.4	105.4
Interest expense, net	108.1	103.2	107.7	107.4	105.5
Debt extinguishment costs	2.4	—	—	—	—
Impairment charges	—	1.1	1.2	—	—
	<u>3,021.3</u>	<u>2,740.7</u>	<u>2,492.0</u>	<u>2,366.1</u>	<u>2,102.4</u>
Income from continuing operations before income taxes	241.1	222.0	208.8	202.3	234.1
Provision for income taxes	<u>82.4</u>	<u>80.3</u>	<u>79.9</u>	<u>80.5</u>	<u>91.2</u>
Income from continuing operations	158.7	141.7	128.9	121.8	142.9
Less: Net income attributable to noncontrolling interests	<u>(3.1)</u>	<u>(2.5)</u>	<u>(2.2)</u>	<u>(1.7)</u>	<u>(1.4)</u>
Income from continuing operations attributable to LifePoint Hospitals, Inc.	<u>\$ 155.6</u>	<u>\$ 139.2</u>	<u>\$ 126.7</u>	<u>\$ 120.1</u>	<u>\$ 141.5</u>

(Dollars in millions)	Year Ended December 31,				
	2010	2009	2008	2007	2006
Balance Sheet Data (as of end of period):					
Cash & cash equivalents	\$ 207.4	\$ 187.2	\$ 75.7	\$ 53.1	\$ 12.2
Working capital	\$ 498.8	\$ 485.9	\$ 376.2	\$ 373.6	\$ 377.7

e424b3

Property & equipment, net	\$ 1,668.6	\$ 1,499.4	\$ 1,416.0	\$ 1,383.0	\$ 1,305.4
Total assets	\$ 4,162.9	\$ 3,873.3	\$ 3,680.3	\$ 3,635.9	\$ 3,638.3
Total debt, excluding unamortized discount of convertible debt instruments	\$ 1,651.7	\$ 1,502.2	\$ 1,516.7	\$ 1,517.1	\$ 1,668.5
Total LifePoint Hospitals, Inc stockholders' equity	\$ 1,887.5	\$ 1,827.7	\$ 1,652.0	\$ 1,629.1	\$ 1,471.5

e424b3

[Table of Contents](#)

(Dollars in millions)	Year Ended December 31,				
	2010	2009	2008	2007	2006
Additional Financial Data:					
Purchases of property and equipment	\$ 168.7	\$ 166.6	\$ 157.6	\$ 158.4	\$ 194.0
Net cash provided by operating activities—continuing operations	\$ 375.7	\$ 350.3	\$ 346.6	\$ 241.4	\$ 257.8
Net cash used in investing activities—continuing operations	\$ (353.6)	\$ (244.1)	\$ (185.3)	\$ (158.3)	\$ (475.8)
Net cash (used in) provided by financing activities—continuing operations	\$ (0.3)	\$ (13.9)	\$ (119.3)	\$ (165.6)	\$ (148.5)

e424b3

[Table of Contents](#)

DESCRIPTION OF OTHER INDEBTEDNESS

Credit Agreement

Terms

Our credit agreement with Citicorp North America, Inc., as administrative agent and the lenders time to time party thereto, Bank of America, N.A., SunTrust Bank and UBS Securities LLC, as co-syndication agents and Citigroup Global Markets Inc. as sole lead arranger and sole bookrunner, provides for Term B Loans, Term A Loans and Revolving Loans. The maturity date of our Term B Loans is contingent upon the refinancing of our Term B Loans beyond their current maturity date of May 15, 2014. Assuming that we refinance our outstanding 3½% Notes beyond their current maturity date on April 15, 2015. If we do not refinance our outstanding 3½% Notes at least 91 days prior to their current maturity date our Term B Loans will mature on February 13, 2014. Additionally, our Term B Loans are subject to additional mandatory prepayments with a certain percentage of excess cash flow and the occurrence of certain other events, as specifically described in our Credit Agreement. Our Term A Loans and our Revolving Loans commenced in 2012. Our Credit Agreement is guaranteed on a senior secured basis by our subsidiaries with certain limited exceptions.

Letters of Credit and Availability

Our Credit Agreement provides for the issuance of letters of credit up to \$75.0 million. As of March 31, 2011, we had \$31.1 million of letters of credit. The letters of credit were related to the self-insured retention level of our general and professional liability insurance and workers' compensation programs. Issued letters of credit reduce the amounts available under our Revolving Loans. In accordance with the terms of our Credit Agreement, the total amount of borrowing were \$318.9 million as of March 31, 2011.

Our Credit Agreement contains uncommitted "accordion" features that permit us to borrow at a later date additional aggregate principal amount of Term B Loans, \$250.0 million of Term A Loans and \$300.0 million of Revolving Loans, subject to obtaining additional lender commitments and other conditions.

Interest Rates

Interest on the outstanding balance of the Term B Loans is payable at an adjusted LIBOR plus a margin of 2.750%. Interest on the Revolving Loans is payable at option at either an adjusted base rate or an adjusted LIBOR plus a margin. The margin on Revolving Loans subject to an adjusted base rate is 2.00% to 2.75% based on our total leverage ratio. The margin on the Revolving Loans subject to an adjusted LIBOR ranges from 2.00% to 2.75% based on our total leverage ratio.

As of March 31, 2011, the applicable annual interest rate under the Term B Loans was 3.07%, which was based on the 90-day Adjusted LIBOR margins. The 90-day Adjusted LIBOR was 0.32% at March 31, 2011. The weighted-average applicable annual interest rate for the three months ended March 31, 2011, under the Term B Loans was 3.09%.

Covenants

Our Credit Agreement requires us to satisfy certain financial covenants, including a minimum interest coverage ratio and a maximum total leverage ratio. The interest coverage ratio can be no less than 3.50:1.00 and the total leverage ratio cannot exceed 3.75:1.00, both determined on a trailing four quarter basis. Our Credit Agreement generally limits the amount we can spend on capital expenditures to no more than 10.0% of annual revenues. We were in compliance with all covenants as of March 31, 2011.

In addition, our Credit Agreement contains customary affirmative and negative covenants, which among other things, limit our ability to incur additional debt, liens, pay dividends, effect transactions with our affiliates,

e424b3

e424b3

[Table of Contents](#)

sell assets, pay subordinated debt, merge, consolidate, enter into acquisitions and effect sale leaseback transactions. It does not contain maturity dates upon a downgrade in our credit rating. However, a downgrade in our credit rating could adversely affect our ability to obtain financing in the future and could increase our cost of borrowings.

Interest Rate Swap

We have an interest rate swap agreement with Citibank, N. A. as counterparty that requires us to make quarterly fixed rate payments on a notional amount at an annual fixed rate of 5.585% while Citibank, N. A. is obligated to make quarterly floating payments to us based on the same referenced notional amount.

3.5% Convertible Senior Subordinated Notes due 2014

Our convertible senior subordinated notes bear interest at the rate of 3.5% per year, payable semi-annually on May 15 and November 15. Our convertible senior subordinated notes are convertible prior to March 15, 2014 under the following circumstances: (1) if the price of our common stock reaches a specified threshold during the specified periods; (2) if the trading price of our convertible senior subordinated notes is below a specified threshold; or (3) upon the occurrence of certain transactions or other events. On or after March 15, 2014, holders may convert our convertible senior subordinated notes at any time prior to the scheduled trading day immediately preceding May 15, 2014, regardless of whether any of the foregoing circumstances has occurred.

Subject to certain exceptions, we will deliver cash and shares of our common stock upon conversion of each \$1,000 principal amount of our convertible senior subordinated notes as follows: (i) an amount in cash, which we refer to as the principal return, equal to the sum of, for each of the 20 volume-weighted average price trading days during the conversion period, the lesser of the daily conversion value for such volume-weighted average price trading day and \$50; and (ii) an amount equal to the sum of, for each of the 20 volume-weighted average price trading days during the conversion period, any excess of the daily conversion value over \$50. Our ability to pay the principal return in cash is subject to important limitations imposed by the credit agreement governing our senior credit facilities or indebtedness we may incur in the future. If we do not make any payments we are obligated to make under the terms of our convertible senior subordinated notes, holders may declare an event of default.

The initial conversion rate is 19.3095 shares of our common stock per \$1,000 principal amount of our convertible senior subordinated notes. This represents an initial conversion price of approximately \$51.79 per share of our common stock. In addition, if certain corporate transactions or control occur prior to maturity, we will increase the conversion rate in certain circumstances.

Upon the occurrence of a fundamental change (as specified in the indenture), each holder of our convertible senior subordinated notes will be entitled to receive, in cash or kind, all of our convertible senior subordinated notes at a purchase price in cash equal to 100% of the principal amount of the 3.5% Notes plus any unpaid interest.

The indenture governing our convertible senior subordinated notes does not contain any financial covenants or any restrictions on the incurrence of senior or secured debt or other indebtedness, or the issuance or repurchase of securities by us. The indenture contains no other provisions to protect holders of our convertible senior subordinated notes in the event of a highly leveraged transaction or other events that do not constitute a fundamental change.

3.25% Convertible Senior Subordinated Debentures due August 15, 2025

Our 3.25% convertible senior subordinated debentures due August 15, 2025 bear interest at the rate of 3.25% per year, payable semi-annually on August 15. Our convertible senior subordinated debentures are convertible (subject to certain limitations imposed by the credit agreement governing our senior credit facilities) under the following circumstances: (1) if the price of our common stock reaches a specified threshold during the specified periods; (2) if the trading price of our convertible senior subordinated debentures is below a specified threshold; (3) if our convertible senior subordinated debentures have a specified trading price; or (4) if

e424b3

e424b3

[Table of Contents](#)

specified corporate transactions or other specified events occur. Subject to certain exceptions, we will deliver cash and shares of our common stock, an amount in cash, which we refer to as the principal return, equal to the lesser of (a) the principal amount of our convertible senior subordinated debentures, which we refer to as the conversion value; and (ii) if the conversion value is greater than the principal return, an amount in cash. Our ability to pay the principal return in cash is subject to important limitations imposed by the credit agreement governing our senior secured credit facilities, in the event of indebtedness we may incur in the future. Based on the terms of the credit agreement governing our senior secured credit facilities, in the event the foregoing conditions to conversion have occurred, our convertible senior subordinated debentures will not be convertible, and holders of our convertible senior subordinated debentures will not be able to declare an event of default under our convertible senior subordinated debentures.

The initial conversion rate for our convertible senior subordinated debentures is 16.3345 shares of our common stock per \$1,000 principal amount of our convertible senior subordinated debentures (subject to adjustment in certain events). This is equivalent to a conversion price of \$61.22 per share of our common stock. If certain corporate transactions that constitute a change of control occur on or prior to February 20, 2013, we will increase the conversion rate in the event a transaction constitutes a public acquirer change of control and we elect to modify the conversion rate into public acquirer common stock.

On or after February 20, 2013, we may redeem for cash some or all of our convertible senior subordinated debentures at any time at the principal amount of our convertible senior subordinated debentures to be purchased, plus any accrued and unpaid interest. Holders may tender some or all of our convertible senior subordinated debentures on February 15, 2013, February 15, 2015 and February 15, 2020 or upon the occurrence of a change, at 100% of the principal amount of our convertible senior subordinated debentures to be purchased, plus any accrued and unpaid interest.

The indenture governing our convertible senior subordinated debentures does not contain any financial covenants or any restrictions on our ability to incur or secure debt or other indebtedness, or the issuance or repurchase of securities by us. The indenture contains no provisions to protect holders of our convertible senior subordinated debentures in the event of a highly leveraged transaction or fundamental change.

e424b3

[Table of Contents](#)

THE EXCHANGE OFFER

General

We are offering to exchange a like principal amount of exchange notes for any or all outstanding notes on the terms and subject to the prospectus and accompanying letter of transmittal. We refer to the offer as the “exchange offer.” You may tender some or all of your outstanding exchange offer.

As of the date of this prospectus, \$400,000,000 aggregate principal amount of 6.625% Senior Notes due 2020 is outstanding. This prospectus, transmittal, is first being sent to all registered holders of outstanding notes known to us on or about June 1, 2011. Our obligation to accept pursuant to the exchange offer is subject to the satisfaction or waiver of certain conditions set forth under “—Conditions to the Exchange Offer.” Each of the conditions will be satisfied and that no waivers will be necessary.

Purpose and Effect of the Exchange Offer

In connection with the private offering and sale of the outstanding notes, we and the guarantors of the notes entered into a registration rights agreement with the purchasers of the outstanding notes in which we agreed, under certain circumstances, to file a registration statement relating to an offer to exchange notes. The following description of the registration rights agreement is only a brief summary of the agreement. It does not constitute a contract, qualified in its entirety by reference to all of the terms, conditions and provisions of the registration rights agreement. For further information, see the registration rights agreement attached as an exhibit to our Current Report on Form 8-K filed with the SEC on September 27, 2010. We also agreed to make efforts to cause the exchange offer to be consummated on the earliest practicable date after the exchange offer registration statement has been filed, but not later than the 360th day following the issuance date of the outstanding notes. The form and terms of the exchange notes will be identical to the form and terms of the outstanding notes, except that the exchange notes will be registered under the Securities Act, and will not contain term provisions for registration rights and additional payments upon a failure to fulfill certain of our obligations under the registration rights agreement. The registration rights agreement was dated September 23, 2010.

Pursuant to the registration rights agreement and under the circumstances set forth below, we and the guarantors of the notes will use our best efforts to cause the SEC to declare effective a shelf registration statement with respect to the resale of the outstanding notes within the time period specified in the agreement and to keep the shelf registration statement effective for up to two years after the effective date of the shelf registration statement.

- if we determine that this exchange offer is not permitted because it would violate any applicable law or applicable interpretation of applicable law;
- if for any other reason the exchange offer is not consummated within 360 days after the issuance date of the outstanding notes; or
- any holder notifies the Company prior to the 20th business day following the consummation of the exchange offer that:
 - (A) the holder is prohibited by law or SEC policy from participating in the exchange offer
 - (B) the holder may not resell the exchange notes acquired by it in the exchange offer to the public without delivering a prospectus, and the exchange offer registration statement is not appropriate or available for such resales by such holder; or
 - (C) such holder is an initial purchaser and holds exchange notes acquired directly from the Company and any of its affiliates.

e424b3

[Table of Contents](#)

If we fail to comply with specified obligations under the registration rights agreement, we will be required to pay special interest to L

These obligations include:

- the obligation to consummate the exchange offer within 360 days after the issuance date of the outstanding notes;
- the obligation to cause a shelf registration statement, if required, to be filed within the applicable timeframes required by the re
- the obligation to cause a shelf registration statement, if required, to be declared effective within the applicable timeframes requ
- the obligation to keep the exchange offer registration statement or the shelf registration statement, as the case may be, effective during the periods specified in the registration rights agreement.

If you wish to exchange your outstanding notes for exchange notes in the exchange offer, you will be required to make the following

- you are not our “affiliate” or an “affiliate” of any guarantor of the notes;
- you are not engaged in, and do not intend to engage in, a distribution of the exchange notes; and
- you will acquire the exchange notes in the ordinary course of your business.

Each broker-dealer that receives exchange notes for its own account in exchange for outstanding notes, where the broker-dealer acq of market-making activities or other trading activities, must acknowledge that (i) it has not entered into any arrangement or understandi of the Company to distribute such exchange notes and (ii) it will deliver a prospectus, as required by law, in connection with any resale of Distribution.” Any broker-dealer who holds outstanding securities acquired for its own account as a result of market-making activitie receives exchange notes in exchange for such outstanding notes pursuant to the exchange offer, may be considered an underwriter; how delivering a prospectus, such broker-dealer will not be deemed to admit that it is an “underwriter” within the meaning of the Securities

Resale of Exchange Notes

Based on interpretations by the SEC set forth in no-action letters issued to third parties, we believe that you may resell or otherwise exchange offer without complying with the registration and prospectus delivery provisions of the Securities Act, if:

- you are acquiring the exchange notes in the ordinary course of your business;
- you do not have an arrangement or understanding with any person to participate in a distribution of the exchange notes;
- you are not our “affiliate” or an “affiliate” of any guarantor of the notes as defined by Rule 405 of the Securities Act; and
- you are not engaged in, and do not intend to engage in, a distribution of the exchange notes.

If you are our “affiliate,” or are engaging in, or intend to engage in, or have any arrangement or understanding with any person to pa exchange notes, or are not acquiring the exchange notes in the ordinary course of your business, then:

- you cannot rely on the position of the SEC set forth in Morgan Stanley & Co. Incorporated (available June 5, 1991) and Exxon (available May 13, 1988), as interpreted in the SEC’s letter to Shearman & Sterling, dated July 2, 1993, or similar no-action let
- in the absence of an exception from the position stated immediately above, you must comply with the registration and prospect Securities Act in connection with any resale of the exchange notes.

e424b3

e424b3

[Table of Contents](#)

This prospectus may be used for an offer to resell, or for the resale or other transfer of exchange notes only as specifically set forth in the prospectus. Only broker-dealers, only broker-dealers that acquired the outstanding notes as a result of market-making activities or other trading activities may offer. Each broker-dealer that receives exchange notes for its own account in exchange for outstanding notes where such outstanding notes were acquired by a broker-dealer as a result of market-making activities or other trading activities must acknowledge that it has not entered into any arrangement or understanding with or an affiliate of the Company to distribute such exchange notes and that it will deliver a prospectus in connection with any resale of the exchange notes. For more details regarding the transfer of exchange notes. Any broker-dealer who holds outstanding securities acquired by a broker-dealer as a result of market-making activities or other trading activities and who receives exchange notes in exchange for such outstanding notes pursuant to the exchange offer is not considered an underwriter; however, by so acknowledging and delivering a prospectus, such broker-dealer will not be deemed to admit to being an underwriter for the purposes of the Securities Act.

Terms of the Exchange Offer

On the terms and subject to the conditions set forth in this prospectus and in the accompanying letter of transmittal, we will accept for exchange any outstanding notes that are validly tendered and not validly withdrawn prior to the expiration date. Outstanding notes may only be tendered in whole and integral multiples of \$1,000 in excess of \$2,000; provided, that the untendered portion of any outstanding note must be in a minimum of \$2,000 principal amount or an integral multiple of \$1,000 of exchange notes in exchange for a corresponding principal amount of exchange notes. In exchange for each outstanding note surrendered in the exchange offer, we will issue exchange notes with a like principal amount.

The form and terms of the exchange notes will be identical in all material respects to the form and terms of the outstanding notes, except that the exchange notes will be registered under the Securities Act and will not contain terms with respect to transfer restrictions, registration rights and additional payments. The exchange notes will be issued under and entitled to the benefits of the indenture governing the outstanding notes. For a description of the indenture, see “Description of the Notes.”

The exchange offer is not conditioned upon any minimum aggregate principal amount of outstanding notes being tendered for exchange.

As of the date of this prospectus, \$400,000,000 aggregate principal amount of the 6.625% Senior Notes due 2020 is outstanding. The accompanying letter of transmittal is being sent to all registered holders of outstanding notes. There will be no fixed record date for determining registered holders eligible to participate in the exchange offer.

We intend to conduct the exchange offer in accordance with the provisions of the registration rights agreement, the applicable requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations of the SEC. Outstanding notes that are tendered in the exchange offer will remain outstanding and continue to accrue interest and will be entitled to the rights and benefits that such holders have under such holders’ outstanding notes and the registration rights agreement, except we will not have any further obligations to provide for the exchange of such notes under the registration rights agreement.

We will be deemed to have accepted for exchange properly tendered outstanding notes when we have given written notice of the exchange offer. The exchange agent will act as agent for the tendering holders for the purposes of receiving the exchange notes from us and delivering exchange notes to the tendering holders. In accordance with the terms of the registration rights agreement, we expressly reserve the right to amend or terminate the exchange offer and to refuse to accept tendered notes upon the occurrence of any of the conditions specified below under “—Conditions to the Exchange Offer.”

If you tender your outstanding notes in the exchange offer, you will not be required to pay brokerage commissions or fees or, subject to the terms of the registration rights agreement, transfer taxes with respect to the exchange of outstanding notes. We will pay all charges and expenses, other than certain applicable taxes, in connection with the exchange offer. It is important that you read “—Fees and Expenses” below for more details regarding fees and expenses.

e424b3

e424b3

[Table of Contents](#)

Expiration Date, Extensions and Amendments

As used in this prospectus, the term “expiration date” means 11:59 p.m., New York City time, on June 28, 2011. However, if we, in our sole discretion, extend the period of time for which the exchange offer is open, the term “expiration date” will mean the latest time and date to which we shall have extended the offer.

To extend the period of time during which an exchange offer is open, we will notify the exchange agent of any extension by written notice, press release or other public announcement to the registered holders of the outstanding notes no later than 9:00 a.m., New York City time, on the day of the previously scheduled expiration date.

We reserve the right, in our sole discretion:

- to delay accepting for exchange any outstanding notes (only in the case that we amend or extend the exchange offer);
- to extend the exchange offer or to terminate the exchange offer if any of the conditions set forth below under “—Conditions to the Exchange Offer” are not satisfied by giving written notice of such delay, extension or termination to the exchange agent; and
- subject to the terms of the registration rights agreement, to amend the terms of the exchange offer in any manner. In the event of an amendment to the exchange offer, including the waiver of a material condition, we will extend the offer period, if necessary, so that at least five business days elapse following notice of the material change.

Any delay in acceptance, extension, termination or amendment will be followed as promptly as practicable by written notice to the registered holders of the notes. If we amend an exchange offer in a manner that we determine to constitute a material change, we will promptly disclose the amendment and the date calculated to inform the holders of applicable outstanding notes of that amendment.

Conditions to the Exchange Offer

Despite any other term of the exchange offer, we will not be required to accept for exchange, or to issue exchange notes in exchange for, any outstanding notes that may terminate or amend the exchange offer as provided in this prospectus prior to the expiration date if in our reasonable judgment:

- the exchange offer, or the making of any exchange by a holder, violates any applicable law or interpretation of the SEC;
- any action or proceeding has been instituted or threatened in writing in any court or by or before any governmental agency with the result that, in our judgment, would reasonably be expected to impair our ability to proceed with the exchange offer.

In addition, we will not be obligated to accept for exchange the outstanding notes of any holder that has not made to us:

- the representations described under “—Purpose and Effect of the Exchange Offer” and “—Procedures for Tendering Outstanding Notes for Exchange or Distribution;” and
- any other representations as may be reasonably necessary under applicable SEC rules, regulations, or interpretations to make a successful registration of the exchange notes under the Securities Act.

We expressly reserve the right at any time or at various times to extend the period of time during which the exchange offer is open. Our extension of the exchange offer will be by acceptance of any outstanding notes by giving oral or written notice of such extension to their holders. We will return any outstanding notes not accepted for exchange.

e424b3

e424b3

[Table of Contents](#)

for any reason without expense to their tendering holder promptly after the expiration or termination of the exchange offer.

We expressly reserve the right to amend or terminate the exchange offer and to reject for exchange any outstanding notes not previously tendered upon the occurrence of any of the conditions of the exchange offer specified above. We will give oral or written notice of any extension, amendment or termination to the holders of the outstanding notes as promptly as practicable. In the case of any extension, such notice will be issued no later than 5 business days after the next business day after the previously scheduled expiration date.

These conditions are for our sole benefit, and we may assert them regardless of the circumstances that may give rise to them or waive them at various times prior to the expiration date in our sole discretion. If we fail at any time to exercise any of the foregoing rights, this failure shall not constitute a waiver of such right. Each such right will be deemed an ongoing right that we may assert at any time or at various times prior to the expiration date.

In addition, we will not accept for exchange any outstanding notes tendered, and will not issue exchange notes in exchange for any such notes at any time any stop order is threatened or in effect with respect to the registration statement of which this prospectus constitutes a part or the Securities Act of 1933 or the Trust Indenture Act of 1939, as amended.

Procedures for Tendering Outstanding Notes

To tender your outstanding notes in the exchange offer, you must comply with either of the following:

- complete, sign and date the letter of transmittal or a facsimile of the letter of transmittal, have the signature(s) on the letter of transmittal, and mail or deliver such letter of transmittal or facsimile thereof to the exchange agent at the address set forth in the "Exchange Agent—Notes" prior to the expiration date; or
- comply with DTC's Automated Tender Offer Program procedures described below.

In addition, you will comply with either of the following conditions:

- the exchange agent must receive certificates for outstanding notes along with the letter of transmittal prior to the expiration date;
- the exchange agent must receive a timely confirmation of book-entry transfer of outstanding notes into the exchange agent's account, and you must comply with the procedures for book-entry transfer described below including a properly transmitted agent's message prior to the expiration date;
- you must comply with the guaranteed delivery procedures described below.

Your tender, if not withdrawn prior to the expiration date, constitutes an agreement between us and you upon the terms and subject to the conditions set forth in this prospectus and in the letter of transmittal.

The method of delivery of outstanding notes, letters of transmittal and all other required documents to the exchange agent is at your option. You may elect to have the exchange agent deliver the documents to you by mail, or that instead of delivery by mail, you use an overnight or hand delivery service, properly insured. In all cases, you should allow sufficient time for delivery to the exchange agent before the expiration date. You should not send letters of transmittal or certificates representing outstanding notes to the exchange agent by broker, dealer, commercial bank, trust company or nominee effect the above transactions for you.

If you are a beneficial owner whose outstanding notes are held in the name of a broker, dealer, commercial bank, trust company, or other nominee, and you wish to tender your outstanding notes, you should promptly instruct the registered holder to tender outstanding notes on your behalf. If you wish to tender your own notes, you must, prior to completing and executing the letter of transmittal and delivering your outstanding notes, either:

e424b3

e424b3

Table of Contents

- make appropriate arrangements to register ownership of the outstanding notes in your name; or
- obtain a properly completed bond power from the registered holder of outstanding notes.

The transfer of registered ownership may take considerable time and may not be able to be completed prior to the expiration date.

Signatures on the letter of transmittal or a notice of withdrawal, as the case may be, must be guaranteed by a member firm of a registered clearing organization, a member of the Financial Industry Regulatory Authority, a commercial bank or trust company having an office or correspondent in the United States, or a "qualified institution" within the meaning of Rule 17A(d)-15 under the Exchange Act unless the outstanding notes surrendered for exchange are to be

- by a registered holder of the outstanding notes who has not completed the box entitled "Special Registration Instructions" or "Special Instructions" on the letter of transmittal; or
- for the account of an eligible guarantor institution.

If the letter of transmittal is signed by a person other than the registered holder of any outstanding notes listed on the outstanding notes, the letter must be endorsed or accompanied by a properly completed bond power. The bond power must be signed by the registered holder as the registered holder of the outstanding notes and an eligible guarantor institution must guarantee the signature on the bond power.

If the letter of transmittal or any certificates representing outstanding notes or bond powers are signed by trustees, executors, administrators, officers of corporations, or others acting in a fiduciary or representative capacity, those persons should also indicate when signing and, if applicable, also submit evidence satisfactory to us of their authority to so act.

The exchange agent and DTC have confirmed that any financial institution that is a participant in DTC's system may use DTC's Automated Tender Offer Program to tender. Participants in the program may, instead of physically completing and signing the letter of transmittal and delivering it to the exchange agent, obtain their acceptance of the exchange by causing DTC to transfer the outstanding notes to the exchange agent in accordance with DTC's Automated Tender Offer procedures for transfer. DTC will then send an agent's message to the exchange agent. The term "agent's message" means a message transmitted to the exchange agent and forming part of the book-entry confirmation, which states that:

- DTC has received an express acknowledgment from a participant in its Automated Tender Offer Program that is tendering outstanding notes to the book-entry confirmation;
- the participant has received and agrees to be bound by the terms of the letter of transmittal, or in the case of an agent's message, the participant has received and agrees to be bound by the notice of guaranteed delivery; and
- we may enforce that agreement against such participant.

DTC is referred to herein as a "book-entry transfer facility."

Acceptance of Exchange Notes

In all cases, we will promptly issue exchange notes for outstanding notes that we have accepted for exchange under the exchange of notes that we timely receives:

- outstanding notes or a timely book-entry confirmation of such outstanding notes into the exchange agent's account at the book-entry confirmation;
- a properly completed and duly executed letter of transmittal and all other required documents or a properly transmitted agent's message.

e424b3

e424b3

[Table of Contents](#)

By tendering outstanding notes pursuant to the exchange offer, you will represent to us that, among other things:

- you are not our “affiliate” or an “affiliate” of any guarantor of the notes within the meaning of Rule 405 under the Securities Act;
- you do not have an arrangement or understanding with any person or entity to participate in a distribution of the exchange notes;
- you are acquiring the exchange notes in the ordinary course of your business.

In addition, each broker-dealer that is to receive exchange notes for its own account in exchange for outstanding notes must represent that it will deliver the exchange notes to the transferee in accordance with the requirements of the Securities Act in connection with any resale of the exchange notes. The letter of transmittal states that by so acknowledging, a broker-dealer will not be deemed to admit that it is an “underwriter” within the meaning of the Securities Act. See “Plan of Exchange Offer.”

Our interpretation of the terms and conditions of the exchange offer, including the letters of transmittal and the instructions to the letter of transmittal, shall govern in the event of all questions as to the validity, form, eligibility, including time of receipt, and acceptance of outstanding notes tendered for exchange. We reserve the absolute right to reject any and all tenders of any particular outstanding notes not properly tendered or to not accept any tender if the acceptance might, in our or our counsel’s judgment, be unlawful. We also reserve the absolute right to waive any defects or irregularities in outstanding notes prior to the expiration date.

Unless waived, any defects or irregularities in connection with tenders of outstanding notes for exchange must be cured within such time as we may determine. Neither we, the exchange agent, nor any other person will be under any duty to give notification of any defect or irregularity in outstanding notes for exchange, nor will we or any of them incur any liability for any failure to give notification. Any outstanding notes that are not properly tendered and as to which the irregularities have not been cured or waived will be returned by the exchange agent to the tenderer as provided in the letter of transmittal, promptly after the expiration date.

Book-Entry Delivery Procedures

Promptly after the date of this prospectus, the exchange agent will establish an account with respect to the outstanding notes at DTCC for purposes of the exchange offer. Any financial institution that is a participant in the book-entry transfer facility’s system may make book-entry delivery of outstanding notes by causing the book-entry transfer facility to transfer those outstanding notes into the exchange agent’s account at the book-entry transfer facility in accordance with the facility’s procedures for such transfer. To be timely, book-entry delivery of outstanding notes requires receipt of a confirmation of a book-entry transfer, “prior to the expiration date. In addition, although delivery of outstanding notes may be effected through book-entry transfer to the exchange agent’s account at the book-entry transfer facility, the letter of transmittal or a manually signed facsimile thereof, together with any required signatures, required documents, or an “agent’s message,” as defined below, in connection with a book-entry transfer, must, in any case, be delivered to the exchange agent at its address set forth on the cover page of the letter of transmittal prior to the expiration date to receive exchange notes. The exchange agent’s account at the book-entry transfer facility or the guaranteed delivery procedure described below must be complied with. Tender will not be deemed made until such documents are received by the exchange agent. Delivery of documents to the book-entry transfer facility does not constitute delivery to the exchange agent.

Holders of outstanding notes who are unable to deliver confirmation of the book-entry tender of their outstanding notes into the exchange agent’s account at the book-entry transfer facility or all other documents required by the letter of transmittal to the exchange agent prior to the expiration date must comply with the guaranteed delivery procedures described below.

e424b3

[Table of Contents](#)

Guaranteed Delivery Procedures

If you wish to tender your outstanding notes, but your outstanding notes are not immediately available or you cannot deliver your letter of transmittal or any other required documents to the exchange agent or comply with the procedures under DTC's Automatic Tender Offer Program, prior to the expiration date, you may still tender if:

- the tender is made through an eligible guarantor institution;
- prior to the expiration date, the exchange agent receives from such eligible guarantor institution either a properly completed and executed letter of transmittal or facsimile thereof, as well as certificate of ownership of the outstanding notes, or a properly transmitted agent's message relating to the notice of guaranteed delivery, by facsimile transmission, mail, or hand delivery or a properly transmitted agent's message relating to the notice of guaranteed delivery, your name and address, the certificate number(s) of such outstanding notes and the principal amount of outstanding notes tendered; and (3) guarantees that, within three New York Stock Exchange trading days after the expiration date, the tendered notes, together with the outstanding notes or a book-entry confirmation (including an agent's message), and any other documents required by the letter of transmittal, will be deposited by the eligible guarantor institution with the exchange agent; and
- the exchange agent receives the properly completed and executed letter of transmittal or facsimile thereof, as well as certificate of ownership of the outstanding notes in proper form for transfer or a book-entry confirmation of transfer of the outstanding notes (including an agent's message), and any other documents required by the letter of transmittal within three New York Stock Exchange trading days after the expiration date.

Upon request, the exchange agent will send to you a notice of guaranteed delivery if you wish to tender your outstanding notes according to the procedures.

Withdrawal Rights

Except as otherwise provided in this prospectus, you may withdraw your tender of outstanding notes at any time prior to 11:59 p.m., on the expiration date. For a withdrawal to be effective:

- the exchange agent must receive a written notice, which may be by telegram, telex, facsimile or letter, of withdrawal at its address, "DTC, Attention: Exchange Agent;" or
- you must comply with the appropriate procedures of DTC's Automated Tender Offer Program system.

Any notice of withdrawal must:

- specify the name of the person who tendered the outstanding notes to be withdrawn;
- identify the outstanding notes to be withdrawn, including the certificate numbers and principal amount of the outstanding notes;
- where certificates for outstanding notes have been transmitted, specify the name in which such outstanding notes were registered with the withdrawing holder.

If certificates for outstanding notes have been delivered or otherwise identified to the exchange agent, then, prior to the release of such certificates, you must:

- the serial numbers of the particular certificates to be withdrawn; and
- a signed notice of withdrawal with signatures guaranteed by an eligible guarantor institution unless you are an eligible guarantor institution.

e424b3

e424b3

[Table of Contents](#)

If outstanding notes have been tendered pursuant to the procedures for book-entry transfer described above, any notice of withdrawal of the account at the book-entry transfer facility to be credited with the withdrawn outstanding notes and otherwise comply with the procedures to determine all questions as to the validity, form, and eligibility, including time of receipt of notices of withdrawal and our determination of the parties. Any outstanding notes so withdrawn will be deemed not to have been validly tendered for exchange for purposes of the exchange offer. Any outstanding notes that have been tendered for exchange but that are not exchanged for any reason will be returned to their holder, without cost to the holder, on the date of withdrawal. The outstanding notes will be credited to an account at the book-entry transfer facility, promptly after withdrawal, rejection of tender or expiration of the exchange offer. Properly withdrawn outstanding notes may be retendered by following the procedures described under “—Procedures for Tendering Outstanding Notes” on or prior to the expiration date.

Exchange Agent

The Bank of New York Mellon Trust Company, N.A. has been appointed as the exchange agent for the exchange offer. The Bank of New York Mellon Trust Company, N.A., also acts as trustee under the indenture governing the notes. You should direct all executed letters of transmittal and all questions and requests in respect to exchange offer procedures, requests for additional copies of this prospectus or of the letters of transmittal, and requests for notes to the exchange agent addressed as follows:

By Mail, Hand Delivery or Overnight Courier:
The Bank of New York Mellon Trust Company, N.A.
c/o The Bank of New York Mellon Corporation
Corporate Trust — Reorganization Unit
480 Washington Boulevard,
27th Floor
Jersey City, New Jersey 07310
Attn: David Mauer — Processor

(if by mail, registered or certified recommended)

By Facsimile:
212-298-1915
Attn: Bondholder Communications

To Confirm by Telephone:
212-815-3000
Attn: Bondholder Communications

If you deliver the letter of transmittal to an address other than the one set forth above or transmit instructions via facsimile other than the address above, your delivery or those instructions will not be effective.

Fees and Expenses

The registration rights agreement provides that we will bear all expenses in connection with the performance of our obligations relating to the exchange offer and the conduct of the exchange offer. These expenses include registration and filing fees, accounting and legal fees and other expenses. We will pay the exchange agent reasonable and customary fees for its services and reasonable out-of-pocket expenses. We will also reimburse the exchange agent for reasonable and customary expenses incurred by them in forwarding this prospectus and other documents to holders of outstanding notes and for handling or tendering for such clients.

We have not retained any dealer manager in connection with the exchange offer and will not pay any fee or commission to any broker or dealer for soliciting tenders of outstanding notes pursuant to the exchange offer.

e424b3

e424b3

[Table of Contents](#)

Accounting Treatment

We will record the exchange notes in our accounting records at the same carrying value as the outstanding notes, which is the aggregate carrying value of the outstanding notes in our accounting records on the date of exchange. Accordingly, we will not recognize any gain or loss for accounting purposes upon the exchange. We will capitalize, as appropriate, the expenses of the exchange offer and amortize them over the life of the notes.

Transfer Taxes

We will pay all transfer taxes, if any, applicable to the exchanges of outstanding notes under the exchange offer. The tendering holder will be responsible for paying any transfer taxes, whether imposed on the registered holder or any other person, if:

- certificates representing outstanding notes for principal amounts not tendered or accepted for exchange are to be delivered to, or by, a person other than the registered holder of outstanding notes tendered;
- tendered outstanding notes are registered in the name of any person other than the person signing the letter of transmittal; or
- a transfer tax is imposed for any reason other than the exchange of outstanding notes under the exchange offer.

If satisfactory evidence of payment of such taxes is not submitted with the letter of transmittal, the amount of such transfer taxes will be paid by the registered holder.

Holders who tender their outstanding notes for exchange notes will not be required to pay any transfer taxes. However, holders who tender their outstanding notes in the name of, or request that outstanding notes not tendered or not accepted in the exchange offer be returned to, a person other than the registered holder will be required to pay any applicable transfer tax.

Consequences of Failure to Exchange

If you do not exchange your outstanding notes for exchange notes under the exchange offer, your outstanding notes will remain subject to the same terms and conditions as such outstanding notes:

- as set forth in the legend printed on the outstanding notes as a consequence of the issuance of the outstanding notes pursuant to the exchange offer; and
- as otherwise set forth in the offering memorandum distributed in connection with the private offering of the outstanding notes.

In general, you may not offer or sell your outstanding notes unless they are registered under the Securities Act or if the offer or sale is exempt from registration under the Securities Act and applicable state securities laws. Except as required by the registration rights agreement, we do not intend to register our outstanding notes under the Securities Act.

Other

Participating in the exchange offer is voluntary, and you should carefully consider whether to accept. You are urged to consult your own counsel regarding your own decision on what action to take.

We may in the future seek to acquire untendered outstanding notes in open market or privately negotiated transactions, through subsidiaries or other entities. We have no present plans to acquire any outstanding notes that are not tendered in the exchange offer or to file a registration statement for the exchange offer of outstanding notes.

e424b3

e424b3

[Table of Contents](#)

DESCRIPTION OF THE EXCHANGE NOTES

LifePoint issued the outstanding notes under the indenture dated as of September 23, 2010 (the “indenture”) among the Company, the Bank of New York Mellon Trust Company, N.A., N.A. as trustee (the “Trustee”). The exchange notes will also be issued under the indenture of the same series of notes previously issued under such indenture.

The following description is a summary of certain provisions of the indenture, the exchange notes, and the guarantees. It does not recite all of the terms of the notes, or the guarantees in their entirety and is qualified in its entirety by reference to such documents. You may request copies of the indenture set forth under “Where You Can Find More Information; Incorporation by Reference.”

The definitions of certain capitalized terms used in the following summary are set forth below under “—Certain Definitions.” For purposes of the summary, the Company include only LifePoint Hospitals Inc. and not its subsidiaries.

The exchange notes will be issued only in fully registered book-entry form without coupons only in minimum denominations of \$2,000,000 or in excess thereof. The exchange notes will be issued in the form of global notes, registered in the name of a nominee of DTC, New York, New York, under the heading “Book-Entry Settlement and Clearance.”

The registered Holder of a note will be treated as the owner of it for all purposes. Only registered Holders will have rights under the notes.

Brief Description of the Notes and the Guarantees

The notes

The notes:

- are senior unsecured obligations of LifePoint;
- are senior in right of payment to all existing and future obligations of LifePoint that are by their terms expressly subordinated to the obligations of the exchange notes, including our 3.5% Convertible Senior Subordinated Notes due 2014 and our 3.25% Convertible Senior Subordinated Notes due 2015;
- are *pari passu* in right of payment with all existing and future unsubordinated obligations of LifePoint;
- are effectively junior to any of LifePoint’s existing and future secured obligations to the extent of the value of the assets securing such obligations;
- are structurally subordinated to all existing and future obligations, including trade payables, of those LifePoint Subsidiaries that are not LifePoint Hospitals Inc.

The guarantees

The notes will be unconditionally guaranteed by each of LifePoint’s Domestic Subsidiaries except the Excluded Subsidiaries.

Each guarantee of the notes:

- is a senior unsecured obligation of the Guarantor;
- is senior in right of payment all existing and future obligations of that Guarantor that are expressly subordinated to its guarantee of the notes.

e424b3

Table of Contents

- is *pari passu* in right of payment with all existing and future unsubordinated obligations of that Guarantor; and
- are effectively junior to any existing and future secured obligations of that Guarantor to the extent of the value of the assets secured by such obligations.

As of March 31, 2011, LifePoint and the Guarantors had approximately:

- \$851.2 million of unsubordinated Indebtedness, \$451.2 million of which was secured and would effectively rank senior to the extent of the value of the collateral securing such Indebtedness; in addition, we would have had the ability to borrow an additional \$400 million under a secured Credit Agreement, including \$350.0 million available under our revolving credit facility thereunder, net of outstanding borrowings and also including \$950.0 million available under the uncommitted accordion features of our term loans and revolving loan facilities, subject to additional lender commitments and the satisfaction of other conditions; and
- \$800.1 million of Subordinated Indebtedness, which may be refinanced with *pari passu* or secured Indebtedness under the terms and circumstances;

As of the date of this prospectus, substantially all of our Subsidiaries will be Restricted Subsidiaries, a portion of which are Excluded Subsidiaries that do not provide Guarantees. Claims of creditors of the Excluded Subsidiaries, including trade creditors, secured creditors and creditors holding claims secured by the Excluded Subsidiaries, will have priority with respect to the assets and earnings of such Subsidiaries over the claims of creditors of LifePoint under the note. As of March 31, 2011, the Excluded Subsidiaries had total indebtedness of approximately \$45.0 million. The Excluded Subsidiaries' total revenues were \$500.0 million, or 9.0% of our total revenues for the three months ended March 31, 2011 and \$358.8 million, or 8.4% of our assets (excluding intercompany assets) of \$425.0 million, or 2.0% of our liabilities (excluding intercompany liabilities) as of March 31, 2011.

Principal, Maturity and Interest

LifePoint will issue the exchange notes in an aggregate principal amount of up to \$400 million. LifePoint may issue additional notes from time to time. Any offering of additional notes is subject to the covenant described below under the caption “—Certain Covenants—Incurrence of Indebtedness.” The notes and any additional notes of the same series subsequently issued under the indenture will be treated as a single class for all purposes, including, without limitation, waivers, amendments, redemptions and offers to purchase. LifePoint will issue notes in minimum denominations of \$1,000 and multiples of \$1,000 in excess thereof. The notes will mature on October 1, 2020.

Interest on the notes will accrue at the rate of 6.625% per annum. Interest on the notes will be payable semi-annually in arrears on April 1 and October 1, 2011. LifePoint will make each interest payment to the Holders of record at the close of business on the immediately preceding business day (whether or not a business day).

Interest on the notes will accrue from the date of original issuance or, if interest has already been paid or duly provided for from the date of the last interest payment or duly provided for. Interest will be computed on the basis of a 360-day year comprised of twelve 30-day months.

Methods of Receiving Payments on the Notes

If a Holder has given wire transfer instructions to LifePoint and the trustee at least 15 days prior to the applicable payment date, all payments on that Holder's notes will be paid in accordance with those instructions, subject to surrender of the note in the case of payment of principal. If a Holder has not given wire transfer instructions, interest on notes will be made at the office or agency of the paying agent and registrar unless LifePoint elects to make interest payments by wire transfer to their address set forth in the register of Holders.

e424b3

e424b3

[Table of Contents](#)

Paying Agent and Registrar for the Notes

The trustee will initially act as paying agent and registrar. LifePoint may change the paying agent or registrar without prior notice to LifePoint or any of its Subsidiaries may act as paying agent or registrar.

Transfer and Exchange

A Holder may transfer or exchange notes in accordance with the indenture. The registrar and the trustee may require a Holder to furnish transfer documents in connection with a transfer of notes. Holders will be required to pay all taxes due on transfer. LifePoint is not required to select notes for redemption. Also, LifePoint is not required to transfer or exchange any note for a period of 15 days before a selection of notes is

Subsidiary Guarantees

The notes will be guaranteed by each of LifePoint's current and future Domestic Subsidiaries except the Excluded Subsidiaries. The guarantee is senior, unconditional, and joint and several obligations of the Guarantors. Each Subsidiary Guarantee will be a senior unsecured obligation of each Guarantor under its Subsidiary Guarantee will be limited as necessary to prevent that Subsidiary Guarantee from constituting a violation of applicable law. See "Risk Factors—Your ability to enforce the guarantees of the notes may be limited."

A Guarantor may not sell or otherwise dispose of all or substantially all of its assets to, or consolidate with or merge with or into (with or without a surviving Person), another Person, other than LifePoint or another Guarantor, unless:

(1) immediately after giving effect to that transaction, no Default or Event of Default exists; and

(2) subject to the provisions of the following paragraph, the Person acquiring the property in any such sale or disposition or the Person resulting from such consolidation or merger assumes all the obligations of that Guarantor under the indenture and its Subsidiary Guarantee pursuant to a form satisfactory to the trustee.

The Subsidiary Guarantee of a Guarantor will be released, and any Person acquiring assets (including by way of merger or consolidation) from such Guarantor shall not be required to assume the obligations of any such Guarantor:

(1) in connection with any sale or other disposition of all or substantially all of the assets of such Guarantor (including by way of merger or consolidation) that is not (either before or after giving effect to such transaction) a Restricted Subsidiary, if the sale or other disposition complies with the first paragraph of the covenant described under "Repurchase at the Option of Holders—Asset Sales";

(2) in connection with any sale of the Capital Stock of such Guarantor to a Person that is not (either before or after giving effect to such transaction) a Restricted Subsidiary, if as a result of such sale such Guarantor ceases to be a Subsidiary of LifePoint and the sale complies with the first paragraph of the covenant described under "Repurchase at the Option of Holders—Asset Sales";

(3) if LifePoint designates such Guarantor to be an Unrestricted Subsidiary or an Excluded Subsidiary in accordance with the requirements set forth in the indenture;

(4) if such Guarantor is otherwise no longer obligated to provide a Subsidiary Guarantee pursuant to the indenture;

(5) upon LifePoint's exercise of its legal defeasance option or covenant defeasance option as described under "Legal Defeasance" in the indenture, if LifePoint's obligations under the indenture and notes are discharged in accordance with the terms of the indenture; or

e424b3

[Table of Contents](#)

(6) pursuant to the covenant described below under the caption “—Certain Covenants—Covenant Suspension.”

Optional Redemption

At any time prior to October 1, 2013, LifePoint may on any one or more occasions redeem up to 35% of the aggregate principal amount (including additional notes) at a redemption price of 106.625% of the principal amount, plus accrued and unpaid interest, if any, to (but not including) the cash proceeds of one or more Equity Offerings; *provided* that:

(1) at least 65% of the aggregate principal amount of such notes remains outstanding immediately after the occurrence of such redemption; and LifePoint and its Subsidiaries); and

(2) the redemption occurs within 180 days of the date of the closing of such Equity Offering.

At any time prior to October 1, 2015, LifePoint may redeem all or a part of the notes, upon not less than 30 nor more than 60 days' notice, 100% of the principal amount thereof, plus the Applicable Redemption Premium and accrued and unpaid interest to (but not including) the date of redemption.

Except pursuant to the preceding two paragraphs, the notes will not be redeemable at LifePoint's option prior to October 1, 2015. On or after October 1, 2015, LifePoint may redeem all or a part of the notes upon not less than 30 nor more than 60 days' notice, at the redemption prices (expressed as percentages of principal amount) below plus accrued and unpaid interest, if any, on the notes redeemed, to (but not including) the applicable redemption date, if redeemed on or after the date beginning on October 1 of the years indicated below:

Period

2015

2016

2017

2018 and thereafter

Mandatory Redemption

Except as set forth below under “—Repurchase at the Option of Holders,” LifePoint is not required to make mandatory redemption of the notes in respect to the notes.

Repurchase at the Option of Holders

Change of control

If a Change of Control occurs, unless LifePoint has exercised its right to redeem all of the notes as described above under “—Optional Redemption,” LifePoint will offer to repurchase all or any part (or multiple of \$1,000 in excess thereof; provided, that the unrepurchased portion of a note must be in a minimum denomination of \$2,000) of the aggregate principal amount of notes repurchased plus accrued and unpaid interest, if any, on the notes repurchased, to (but not including) the cash proceeds of one or more Equity Offerings; *provided* that, within 30 days following any Change of Control, LifePoint will mail a notice to each Holder stating the transaction or transactions that constitute the Change of Control and offering to repurchase notes on the Change of Control Payment Date specified in the notice, which date will be no earlier than 30 days after the date such notice is mailed, pursuant to the procedures required by the indenture and described in such notice. LifePoint will comply with the requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any other securities laws and regulations thereunder that are applicable in connection with the repurchase of the notes as a result of a Change of Control. To the extent that the provisions of the Exchange Act or any other securities laws and regulations conflict with the Change of Control provisions of the indenture, LifePoint will comply with the applicable securities laws and regulations.

e424b3

e424b3

[Table of Contents](#)

will not be deemed to have breached its obligations under the Change of Control provisions of the indenture by virtue of such conflict.

On the Change of Control Payment Date, LifePoint will, to the extent lawful:

- (1) accept for payment all notes or portions of notes properly tendered pursuant to the Change of Control Offer;
- (2) deposit with the paying agent an amount equal to the Change of Control Payment in respect of all notes or portions of notes properly tendered;
- (3) deliver or cause to be delivered to the trustee the notes properly accepted together with an officers' certificate stating the aggregate principal amount of notes being purchased by LifePoint.

The paying agent will promptly mail to each Holder of notes properly tendered the Change of Control Payment for such notes, and to each Holder (or cause to be transferred by book entry) to each Holder a new note equal in principal amount to any unpurchased portion of the notes properly tendered, *provided* that each new note will be in a principal amount of \$2,000 or an integral multiple of \$1,000 in excess thereof. LifePoint will mail the new notes to each Holder on or as soon as practicable after the Change of Control Payment Date. The provisions described above that relate to the Change of Control Offer following a Change of Control will be applicable whether or not any other provisions of the indenture are applicable.

LifePoint will not be required to make a Change of Control Offer upon a Change of Control if a third party makes the Change of Control Offer on or as soon as practicable after the Change of Control Payment Date, and if such Change of Control Offer is made in compliance with the requirements set forth in the indenture applicable to a Change of Control Offer made by LifePoint. Any Change of Control Offer may be made in advance of, and in connection with, such Change of Control.

A Change of Control Offer may be made in advance of a Change of Control, and conditioned upon such Change of Control, if a default under the indenture occurs prior to the Change of Control at the time of making of the Change of Control Offer.

The definition of Change of Control includes a phrase relating to the direct or indirect sale, transfer, conveyance or other disposition of all or substantially all of the properties or assets of LifePoint and its Restricted Subsidiaries taken as a whole. Although there is a limited body of case law interpreting the phrase, there is no precise established definition of the phrase under applicable law. Accordingly, the ability of a Holder of notes to require LifePoint to make a Change of Control Offer as a result of a sale, lease, transfer, conveyance or other disposition of less than all of the assets of LifePoint and its Restricted Subsidiaries taken as a whole may be uncertain.

Under clause (4) of the definition of Change of Control, a Change of Control will occur when a majority of LifePoint's board of directors is replaced. In a recent decision in connection with a proxy contest, the Delaware Court of Chancery held that the occurrence of a change of control under the definition may nevertheless be avoided if the existing directors were to approve the slate of new director nominees (who would constitute a majority of the board of directors), provided the incumbent directors give their approval in the good faith exercise of their fiduciary duties owed to the corporation. In certain circumstances involving a significant change in the composition of LifePoint's board of directors, including in connection with the replacement of the board of directors does not endorse a dissident slate of directors but approves them as Continuing Directors, holders of the notes may not be able to make a Change of Control Offer.

The Change of Control purchase feature of the notes may in certain circumstances make more difficult or discourage a sale or takeover of LifePoint or the removal of incumbent management. The Change of Control purchase feature is a result of negotiations between us and the initial purchasers of the notes to engage in a transaction involving a Change of Control, although it is possible that we could decide to do so in the future. Subject to the terms of the indenture, we could, in the future, enter into certain other transactions,

e424b3

[Table of Contents](#)

including acquisitions, refinancings or other recapitalizations, that would not constitute a Change of Control under the indenture, but that would increase the amount of indebtedness outstanding at such time or otherwise affect our capital structure or credit ratings. Restrictions on our ability to incur additional indebtedness are contained in the “Incurrence of Indebtedness and Issuance of Preferred Stock” covenant. Such restrictions can only be waived with the consent of the Holders of at least a majority in principal amount of the notes then outstanding. Except for the limitations contained in such covenants, however, the indenture will not contain any provisions that would afford Holders protection in the event of a highly leveraged transaction. Future indebtedness that we may incur may contain prohibitions that would constitute a Change of Control or require the repurchase of such indebtedness upon a Change of Control. Moreover, the exercise of our right to repurchase notes that would require us to repurchase their notes could cause a default under such indebtedness, even if the Change of Control itself does not, due to the terms of the indenture governing the repurchase on us.

The provisions under the indenture relative to our obligation to make an offer to repurchase the notes as a result of a Change of Control are subject to the consent of the holders of a majority in principal amount of the notes.

Asset Sales

LifePoint will not, and will not permit any of the Restricted Subsidiaries to, consummate an Asset Sale unless:

- (1) LifePoint (or a Restricted Subsidiary) receives consideration at the time of the Asset Sale at least equal to the fair market value of the notes then issued or sold or otherwise disposed of;
- (2) the fair market value is determined by LifePoint’s Board of Directors and evidenced by a resolution of the Board of Directors;
- (3) at least 75% of the consideration received in the Asset Sale by LifePoint or such Restricted Subsidiary is in the form of cash, cash equivalents or Replacement Assets. For purposes of this provision, each of the following will be deemed to be cash:
 - (a) any liabilities, as shown on LifePoint’s or any Restricted Subsidiary’s most recent balance sheet, of LifePoint or any Restricted Subsidiary (including contingent liabilities and liabilities that are by their terms subordinated to the notes or any Subsidiary Guarantee) that are assumed by LifePoint or such Restricted Subsidiary in the Asset Sale and from which LifePoint or such Restricted Subsidiary is released from further liability;
 - (b) any securities, notes or other obligations received by LifePoint or any such Restricted Subsidiary from such transferee that are converted by the Restricted Subsidiary into cash within 180 days of receipt, to the extent of the cash received in that conversion; and
 - (c) any Designated Non-cash Consideration received by LifePoint or any of its Restricted Subsidiaries in such Asset Sale that is taken together with all other Designated Non-cash Consideration received pursuant to this clause (c) that is at that time outstanding and not repurchased at the time of the receipt of such Designated Non-cash Consideration (with the fair market value of each item of Designated Non-cash Consideration at the time received and without giving effect to subsequent changes in value).

Within 365 days after the receipt of any Net Proceeds from an Asset Sale, LifePoint or a Restricted Subsidiary may apply those Net Proceeds:

- (1) to repay, prepay, redeem or purchase (x) Indebtedness of LifePoint or any Guarantor that is not Subordinated Indebtedness or (y) Indebtedness of a Restricted Subsidiary that is not a Guarantor;
- (2) to acquire all or substantially all of the assets of, or a majority of the Voting Stock of, another Permitted Business;
- (3) to make a capital expenditure;
- (4) to acquire Replacement Assets; or

e424b3

e424b3

[Table of Contents](#)

(5) to acquire other long-term assets that are used or useful in a Permitted Business.

LifePoint or the Restricted Subsidiary will be deemed to have complied with the immediately preceding sentence with respect to any binding agreement to make an acquisition or capital expenditure permitted pursuant to clause (2), (3), (4) or (5) of the immediately preceding sentence to such Net Proceeds within such 365 days; *provided* that, if the relevant acquisition or capital expenditure is not consummated or completed later of (x) 365 days after the receipt of the relevant Net Proceeds and (y) 180 days after the date of such binding agreement, such Net Proceeds.” Pending the final application of any Net Proceeds, LifePoint or the Restricted Subsidiary may temporarily invest the Net Proceeds prohibited by the indenture.

Any Net Proceeds from Asset Sales that are not applied or invested as provided in the preceding paragraph will constitute Excess Proceeds. If the amount of Excess Proceeds exceeds \$50 million, LifePoint will make an offer (an “*Asset Sale Offer*”) to all Holders of notes (and, at the option of LifePoint, to all Holders of any Subordinated Indebtedness of LifePoint or any Guarantor that is not Subordinated Indebtedness and/or any Indebtedness of any Restricted Subsidiary (such other Indebtedness”)) to purchase the maximum principal amount of notes (and such other Indebtedness), in minimum denominations of \$1,000 or multiples of \$1,000 in excess thereof; *provided*, that the unrepurchased portion of a note must be in a minimum denomination of \$2,000 or multiples thereof purchase price of 100% of their principal amount (or, in the event such other Indebtedness was issued with significant original issue discount, the purchase price of 100% of their principal amount, plus accrued but unpaid interest (or, in respect of such other Indebtedness, such lesser price, if any, as may be determined by the trustee) in accordance with the procedures (including prorating in the event of oversubscription) set forth in the indenture. To the extent the aggregate principal amount of notes (and such other Indebtedness) tendered pursuant to such an offer is less than the Excess Proceeds, LifePoint may use any remaining Excess Proceeds for its corporate purposes. If the aggregate principal amount of notes (and such other Indebtedness) surrendered by holders thereof exceeds the aggregate principal amount of notes (and such other Indebtedness) tendered, the trustee shall select the notes to be purchased in the manner described in the indenture. Upon completion of each Asset Sale Offer, the amount of Excess Proceeds shall reset at zero.

LifePoint will comply with the requirements of Rule 14e-1 under the Exchange Act and any other securities laws and regulations that may be applicable in connection with each repurchase of notes pursuant to an Asset Sale Offer. To the extent that the provisions of the indenture conflict with the Asset Sale provisions of the indenture, LifePoint will comply with the applicable securities laws and regulations and will discharge its obligations under the Asset Sale provisions of the indenture by virtue of such conflict.

Selection and notice

If less than all of the notes are to be redeemed at any time, the trustee will select notes for redemption on a pro rata basis, by lot or by any other method that is fair and appropriate.

No notes of \$2,000 or less can be redeemed in part. Notices of redemption will be mailed by first class mail at least 30 but not more than 60 days prior to the redemption date to each Holder of notes to be redeemed at its registered address, except that redemption notices may be mailed more than 60 days prior to the redemption date if a notice is issued in connection with a defeasance of the notes or a satisfaction and discharge of the indenture. Notices of redemption may be issued on certain events, including equity offerings.

If any note is to be redeemed in part only, the notice of redemption that relates to that note will state the portion of the principal amount of the note to be redeemed. A new note in principal amount equal to the unredeemed portion of the original note will be issued in the name of the Holder of the original note. Notes called for redemption become due on the date fixed for redemption. On and after the redemption date, interest ceases to accrue on notes called for redemption.

e424b3

[Table of Contents](#)

Certain Covenants

Covenant Suspension

From and after the first date on which both (a) the notes are rated Investment Grade by each of Moody's Investor Service, Inc. ("Moody's") and S&P Ratings Group ("S&P" and together with Moody's the "Rating Agencies") and (b) there shall not exist a Default or Event of Default under the events described in the foregoing clauses (a) and (b) being collectively referred to as a "Covenant Suspension Event"), LifePoint and the Restricted Subsidiaries will no longer be subject to the covenants described below under the captions "—Repurchase at the Option of Holders—Asset Sales," "—Restrictions on Redemption of Secured Indebtedness and Issuance of Preferred Stock," "—Liens," "—Dividend and other Payment Restrictions Affecting Restricted Subsidiaries," "—Leaseback Transactions," clause (4) of the first paragraph under "—Merger, Consolidation or Sale of Assets," "—Transactions with Affiliates," "—Subsidiary Guarantees" (collectively, the "Suspended Covenants"); provided that, during the Suspension Period (as defined below), LifePoint and the Restricted Subsidiaries will be subject to the covenant described below under the caption "—Limitation on Secured Indebtedness". Upon the occurrence of a "Covenant Suspension Event" ("Suspension Date"), the Subsidiary Guarantees of each of the Guarantors will be automatically released.

In the event that LifePoint and the Restricted Subsidiaries are not subject to the Suspended Covenants under the indenture for any period of time under the foregoing, and on any subsequent date (the "Reversion Date") one or both of the Rating Agencies withdraw their Investment Grade rating from the notes below an Investment Grade rating then, following the Reversion Date, LifePoint and the Restricted Subsidiaries will again be subject to the Covenants under the indenture and all required Subsidiary Guarantees will be reinstated and issued. Following the Reversion Date, LifePoint and the Restricted Subsidiaries will not be subject to the covenant described below under the caption "—Limitation on Secured Indebtedness."

The period of time between the Suspension Date and the Reversion Date is referred to in this description as the "Suspension Period." In the event of a Covenant Suspension Event, the amount of Excess Proceeds from Net Proceeds shall be reset at zero. In the event of any such reinstatement of the notes to be taken by LifePoint or any of its Restricted Subsidiaries prior to such reinstatement will give rise to a Default or Event of Default under the terms of the notes. Calculations made after the Reversion Date of the amount available to be made as Restricted Payments under the covenant described below under the caption "Restricted Payments" will be made as though such covenant had been in effect since the Issue Date and during the Suspension Period. For purposes of the "—Limitation on Secured Indebtedness and Issuance of Preferred Stock" covenant, all Indebtedness incurred, or Disqualified Stock or preferred stock issued, during the Suspension Period shall be classified to have been incurred or issued pursuant to clause (2) of the second paragraph of such covenant. For purposes of the "—Liens" covenant, any Lien securing Indebtedness, which Lien was permitted by the "—Limitation on Secured Indebtedness" covenant and did not require the consent of the note Holders for its benefit of note Holders pursuant to the requirements of the "—Limitation on Secured Indebtedness" covenant, shall be deemed to have been permitted so that it is classified as permitted under clause (5) of the definition of "Permitted Lien." For purposes of the "—Dividend and other Payments" covenant, on the Reversion Date, any encumbrance or restriction on the ability of any Restricted Subsidiary to make such payments as provided in clause (3) of the first paragraph thereof created, otherwise caused or permitted to exist or become effective during the Suspension Period shall be deemed to have been created, otherwise caused or permitted to exist or become effective on the Issue Date, so that it is classified as permitted under clause (1) of the second paragraph of such covenant. For purposes of the "—Transactions with Affiliates" covenant, on the Reversion Date, any Affiliate Transaction entered into or permitted to exist during the Suspension Period shall be deemed to have been entered into or permitted to exist on the Issue Date, so that it is classified as permitted under clause (2) of the second paragraph of such covenant.

In the event Moody's or S&P is no longer in existence or issuing ratings, such organization may be replaced by a nationally recognized rating agency (as defined in Rule 436 under the Securities Act) designated by LifePoint with notice to the trustee and the foregoing provisions will apply to the replacement rating agency.

e424b3

[Table of Contents](#)

Limitation on Secured Indebtedness

During any Suspension Period, LifePoint will not, and will not permit any Subsidiary that is not an Excluded Subsidiary to, incur any (other than a Permitted Lien) on any Principal Property or on any share of stock or Indebtedness of a Subsidiary without making effective such Restricted Subsidiary, as the case may be, will secure the notes equally and ratably with (or, if the Indebtedness to be secured by such payment to the notes, prior to) the Indebtedness so secured until such time as such Indebtedness is no longer secured by a Lien, unless the Indebtedness secured by all such Liens (excluding any Permitted Lien) would not exceed 5% of Total Assets. Any Lien created for the purpose pursuant to the preceding sentence shall provide by its terms that such Lien shall be automatically and unconditionally released and discharged upon the discharge of the initial Lien. For purposes of this “Limitation on Secured Indebtedness” covenant, “*Excluded Subsidiary*” shall include, but not be limited to, included within the meaning thereof, any Subsidiary that is an Unrestricted Subsidiary on the Suspension Date.

Restricted Payments

LifePoint will not, and will not permit any of its Restricted Subsidiaries to, directly or indirectly:

- (1) declare or pay any dividend or make any other payment or distribution on account of LifePoint’s or any Restricted Subsidiary’s without limitation, any payment in connection with any merger or consolidation involving LifePoint or any of its Restricted Subsidiaries, or to the holders of LifePoint’s or any of its Restricted Subsidiaries’ Equity Interests in their capacity as such (other than dividends or distributions (other than Disqualified Stock) of LifePoint or to LifePoint or a Restricted Subsidiary);
- (2) purchase, redeem or otherwise acquire or retire for value (including, without limitation, in connection with any merger or consolidation, Equity Interests of LifePoint;
- (3) make any voluntary or optional payment on or with respect to, or purchase, redeem, defease or otherwise acquire or retire for value, any Indebtedness, except a payment of interest or principal at the Stated Maturity thereof or the purchase, redemption, defeasance, acquisition or retirement of such Indebtedness within 365 days of the Stated Maturity thereof; or
- (4) make any Restricted Investment

(all such payments and other actions set forth in these clauses (1) through (4) above being collectively referred to as “*Restricted Payments*”), giving effect to such Restricted Payment:

- (1) no Default or Event of Default has occurred and is continuing or would occur as a consequence of such Restricted Payment;
- (2) LifePoint would, at the time of such Restricted Payment and after giving pro forma effect thereto as if such Restricted Payment had been made, the applicable four-quarter period, have been permitted to incur at least \$1.00 of additional Indebtedness pursuant to the Fixed Charge Coverage Ratio in the first paragraph of the covenant described below under the caption “—Incurrence of Indebtedness and Issuance of Preferred Stock”; and
- (3) such Restricted Payment, together with the aggregate amount of all other Restricted Payments made by LifePoint and its Restricted Subsidiaries since January 1, 2010 (excluding Restricted Payments permitted by clauses (2), (3), (4), (6), (7), (8), (9), (10), (12), (13), (14) and (15) of the next section), does not exceed, in the aggregate, sum, without duplication, of:
 - (a) 50% of the Consolidated Net Income of LifePoint for the period (taken as one accounting period) from June 30, 2010 to the end of the ended fiscal quarter for which internal financial statements are available at the time of such Restricted Payment (or, if such Consolidated Net Income is a deficit, less 100% of such deficit), *plus*

e424b3

e424b3

Table of Contents

(b) 100% of the aggregate net cash proceeds received by LifePoint since June 30, 2010 as a contribution to its common equity or from the issue or sale of convertible or exchangeable Disqualified Equity Interests of LifePoint (other than Disqualified Stock) or from the issue or sale of convertible or exchangeable Disqualified Debt Securities of LifePoint (other than Disqualified Debt Securities) that have been converted into or exchanged for such Equity Interests of LifePoint (other than Equity Interests of LifePoint (other than Disqualified Stock) or from the issue or sale of convertible or exchangeable Disqualified Debt Securities of LifePoint (other than Disqualified Debt Securities) sold to a Restricted Subsidiary), *plus*

(c) to the extent that any Restricted Investment that was made after June 30, 2010 is sold for cash or Cash Equivalents (or a combination thereof), the lesser of (i) the return of capital with respect to such Restricted Investment, *plus*

(d) an amount equal to the sum of (x) the net reduction in Investments in Unrestricted Subsidiaries resulting from cash dividends or other transfers of assets, in each case to LifePoint or any Restricted Subsidiary from Unrestricted Subsidiaries, plus (y) the portion of the fair market value of the net assets of an Unrestricted Subsidiary at the time such Unrestricted Subsidiary was sold to a Restricted Subsidiary, in each case since June 30, 2010 (*provided, however*, that the foregoing sum shall not exceed, in the case of (y), the amount of Investments made since June 30, 2010 by LifePoint or any Restricted Subsidiary that were treated as Restricted Payments), *plus* the amount of Investments made since June 30, 2010 by LifePoint or any Restricted Subsidiary that were treated as Restricted Payments, *plus* the amount will be included under this clause (d) to the extent it is already included in clauses (a), (b) or (c) above).

The preceding provisions will not prohibit:

(1) the payment of any dividend within 60 days after the date of declaration of the dividend, if at the date of declaration the dividend is not in violation of the provisions of the indenture;

(2) the redemption, repurchase, retirement, defeasance or other acquisition of any Subordinated Indebtedness of LifePoint or any Restricted Subsidiary in exchange for, or out of the net cash proceeds of the substantially concurrent sale (other than to a Restricted Subsidiary) of Equity Interests of LifePoint (other than Disqualified Stock);

(3) the defeasance, redemption, repurchase or other acquisition of Subordinated Indebtedness of LifePoint or any Restricted Subsidiary from an incurrence of (a) Permitted Refinancing Indebtedness or (b) any other Indebtedness to the extent that the Consolidated Senior Indebtedness of LifePoint or any Restricted Subsidiary as of the most recently ended four full fiscal quarters for which internal financial statements are available immediately preceding the date on which the Subordinated Indebtedness is incurred is less than 4.5 to 1, determined on a *pro forma* basis (including a *pro forma* application of the Subordinated Indebtedness had been incurred at the beginning of such four-quarter period);

(4) the payment of any dividend or similar distribution by a Restricted Subsidiary to the holders of its Equity Interests on a *pro rata* basis;

(5) the repurchase, redemption or other acquisition or retirement for value of any Equity Interests of LifePoint or any Restricted Subsidiary by any director or employee of LifePoint or any Subsidiary of LifePoint in connection with any management equity subscription agreement, disability, severance or benefit plan or agreement, any stock option or incentive plan or agreement, any employment agreement or agreement, *provided* that the aggregate price paid for all such repurchased, redeemed, acquired or retired Equity Interests may not exceed \$15 million (plus unused amounts in any calendar year being carried over to succeeding years);

(6) the repurchase of Equity Interests deemed to occur upon the exercise of stock options or stock appreciation rights or the lapse of such stock options or stock appreciation rights to the extent such Equity Interests represent a portion of the exercise price of those stock options or stock appreciation rights or the exercise price of such stock options, stock appreciation rights or restricted stock;

e424b3

[Table of Contents](#)

(7) the repurchase of any class of Capital Stock of a Restricted Subsidiary (other than Disqualified Stock) if such repurchase is not in compliance with the terms of the indenture for such class of Capital Stock;

(8) the payment of any scheduled dividend or similar distribution, and any scheduled repayment of the stated amount, liquidation preference, or any other payment due at final maturity or on any scheduled redemption or repurchase date, in respect of any series of preferred stock or similar securities of a Restricted Subsidiary (including Disqualified Stock), *provided* that such series of preferred stock or similar securities was issued in compliance with the terms of the Indebtedness and Issuance of Preferred Stock” covenant;

(9) payments in lieu of fractional shares;

(10) the purchase of any Indebtedness that is subordinate to the notes at a purchase price no greater than 101% of the principal amount of such Indebtedness, in connection with a Change of Control in accordance with provisions similar to those described under the caption “—Repurchase at the Option of Holder” in the notes, provided that prior to such purchase LifePoint has made the Change of Control Offer as provided in such section and has purchased all notes in connection with such Change of Control Offer;

(11) payments or distributions to dissenting stockholders pursuant to applicable law in connection with any merger, consolidation, or other corporate transaction, in accordance with the terms of the indenture;

(12) the purchase, redemption, cancellation or other retirement for a nominal value per right of any rights granted to holders of LifePoint Preferred Stock pursuant to a shareholder rights plan;

(13) the repurchase, redemption or other acquisition of Disqualified Stock of LifePoint or any of its Restricted Subsidiaries in exchange for cash, in connection with a substantially concurrent offering of, Disqualified Stock of LifePoint; and

(14) the repurchase of Equity Interests of LifePoint in an aggregate amount not to exceed \$225 million; and

(15) additional Restricted Payments pursuant to this clause (15) in an aggregate amount not to exceed \$300 million at the time of such Restricted Payment being valued as of the date made and without regard to subsequent changes in value);

provided, that at the time of, and after giving effect to, any Restricted Payment permitted under subclause (b) of clause 3 and clause (15) above, such Restricted Payment is continuing or would be caused thereby.

The amount of all Restricted Payments (other than cash) will be the fair market value on the date of the Restricted Payment of the assets of LifePoint or such Restricted Subsidiary, as the case may be, transferred or issued by LifePoint or such Restricted Subsidiary, as the case may be, pursuant to the Restricted Payment. The fair market value of the assets of LifePoint or such Restricted Subsidiary that are required to be valued by this covenant will be determined by the Board of Directors of LifePoint in good faith, whose determination shall be final and conclusive.

For purposes of determining compliance with this “Restricted Payments” covenant, in the event that a Restricted Payment meets the criteria of any of the categories of Restricted Payments described in clauses (1) through (15) above, or is entitled to be incurred pursuant to the first paragraph of clause (15) above, LifePoint is entitled to classify such Restricted Payment (or portion thereof) on the date of its payment or later reclassify such Restricted Payment (or portion thereof) if it complies with this covenant.

Incurrence of Indebtedness and Issuance of Preferred Stock

LifePoint will not, and will not permit any of its Restricted Subsidiaries to, directly or indirectly, create, incur, issue, assume, guarantee, or become directly or indirectly liable, contingently or otherwise, with respect to (collectively, “*incur*”) any Indebtedness (including Acquired Debt), and LifePoint will not permit any of its Restricted Subsidiaries to issue any shares of preferred stock; *provided, however*, that LifePoint and its Restricted Subsidiaries may incur Indebtedness (including Acquired Debt) and LifePoint may issue Disqualified Stock and any Restricted Subsidiary may issue preferred stock if the Fixed Charge Coverage Ratio for LifePoint’s most recently ended four full fiscal quarters for which internal financial statements are available is at least 1.25 to 1.00.

e424b3

preceding the date on which such additional

e424b3

Table of Contents

Indebtedness is incurred or such Disqualified Stock or preferred stock is issued would have been at least 2.0 to 1, determined on a pro forma application of the net proceeds therefrom), as if the additional Indebtedness had been incurred or the Disqualified Stock or preferred stock had been issued, at the beginning of such four-quarter period.

The first paragraph of this covenant will not prohibit the following (collectively, “*Permitted Debt*”):

(1) the incurrence by LifePoint and its Restricted Subsidiaries of additional Indebtedness and letters of credit under Credit Facilities at any one time outstanding under this clause (1) (with letters of credit being deemed to have a principal amount equal to the maximum amount of such letters of credit) and its Restricted Subsidiaries thereunder) not to exceed \$1,000 million (less the aggregate principal amount of Indebtedness incurred or outstanding pursuant to clause (17) of this paragraph);

(2) Existing Indebtedness;

(3) the incurrence by LifePoint and the Guarantors of Indebtedness represented by (a) the notes and the related Subsidiary Guarantees and (b) the Exchange Notes and the Exchange Subsidiary Guarantees to be issued pursuant to the indenture in exchange for the notes in accordance with the terms of the Registration Rights Agreement;

(4) the incurrence by LifePoint or any of its Restricted Subsidiaries of Indebtedness represented by Capital Lease Obligations, money obligations, in each case, incurred for the purpose of financing all or any part of the purchase price or cost of construction or equipment used in the business of LifePoint or such Subsidiary, in an aggregate principal amount, including all Permitted Refinancing, to refinance or replace any Indebtedness incurred pursuant to this clause (4), not to exceed the greater of \$100 million and 2.5% of Total Assets;

(5) the incurrence by LifePoint or any of its Restricted Subsidiaries of Permitted Refinancing Indebtedness in exchange for, or the extension, refinancing, renewal, replacement, defeasance, or refund of Indebtedness (other than intercompany Indebtedness) that was permitted by the first paragraph of this covenant or clauses (2), (3), (4), (12), (13), (15), (26) or this clause (5) of this paragraph;

(6) the incurrence by LifePoint or any of its Restricted Subsidiaries of intercompany Indebtedness or the issuance of Disqualified Stock among LifePoint and any of its Restricted Subsidiaries; provided, however, that (a) any subsequent issuance or transfer of Equity Instruments, Indebtedness, Disqualified Stock or Preferred Stock being held by a Person other than LifePoint or a Restricted Subsidiary and (b) any subsequent issuance or transfer of Equity Instruments, Indebtedness, Disqualified Stock or Preferred Stock to a Person that is not either LifePoint or a Restricted Subsidiary, will be deemed to be an incurrence of such Indebtedness, Disqualified Stock or Preferred Stock by LifePoint or such Restricted Subsidiary, as the case may be, under clause (6);

(7) the incurrence by LifePoint or any of its Restricted Subsidiaries of Hedging Obligations that are incurred for the purpose of financing with respect to any Indebtedness that is permitted by the terms of the indenture to be outstanding or (b) exchange rate risk with respect to any agreement or Indebtedness, or with respect to any asset, of such Person that is payable or denominated in a currency other than U.S. dollars;

(8) the guarantee by LifePoint or any of the Restricted Subsidiaries of Indebtedness of LifePoint or a Restricted Subsidiary that is not another provision of this covenant;

(9) the accrual of interest, the accretion or amortization of original issue discount, the payment of interest on any Indebtedness incurred with the same terms, and the payment of dividends on preferred stock (including Disqualified Stock) in the form of additional shares of common stock (including Disqualified Stock) will not be deemed to be an incurrence of Indebtedness or an issuance of

e424b3

Table of Contents

preferred stock (including Disqualified Stock) for purposes of this covenant; *provided*, in each such case, that the amount thereof is LifePoint as accrued;

(10) Indebtedness of LifePoint or any Restricted Subsidiary consisting of guarantees, indemnities, hold backs or obligations in re in connection with the acquisition or disposition of assets, including, without limitation, shares of Capital Stock of Restricted Subsidiaries or obligations incurred in connection with the acquisition or disposition of assets which are contingent on the performance of the assets;

(11) Indebtedness represented by (a) letters of credit for the account of LifePoint or any Restricted Subsidiary or (b) other obligations pursuant to any surety bond or other similar arrangements, to the extent that such letters of credit and other obligations, as the case may be, are security for workers' compensation claims, payment obligations in connection with self-insurance, in connection with participation in pension or other programs or other similar requirements in the ordinary course of business;

(12) the incurrence by LifePoint or any Restricted Subsidiary of Indebtedness to the extent the proceeds thereof are used to purchase a Control Offer or to defease or discharge notes in accordance with the terms of the indenture;

(13) Indebtedness arising from the honoring by a bank or other financial institution of a check, draft or similar instrument in advance of funds (including overdrafts) drawn against insufficient funds in the ordinary course of business; provided, however, that such Indebtedness is extinguished at the time of incurrence;

(14) Indebtedness incurred in the ordinary course of business in connection with cash pooling arrangements, cash management arrangements or in the ordinary course of business in respect of netting services, overdraft protections and similar arrangements in each case in connection with bank accounts;

(15) Indebtedness consisting of (a) the financing of insurance premiums or (b) take or pay obligations in supply agreements, in each case in the ordinary course of business;

(16) Indebtedness of LifePoint and its Subsidiaries representing the obligation of such Person to make payments with respect to the salaries, bonus, Capital Stock of officers, employees or directors (or their estates) of LifePoint or such Subsidiaries pursuant to the terms of employment contracts, agreements, benefit plans or similar documents;

(17) Indebtedness incurred by a Securitization Subsidiary in connection with a Qualified Securitization Transaction that is not recourse to LifePoint or its Restricted Subsidiaries; *provided, however*, that in the event such Securitization Subsidiary ceases to qualify as a Securitization Subsidiary, recourse becomes recourse to LifePoint or any of its Restricted Subsidiaries, such Indebtedness will, in each case, be deemed to be, and must be repaid, as Indebtedness incurred at such time (or at the time initially incurred) under one more of the other provisions of this covenant;

(18) the disposition of accounts receivable in connection with receivables factoring arrangements in the ordinary course of business;

(19) unsecured Indebtedness in respect of obligations of LifePoint or any of its Restricted Subsidiaries to pay the deferred purchase price of goods or progress payments in connection with such goods and services; provided that such obligations are incurred in connection with open account sales on customary trade terms (which require that all such payments be made within 60 days after the incurrence of the related obligations);

(20) Indebtedness representing deferred compensation to employees of LifePoint or any of its Restricted Subsidiaries incurred in the ordinary course of business;

e424b3

Table of Contents

(21) reimbursement obligations with respect to letters of credit, bank guarantees, warehouse receipts or similar instruments issued by LifePoint and Indebtedness of LifePoint in respect of letters of credit issued by LifePoint for its own account or for the account of any of its Restricted Subsidiaries;

(22) Indebtedness arising from any Sale and Leaseback Transaction, *provided* that the principal amount of any Indebtedness incurred shall not exceed (a) \$35 million less (b) the aggregate amount of Permitted Refinancing Indebtedness incurred to refinance Indebtedness incurred pursuant to this clause;

(23) Physician Support Obligations incurred by LifePoint or any Restricted Subsidiary;

(24) Indebtedness incurred on behalf of or representing Guarantees of Indebtedness of Permitted Joint Ventures of LifePoint or any Restricted Subsidiary in excess of \$35 million at any one time outstanding;

(25) the incurrence by LifePoint or any of its Restricted Subsidiaries of additional Indebtedness (which may include, but is not limited to, Indebtedness referred to in the foregoing clauses (1) through (24) and clause (26)) in an aggregate principal amount (or accreted value, as applicable) exceeding, including all Permitted Refinancing Indebtedness incurred to refund, refinance or replace any Indebtedness incurred pursuant to this clause, the greater of \$200 million and 5.0% of Total Assets; and

(26) Indebtedness of a Restricted Subsidiary outstanding on the date on which such Restricted Subsidiary was acquired by LifePoint or any Restricted Subsidiary (other than Indebtedness incurred as consideration in, or to provide all or any portion of the funds or credit support utilized in, a series of transactions pursuant to which such Restricted Subsidiary became a Subsidiary of LifePoint or was otherwise acquired by LifePoint or any Restricted Subsidiary in effect thereto, (a) LifePoint would be permitted to incur at least \$1 of additional Indebtedness pursuant to the Fixed Charge Coverage Ratio set forth above, or (b) the Fixed Charge Coverage Ratio would be no worse than immediately prior thereto.

For purposes of determining compliance with this “Incurrence of Indebtedness and Issuance of Preferred Stock” covenant, in the event Indebtedness meets the criteria of more than one of the categories of Permitted Debt described in clauses (1) through (26) above, or is excluded from the first paragraph of this covenant, LifePoint will be permitted to classify and reclassify such item of Indebtedness in any manner that complies with the Indebtedness under Credit Facilities outstanding on the date on which notes are first issued and authenticated under the indenture will be determined as of such date in reliance on the exception provided by clause (1) of the definition of Permitted Debt.

Notwithstanding any other provision of this covenant, the maximum amount of Indebtedness that may be incurred pursuant to this covenant shall not be exceeded with respect to any Indebtedness solely as a result of fluctuations in exchange rates or currency values.

Guarantees of, or obligations in respect of letters of credit relating to, Indebtedness that is otherwise included in the determination of the amount of Indebtedness shall not be included in the determination of such amount of Indebtedness; *provided* that the incurrence of the Indebtedness represented by such letters of credit, as the case may be, was in compliance with this covenant.

Liens

LifePoint will not, and will not permit any Restricted Subsidiary to, directly or indirectly, issue, assume or guarantee any Indebtedness secured by a Permitted Lien) on any property or asset now owned or hereafter acquired by LifePoint or such Restricted Subsidiary without making equal and adequate security for all notes then or thereafter outstanding will be secured by a Lien equally and ratably with or prior to any and all other obligations thereunder. All obligations shall be so secured. Any Lien created for the benefit of the holders of the notes pursuant to the preceding sentence shall promptly be automatically and unconditionally released and discharged upon the release and discharge of the initial Lien.

e424b3

[Table of Contents](#)

Dividend and other Payment Restrictions Affecting Restricted Subsidiaries

LifePoint will not, and will not permit any of its Restricted Subsidiaries to, directly or indirectly, create or permit to exist or become an encumbrance or restriction on the ability of any Restricted Subsidiary to:

- (1) pay dividends or make any other distributions on its Capital Stock to LifePoint or any of its Restricted Subsidiaries, or with respect to its participation in, or measured by, its profits, or pay any indebtedness owed to LifePoint or any of its Restricted Subsidiaries;
- (2) make loans or advances to LifePoint or any of its Restricted Subsidiaries; or
- (3) transfer any of its properties or assets to LifePoint or any of its Restricted Subsidiaries.

However, the preceding restrictions will not apply to encumbrances or restrictions existing under or by reason of:

- (1) agreements governing Existing Indebtedness and Credit Facilities or other agreements as in effect on the Issue Date and any amendments, restatements, renewals, increases, supplements, refundings, replacements or refinancings of those agreements, *provided* that the amendments, restatements, renewals, increases, supplements, refundings, replacement or refinancings are not materially more restrictive, taken as a whole, than the dividend and other payment restrictions than those contained in those agreements on the Issue Date;
- (2) the indenture, the notes, the Subsidiary Guarantees, the Exchange Notes and the Exchange Subsidiary Guarantees;
- (3) applicable law;
- (4) any instrument governing Indebtedness or Capital Stock of a Person, or such encumbrances or restrictions with respect to other assets acquired by LifePoint or any of its Restricted Subsidiaries as in effect at the time of such acquisition (except to the extent such encumbrance or restriction on Indebtedness was incurred in connection with or in contemplation of such acquisition), which encumbrance or restriction is not applicable to the properties or assets of any Person, other than the Person, the property or assets of the Person, so acquired, *provided* that, in the case of such acquisition, it was permitted by the terms of the indenture to be incurred;
- (5) customary non-assignment provisions in leases, licences and other agreements entered into in the ordinary course of business;
- (6) purchase money obligations or Capital Lease Obligations for property acquired or leased in the ordinary course of business that is not the property or the assets otherwise subject thereto of the nature described in clause (3) of the preceding paragraph;
- (7) any agreement for the sale or other disposition of a Restricted Subsidiary or any assets thereof that restricts distributions by the sale or other disposition;
- (8) Permitted Refinancing Indebtedness, provided that the restrictions contained in the agreements governing such Permitted Refinancing are not materially more restrictive, taken as a whole, than those contained in the agreements governing the Indebtedness being refinanced;
- (9) Liens securing Indebtedness otherwise permitted to be incurred under the provisions of the covenant described above under the heading "Covenants";
- (10) provisions with respect to the disposition or distribution of assets or property in joint venture agreements, assets sale agreements or other similar agreements entered into in the ordinary course of business;

e424b3

Table of Contents

(11) restrictions imposed in connection with a financing transaction involving a sale or other disposition of accounts receivable a limitation, in connection with a securitization or similar financing) or in connection with a financing involving a subsidiary trust or s permitted by the covenant described above under the caption “—Incurrence of Indebtedness and Issuance of Preferred Stock”, *provi* materially adversely affect LifePoint’s ability to pay interest and principal on the notes when due;

(12) restrictions on cash or other deposits or net worth imposed by customers under contracts entered into in the ordinary course governmental agencies or authorities;

(13) in the case of clause (3) of the preceding paragraph, encumbrances or restrictions arising or agreed to in the ordinary course Indebtedness and that do not materially detract from the value of the property or assets of LifePoint and its Restricted Subsidiaries;

(14) encumbrances or restrictions contained in the terms of Indebtedness if the encumbrance or restriction is not materially more customary in comparable financings and will not materially affect LifePoint’s ability to make principal or interest payments on the n LifePoint in good faith); and

(15) agreements with respect to Insurance Subsidiaries or with respect to securities thereof, in each case in connection with the o

Limitation on Sale and Leaseback Transactions

LifePoint will not, and will not permit any Restricted Subsidiary to, enter into any Sale and Leaseback Transaction with respect to a or the Restricted Subsidiary would be entitled to:

(1) incur Indebtedness in an amount equal to the Attributable Debt with respect to such Sale and Leaseback Transaction pursuant under the caption “— Incurrence of Indebtedness and Issuance of Preferred Stock”; and

(2) create a Lien on such property securing such Attributable Debt pursuant to the covenant described above under the caption “—

In which case, the corresponding Indebtedness and Lien will be deemed incurred pursuant to those provisions.

Merger, Consolidation or Sale of Assets

LifePoint may not, directly or indirectly: (1) consolidate or merge with or into another Person (whether or not LifePoint is the survivor transfer, convey or otherwise dispose of all or substantially all of the properties or assets of LifePoint and its Restricted Subsidiaries tak transactions, to another Person; unless:

(1) either: (a) LifePoint is the surviving corporation; or (b) the Person formed by or surviving any such consolidation or merger (such sale, assignment, transfer, conveyance or other disposition has been made is a Person organized or existing under the laws of th United States or the District of Columbia;

(2) the Person formed by or surviving any such consolidation or merger (if other than LifePoint) or the Person to which such sale or other disposition has been made assumes all the obligations of LifePoint under the notes and the indenture pursuant to a supplement satisfactory to the trustee;

(3) immediately after such transaction, on a pro forma basis giving effect to such transaction or series of transactions (and treating Restricted Subsidiary incurred in connection with or as a result of such transaction or series of transactions as having been incurred Default or Event of Default exists; and

e424b3

e424b3

[Table of Contents](#)

(4) except in the case of a transaction entered into to reincorporate LifePoint in another jurisdiction, LifePoint or the Person formed by such consolidation or merger (if other than LifePoint), or to which such sale, assignment, transfer, conveyance or other disposition has been made, shall be deemed to have entered into such transaction after giving *pro forma* effect thereto and any related financing transactions as if the same had occurred at the beginning of the period (a) be permitted to incur at least \$1.00 of additional Indebtedness pursuant to the Fixed Charge Coverage Ratio test set forth in the first paragraph described above under the caption “—Incurrence of Indebtedness and Issuance of Preferred Stock” or (b) have a Fixed Charge Coverage Ratio of LifePoint for such applicable four-quarter period without giving *pro forma* effect to such transaction or transactions.

In addition, LifePoint may not, directly or indirectly, lease all or substantially all of the properties or assets of LifePoint and its Restricted Subsidiaries in one or more related transactions, to any other Person. This “Merger, Consolidation or Sale of Assets” covenant will not apply to a sale, lease, transfer, conveyance or other disposition of assets between or among LifePoint and any of the Guarantors.

Upon any consolidation or merger, or any sale, assignment, transfer, conveyance, transfer or other disposition of all or substantially all of the properties or assets of LifePoint and its Restricted Subsidiaries, taken as a whole, in accordance with the foregoing provisions, the successor Person formed by such consolidation or merger, or to which such sale, assignment, transfer, conveyance or other disposition is made, shall succeed to, and be substituted for, LifePoint under the indenture with the same effect as if such successor had been named as LifePoint therein. When such successor assumes the obligations of its predecessor under the indenture and the notes following a consolidation or merger, or any sale, assignment, transfer, conveyance or other disposition of all or substantially all of the assets of the predecessor in accordance with the foregoing provisions, the predecessor shall be released from its obligations.

Designation of Restricted and Unrestricted Subsidiaries

The Board of Directors of LifePoint may designate any Restricted Subsidiary to be an Unrestricted Subsidiary if that designation would not result in a Restricted Subsidiary being designated as an Unrestricted Subsidiary, the aggregate fair market value of all outstanding Investments owned by LifePoint and its Restricted Subsidiaries in the Subsidiary so designated will be deemed to be an Investment made as of the time of the designation and will reduce the amount of Payments under the first paragraph of the covenant described above under the caption “—Restricted Payments” or Permitted Investments. Such designation will only be permitted if the Investment would be permitted at that time and if the Restricted Subsidiary otherwise meets the requirements of a Subsidiary. The Board of Directors of LifePoint may re-designate any Unrestricted Subsidiary to be a Restricted Subsidiary if the redesignation meets the requirements of a Restricted Subsidiary. As of the Issue Date, our Subsidiary, Life Indemnity, LTD, is an Unrestricted Subsidiary.

Transactions with Affiliates

LifePoint will not, and will not permit any of its Restricted Subsidiaries to, make any payment to, or sell, lease, transfer or otherwise dispose of, any assets to, or purchase any property or assets from, or enter into or make or amend any transaction, contract, agreement, understanding, arrangement or other transaction for the benefit of, any Affiliate (each, an “*Affiliate Transaction*”), unless:

(1) the Affiliate Transaction is on terms that are no less favorable to LifePoint or the relevant Restricted Subsidiary than those that would be obtained in a comparable transaction by LifePoint or such Restricted Subsidiary with an unrelated Person; and

(2) with respect to any Affiliate Transaction or series of related Affiliate Transactions involving aggregate consideration in excess of \$100,000, the trustee a resolution of LifePoint’s Board of Directors set forth in an officers’ certificate certifying that such Affiliate Transaction has been approved by a majority of the disinterested members of LifePoint’s Board of Directors, or a certificate of the Holders of such Affiliate Transaction from a financial point of view issued by an accounting, appraisal or investment banking firm or other independent third party in the United States.

e424b3

e424b3

Table of Contents

The following items will not be deemed to be Affiliate Transactions and, therefore, will not be subject to the provisions of the prior

(1) directors' fees, indemnification and similar arrangements, consulting fees, employee salaries, bonuses or employment agreements, disability, severance or employee benefit arrangements and incentive arrangements with, and loans and advances to, any officer, director or employee in the ordinary course of business,

(2) performance of all agreements in existence on the Issue Date and any modification thereto or any transaction contemplated therefor so long as such modification or replacement is not materially more disadvantageous to LifePoint or any of its Restricted Subsidiaries than the agreement in effect on the Issue Date;

(3) transactions in connection with a financing transaction involving a sale or other disposition of accounts receivable and related assets (including, but not limited to, a securitization or similar financing) or in connection with a financing involving a subsidiary trust or similar arrangement, as permitted by the covenant described above under the caption "—Incurrence of Indebtedness and Issuance of Preferred Stock";

(4) transactions in the ordinary course of business with any joint venture that is otherwise permitted by the indenture; *provided*, that such transactions are not between or among LifePoint and/or any of its Subsidiaries on the one hand and third parties that are not otherwise Affiliates of LifePoint on the other;

(5) transactions between or among LifePoint and/or its Restricted Subsidiaries;

(6) transactions with a Person (other than an Unrestricted Subsidiary) that is an Affiliate of LifePoint solely because LifePoint or its Restricted Subsidiaries have an Equity Interest in, or controls, such Person;

(7) sales of Equity Interests (other than Disqualified Stock) to Affiliates of LifePoint and the granting of registration and other covenants in connection therewith;

(8) Restricted Payments and Permitted Investments that are permitted by the provisions of the indenture described above under the caption "—Restricted Payments and Permitted Investments";

(9) transactions complying with the covenant described above under the caption "—Merger, Consolidation or Sale of Assets";

(10) pledges of Equity Interests of Unrestricted Subsidiaries;

(11) any transaction effected as part of a Qualified Securitization Financing; and

(12) any transaction with an Insurance Subsidiary in the ordinary course of business.

Additional Subsidiary Guarantees

If LifePoint or any of its Restricted Subsidiaries acquires or creates another Domestic Subsidiary after the Issue Date, then that newly acquired Subsidiary (other than an Excluded Subsidiary) will become a Guarantor and execute a supplemental indenture and deliver an opinion of counsel as trustee as promptly as possible after the end of the fiscal quarter in which it was acquired or created.

Reports

Whether or not required by the Commission, so long as any notes are outstanding, LifePoint will furnish to the Holders of notes and to the Commission will not accept such filing), within the time periods specified in the Commission's rules and regulations:

(1) all quarterly and annual financial information that would be required to be contained in a filing with the Commission on Form 10-Q and Form 10-K, respectively, required to file such Forms, including a

e424b3

e424b3

Table of Contents

“Management’s Discussion and Analysis of Financial Condition and Results of Operations” and, with respect to the annual information financial statements by LifePoint’s certified independent accountants; and

(2) all current reports that would be required to be filed with the Commission on Form 8-K if LifePoint were required to file such information accepted for filing with the Commission shall be deemed to have been furnished to Holders of the notes.

Events of Default and Remedies

Each of the following is an Event of Default with respect to the notes:

- (1) default for 30 days in the payment when due of interest on the notes;
- (2) default in payment when due of the principal of, or premium, if any, on the notes (including the failure to repurchase notes pursuant to a Redemption or Asset Sale Offer);
- (3) failure by LifePoint or any of its Restricted Subsidiaries to comply with the covenants described above under the caption “—Consolidation or Sale of Assets;”
- (4) failure by LifePoint or any of its Restricted Subsidiaries for 60 days after notice to comply with any of the other agreements in the indenture;
- (5) default under any mortgage, indenture or instrument under which there may be issued or by which there may be secured or evidenced by LifePoint or any of its Restricted Subsidiaries (or the payment of which is guaranteed by LifePoint or any of its Restricted Subsidiaries) if such Indebtedness or guarantee now exists, or is created after the Issue Date, if that default:
 - (a) is caused by a failure to pay principal of such Indebtedness at its final stated maturity after giving effect to any grace period or the date of such default (a “*Payment Default*”); or
 - (b) results in the acceleration of such Indebtedness prior to its express maturity,

and, in each case, the principal amount of any such Indebtedness, together with the principal amount of any other such Indebtedness under the indenture, is in Default or the maturity of which has been so accelerated, aggregates \$25 million or more;

- (6) failure by LifePoint or any of its Restricted Subsidiaries to pay final, non-appealable judgments aggregating in excess of \$25 million or insurance or as to which an insurer has not acknowledged coverage in writing, which judgments are not paid, discharged or stayed for 60 days;
- (7) except as permitted by the indenture, any Subsidiary Guarantee of a Significant Subsidiary of notes shall be held in any final, judgment to be unenforceable or invalid or shall cease for any reason to be in full force and effect or any Guarantor that is a Significant Subsidiary of any such Guarantor, shall deny or disaffirm its obligations under its Subsidiary Guarantee for the notes; and
- (8) certain events of bankruptcy or insolvency described in the indenture with respect to LifePoint or any of its Restricted Subsidiaries.

A Default under clause (4) is not an Event of Default in respect of the notes until the trustee or the Holders of at least 25% in principal amount of the notes notify LifePoint and the trustee (in the case of a notice given by holders) of the Default and LifePoint does not cure such default within 30 days of such notice. Such notice must specify the Default, demand that it be remedied and state that such notice is a “Notice of Default.”

e424b3

[Table of Contents](#)

In the case of an Event of Default arising from certain events of bankruptcy or insolvency with respect to LifePoint, all outstanding notes may be declared due and payable immediately without further action or notice. If any other Event of Default occurs and is continuing, the trustee or the Holders of at least a majority of the then outstanding notes may declare all the notes to be due and payable immediately.

Holders of the notes may not enforce the indenture or the notes except as provided in the indenture. Subject to certain limitations, Holders of a majority in aggregate principal amount of the then outstanding notes may direct the trustee in its exercise of any trust or power. The trustee may withhold from Holders notice of a continuing Default or Event of Default if it determines that withholding notice is in their interest, except a Default or Event of Default that results in the acceleration of principal or interest.

The Holders of a majority in aggregate principal amount of the notes then outstanding by notice to the trustee may on behalf of the Holders of the notes existing Default or Event of Default and its consequences under the indenture except a continuing Default or Event of Default in the payment of principal of, the notes.

LifePoint is required to deliver to the trustee annually a statement regarding compliance with the indenture. Upon becoming aware of a Default or Event of Default, LifePoint is required to deliver to the trustee a statement specifying such Default or Event of Default.

No Personal Liability of Directors, Officers, Employees and Stockholders

No director, officer, employee, incorporator or stockholder of LifePoint or any Guarantor, as such, will have any liability for any obligations of LifePoint or any Guarantors under the notes, the indenture, the Subsidiary Guarantees, or for any claim based on, in respect of, or by reason of, such obligations. Each Holder of notes by accepting a note waives and releases all such liability. The waiver and release are part of the consideration for issuance of the notes and shall be effective to waive liabilities under the federal securities laws.

Legal Defeasance and Covenant Defeasance

LifePoint may, at its option and at any time, elect to have all of its obligations discharged with respect to the outstanding notes and all of the obligations of the Guarantors discharged with respect to their Subsidiary Guarantees (“*Legal Defeasance*”) except for:

- (1) the rights of Holders of outstanding notes to receive payments in respect of the principal of, or interest or premium on, such notes or to receive payments from the trust referred to below;
- (2) LifePoint’s obligations with respect to the notes concerning issuing temporary notes, registration of notes, mutilated, destroyed or lost notes, the maintenance of an office or agency for payment and money for security payments held in trust;
- (3) the rights, powers, trusts, duties and immunities of the trustee, and LifePoint’s and the Guarantor’s obligations in connection with the notes;
- (4) the Legal Defeasance provisions of the indenture.

In addition, LifePoint may, at its option and at any time, elect to have the obligations of LifePoint and the Guarantors released with respect to the obligations described in the indenture (“*Covenant Defeasance*”) and thereafter any omission to comply with those covenants will not constitute a Default or Event of Default with respect to the notes. In the event Covenant Defeasance occurs in respect of the notes, certain events (not including non-payment, bankruptcy, liquidation and insolvency events with respect to LifePoint) described under “—Events of Default and Remedies” will no longer constitute an Event of Default or Event of Default with respect to the notes.

In order to exercise either Legal Defeasance or Covenant Defeasance:

- (1) LifePoint must irrevocably deposit with the trustee, in trust, for the benefit of the Holders of the notes, cash in U.S. dollars sufficient to pay the Securities, the scheduled payments of principal of and

e424b3

e424b3

Table of Contents

interest on which will be sufficient, or a combination of cash in U.S. dollars and non-callable Government Securities, the scheduled on which will together with such cash be sufficient, in the opinion of a nationally recognized firm of independent public accountants reinvestment of interest, to pay the principal of, or interest and premium on, the outstanding notes on the stated maturity or on the ap may be, and LifePoint must specify whether such notes are being defeased to maturity or to a particular redemption date;

(2) in the case of Legal Defeasance, LifePoint has delivered to the trustee an opinion of counsel in form reasonably acceptable to (a) LifePoint has received from, or there has been published by, the Internal Revenue Service a ruling or (b) since the Issue Date, the applicable federal income tax law, in either case to the effect that, and based thereon such opinion of counsel will confirm that, the I not recognize income, gain or loss for federal income tax purposes as a result of such Legal Defeasance and will be subject to federal in the same manner and at the same times as would have been the case if such Legal Defeasance had not occurred;

(3) in the case of Covenant Defeasance, LifePoint has delivered to the trustee an opinion of counsel in form reasonably acceptable Holders of the outstanding notes will not recognize income, gain or loss for federal income tax purposes as a result of such Covenant D federal income tax on the same amounts, in the same manner and at the same times as would have been the case if such Covenant D

(4) no Default or Event of Default has occurred and is continuing on the date of such deposit (other than a Default or Event of D of funds to be applied to such deposit and the grant of any Lien securing such borrowing);

(5) such Legal Defeasance or Covenant Defeasance will not result in a breach or violation of, or constitute a default under any m (other than the indenture and the agreements governing any other Indebtedness being defeased, discharged or replaced) to which Lif party or by which LifePoint or any of its Subsidiaries is bound;

(6) LifePoint must deliver to the trustee an officers' certificate stating that the deposit was not made by LifePoint with the intent over the other creditors of LifePoint with the intent of defeating, hindering, delaying or defrauding creditors of LifePoint or others; and

(7) LifePoint must deliver to the trustee an officers' certificate and an opinion of counsel, each stating that all conditions precede or the Covenant Defeasance have been complied with or waived.

Notwithstanding the foregoing, the opinion of counsel required by clause (2) above with respect to a Legal Defeasance need not be delivered to the trustee for cancellation (i) have become due and payable or (ii) will become due and payable on the maturity date or on (in the case of a redemption) under arrangements satisfactory to the trustee for the giving of notice of redemption by the trustee in the n LifePoint.

Amendment, Supplement and Waiver

Except as provided in the next two succeeding paragraphs, the indenture or the notes may be amended or supplemented with the con majority in principal amount of the notes then outstanding (including, without limitation, consents obtained in connection with a purcha offer for, notes), and any existing default or compliance with any provision of the indenture or the notes may be waived with the conser principal amount of the then outstanding notes (including, without limitation, consents obtained in connection with a purchase of, or ter notes).

Without the consent of each Holder affected, an amendment or waiver may not (with respect to any notes held by a non-consenting

e424b3

Table of Contents

- (1) reduce the principal amount of notes whose Holders must consent to an amendment, supplement or waiver;
- (2) reduce the principal of or change the fixed maturity of any note or alter the provisions with respect to the redemption of the notes to the covenants described above under the caption “—Repurchase at the Option of Holders” and other than notice provisions with respect to LifePoint);
- (3) reduce the rate of or change the time for payment of interest on any note;
- (4) waive a Default or Event of Default in the payment of principal of, or interest or premium on, the notes (except a rescission of the notes) by the Holders of at least a majority in aggregate principal amount of the notes and a waiver of the payment default in respect of the notes;
- (5) make any note payable in money other than that stated in the notes;
- (6) make any change in the provisions of the indenture relating to waivers of past Defaults or the rights of Holders of notes to receive interest or premium on, the notes;
- (7) after the date of an event giving rise to a redemption, waive a redemption payment with respect to any note (other than a payment of principal) under the covenants described above under the caption “—Repurchase at the Option of Holders”);
- (8) release any Guarantor from any of its obligations under its Subsidiary Guarantee or the indenture, except in accordance with the terms of the indenture;
- (9) make any change in the preceding amendment and waiver provisions.

Notwithstanding the preceding, without the consent of any Holder of notes, LifePoint, the Guarantors, if applicable, and the trustee may make any change in the indenture or the notes:

- (1) to cure any ambiguity, defect or inconsistency;
- (2) to provide for uncertificated notes in addition to or in place of certificated notes;
- (3) to provide for the assumption of LifePoint’s or a Guarantor’s obligations to Holders of notes in the case of a merger or consolidation of LifePoint or a Guarantor, or the sale, lease, conveyance or otherwise disposition of all or substantially all of LifePoint’s or a Guarantor’s assets;
- (4) to make any change that would provide any additional rights or benefits to the Holders of notes or that does not adversely affect the obligations of LifePoint or a Guarantor under the indenture of any such Holder;
- (5) to comply with requirements of the Commission in order to effect or maintain the qualification of the indenture under the Trust Indenture Act;
- (6) to allow any Guarantor to execute a supplemental indenture and/or a Subsidiary Guarantee with respect to the notes;
- (7) to evidence and provide the acceptance of the appointment of a successor trustee under the indenture;
- (8) to mortgage, pledge, hypothecate or grant a security interest in favor of the trustee for the benefit of the Holders of notes as a condition to the making, issuing, selling, delivering or performance of LifePoint’s or a Guarantor’s obligations;
- (9) to release a Guarantor from its Subsidiary Guarantee pursuant to the terms of the indenture when permitted or required pursuant to the terms of the indenture.

e424b3

[Table of Contents](#)

(10) to conform the text of the indenture, the notes or the Subsidiary Guarantees to any provision of this Description of Notes to which the Description of Notes was intended to be a substantially verbatim recitation of a provision of the indenture, the notes or the Subsidiary Guarantees.

Satisfaction and Discharge

The indenture will be discharged and will cease to be of further effect as to all notes issued thereunder, when:

(1) either:

(a) all notes that have been authenticated, except lost, stolen or destroyed notes that have been replaced or paid and notes for which cash has been deposited in trust and thereafter repaid to LifePoint, have been delivered to the trustee for cancellation; or

(b) all notes that have not been delivered to the trustee for cancellation have become due and payable by reason of the mailing of a notice of redemption otherwise or will become due and payable within one year and LifePoint or any Guarantor has irrevocably deposited or caused to be deposited in trust funds in trust solely for the benefit of the Holders of notes, cash in U.S. dollars, non-callable Government Securities, the scheduled interest on which will be sufficient, or a combination of cash in U.S. dollars and non-callable Government Securities, the scheduled interest on which will, together with such cash, be sufficient, in the opinion of a nationally recognized firm of independent public accountants (which firm only be provided if non-callable Government Securities have been deposited), without consideration of any reinvestment of interest, to pay the indebtedness on the notes not delivered to the trustee for cancellation for principal, premium and accrued interest to the date of maturity;

(2) no Default or Event of Default with respect to the notes has occurred and is continuing on the date of the deposit (other than a Default or Event of Default resulting from the borrowing of funds to be applied to such deposit and any similar deposit relating to other Indebtedness and, in each case, to secure such borrowing) and the deposit will not result in a breach or violation of, or constitute a default under, any other instrument to which LifePoint is a party or by which LifePoint or any Guarantor is bound (other than with respect to the borrowing of funds to make the deposit referred to in (1)); discharge and any similar deposit relating to other Indebtedness and in each case the granting of Liens to secure such borrowings);

(3) LifePoint or any Guarantor has paid or caused to be paid all sums payable by it under the indenture with respect to the notes; and

(4) LifePoint has delivered irrevocable instructions to the trustee under the indenture to apply the deposited money toward the payment of the notes at their redemption date, as the case may be.

In addition, LifePoint must deliver an officers' certificate and an opinion of counsel to the trustee stating that all conditions precedent to the discharge have been satisfied or waived.

Concerning the Trustee

If the trustee becomes a creditor of LifePoint or any Guarantor, the indenture limits its right to obtain payment of claims in certain cases and to receive in respect of any such claim as security or otherwise. The trustee will be permitted to engage in other transactions; however, if the trustee is a creditor, it must eliminate such conflict within 90 days, apply to the Commission for permission to continue or resign.

The Holders of a majority in principal amount of the then outstanding notes will have the right to direct the time, method and place of payment and to exercise any remedy available to the trustee, subject to certain exceptions. The indenture provides that in case an Event of Default occurs, the trustee will be required, in the exercise of its power, to use the degree of care of a prudent man in the conduct of his own affairs. Subject to such limitations, the trustee will be under no obligation to exercise any of its rights or powers under the

e424b3

e424b3

[Table of Contents](#)

indenture at the request of any Holder of notes, unless such Holder has offered to the trustee security and indemnity satisfactory to it as

Certain Definitions

Set forth below are certain defined terms used in the indenture. Reference is made to the indenture for a full disclosure of all such terms used herein for which no definition is provided.

“3.25% Convertible Senior Subordinated Debentures due 2025” means the \$225 million in aggregate principal amount of 3.25% Convertible Senior Subordinated Debentures due 2025 issued by LifePoint pursuant to an indenture dated August 10, 2005 between LifePoint and Citibank, N.A., as trustee.

“3.5% Convertible Senior Subordinated Notes due 2014” means the \$575 million in aggregate principal amount of 3.5% Convertible Senior Subordinated Notes due 2014 issued by LifePoint pursuant to an indenture dated May 29, 2007 between LifePoint and The Bank of New York Mellon Trust Company, N.A., as trustee.

“Acquired Debt” means, with respect to any specified Person:

(1) Indebtedness of any other Person existing at the time such other Person is merged with or into or became a Restricted Subsidiary of LifePoint, whether or not such Indebtedness is incurred in connection with, or in contemplation of, such other Person merging with or into, or becoming a Restricted Subsidiary of LifePoint; and

(2) Indebtedness secured by a Lien encumbering any asset acquired by such specified Person (limited to the maximum amount of such Indebtedness with respect to such Lien).

“Affiliate” of any specified Person means any other Person directly or indirectly controlling or controlled by or under direct or indirect control of such specified Person. For purposes of this definition, “control,” as used with respect to any Person, means the possession, directly or indirectly, of the direction of the management or policies of such Person, whether through the ownership of voting securities, by agreement or otherwise. Ownership of 10% or more of the Voting Stock of a Person will be deemed to be control. For purposes of this definition, the terms “control” and “common control with” have correlative meanings.

“Applicable Redemption Premium” means, with respect to any note on any redemption date, the excess of

(1) the present value at such redemption date of the redemption price of such note if such note were redeemed on October 1, 2015, over the present value at such redemption date of the redemption price of such note if such note were redeemed on October 1, 2015 (not including any portion of such payments of interest accrued to the redemption date) over the Treasury Rate at such redemption date plus 50 basis points, over

(2) the then-outstanding principal amount of the note.

“Asset Sale” means:

(1) the sale, lease, conveyance or other disposition by LifePoint or any of its Restricted Subsidiaries of any assets, other than sale in the ordinary course of business consistent with past practices; *provided* that the sale, conveyance or other disposition of all or substantially all of the assets of its Restricted Subsidiaries taken as a whole will be governed by the covenant described above under the caption “—Repurchase at the Option of LifePoint” and/or the covenant described above under the caption “—Certain Covenants—Merger, Consolidation or Sale of Assets” and the Sale covenant; and

(2) the issuance of Equity Interests (other than directors’ qualifying shares) by any Restricted Subsidiary or the sale of Equity Interests by any Restricted Subsidiary.

Notwithstanding the preceding, the following items will not be deemed to be Asset Sales:

e424b3

e424b3

Table of Contents

- (1) any single transaction or series of related transactions that involves assets having a fair market value of less than \$30 million;
- (2) a transfer of assets between or among LifePoint and one or more Restricted Subsidiaries;
- (3) an issuance of Equity Interests by a Restricted Subsidiary to LifePoint or to another Restricted Subsidiary;
- (4) the sale, lease, assignment, sublease or other disposition of equipment, inventory, accounts receivable or other assets in the ordinary course of business;
- (5) the sale or other disposition of cash or Cash Equivalents;
- (6) a Restricted Payment (or Payment that would constitute a Restricted Payment but for the exclusions from the definition thereof permitted by the covenant described above under the caption “—Certain Covenants—Restricted Payments”;
- (7) a sale or other disposition of accounts receivable and related assets in connection with a financing transaction involving such assets in connection with a securitization or similar financing);
- (8) any disposition of property in the ordinary course of business by LifePoint or any Restricted Subsidiary that, in the good faith judgment of LifePoint, has become obsolete, worn out, damaged or no longer useful in the conduct of the business of LifePoint or the Restricted Subsidiary;
- (9) any Asset Swap;
- (10) any sale of securities constituting Equity Interests that are issued by a subsidiary trust or other financing vehicle in a transaction described above under the caption “—Certain Covenants—Incurrence of Indebtedness and Issuance of Preferred Stock;”
- (11) the discount or forgiveness of accounts receivable in the ordinary course of business in connection with the collection or conversion of accounts receivable;
- (12) licenses and sublicenses by LifePoint or any of its Restricted Subsidiaries of software or intellectual property in the ordinary course of business with past practice;
- (13) a Sale and Leaseback Transaction, *provided* that at least 75% of the consideration paid to LifePoint or the Restricted Subsidiary in the Transaction consists of cash received at closing;
- (14) the sale, transfer or other disposition of Hedging Obligations incurred pursuant to the covenant described above under the caption “—Certain Covenants—Incurrence of Indebtedness and Issuance of Preferred Stock”;
- (15) the creation of any Permitted Lien and dispositions in connection with Permitted Liens;
- (16) dispositions of assets resulting from the assertion by federal, state or local governmental authorities (or similarly empowered agencies) of eminent domain, condemnation or expropriation or similar rights;
- (17) long-term leases of Hospitals to another Person; *provided* that the aggregate book value of all such properties subject to such leases does not exceed 10% of the Total Assets of LifePoint;
- (18) sales of assets received by LifePoint or any of its Restricted Subsidiaries upon the foreclosure on a Lien; and
- (19) the disposition of Receivables and Related Assets in a Qualified Securitization Transaction.

“Asset Sale Offer” has the meaning set forth in the covenant described above under the caption “—Repurchase at the Option of Holders”.

e424b3

e424b3

Table of Contents

“*Asset Swap*” means an exchange by LifePoint or any Restricted Subsidiary of property or assets for property or assets of another Person, where the applicable Restricted Subsidiary, as the case may be, receives consideration at the time of such exchange at least equal to the fair market value of the property sold, issued or otherwise disposed of (as evidenced by a resolution of LifePoint’s Board of Directors), and (ii) at least 75% of the net proceeds of such exchange constitutes assets or other property of a kind usable by LifePoint and its Restricted Subsidiaries in a Permitted Business; *provided*, however, that the Net Proceeds of such exchange shall constitute Net Proceeds of the Restricted Subsidiary. “Repurchase at the Option of Holders—Asset Sales.”

“*Attributable Debt*” means, in respect of a Sale and Leaseback Transaction, the present value, discounted at the interest rate implicit in the Transaction, of the total obligations of the lessee for rental payments during the remaining term of the lease in the Sale and Leaseback Transaction.

“*Beneficial Owner*” has the meaning assigned to such term in Rule 13d-3 and Rule 13d-5 under the Exchange Act, except that in calculating the percentage of ownership of any particular “person” (as that term is used in Section 13(d)(3) of the Exchange Act), such “person” will be deemed to have beneficial ownership of any securities if such “person” has the right to acquire by conversion or exercise of other securities, whether such right is currently exercisable or is exercisable only upon the occurrence of a subsequent condition. The terms “*Beneficially Owns*” and “*Beneficially Owned*” have a corresponding meaning.

“*Board of Directors*” means:

- (1) with respect to a corporation, the board of directors of the corporation (or any duly authorized committee thereof);
- (2) with respect to a partnership, the Board of Directors (or any duly authorized committee thereof) of the general partner of the partnership;
- (3) with respect to a limited liability company, the managing member or members or any controlling committee of managing members;
- (4) with respect to any other Person, the board or committee of such Person serving a similar function.

“*Capital Lease Obligation*” means, at the time any determination is to be made, the amount of the liability in respect of a capital lease obligation that is required to be capitalized on a balance sheet in accordance with GAAP.

“*Capital Stock*” means:

- (1) in the case of a corporation, corporate stock;
- (2) in the case of an association or business entity, any and all shares, interests, participations, rights or other equivalents (however denominated);
- (3) in the case of a partnership or limited liability company, partnership or membership interests (whether general or limited); and
- (4) any other interest or participation that confers on a Person the right to receive a share of the profits and losses of, or distributions from, the entity.

“*Cash Equivalents*” means:

- (1) United States dollars;
- (2) Securities constituting direct obligations of the United States or any agency or instrumentality of the United States, the payment of which is guaranteed by a full faith and credit obligation of the United States, maturing in three years or less from the date of acquisition thereof;

e424b3

Table of Contents

(3) securities constituting direct obligations of any State or municipality within the United States maturing in three years or less from the date of issuance which, in any such case, at the time of acquisition by LifePoint or any Restricted Subsidiary, is accorded one of the two highest long-term debt ratings by S&P or Moody's or any other United States nationally recognized credit rating agency of similar standing;

(4) certificates of deposit with a maturity of one year or less or bankers' acceptances issued by a bank or trust company having capital assets aggregating at least \$500 million and having a short-term unsecured debt rating of at least "P-1" by Moody's or "A-1" by S&P;

(5) eurodollar time deposits with maturities of one year or less and overnight bank deposits with any bank or trust company having capital assets aggregating at least \$500 million and having a short-term unsecured debt rating of at least "P-1" by Moody's or "A-1" by S&P;

(6) repurchase obligations with a term of not more than thirty days for underlying securities of the types described in clauses (2), (3), (4) and (5) with any financial institution meeting the qualifications specified in such clauses above;

(7) commercial paper maturing in 365 days or less from the date of issuance which, at the time of acquisition by LifePoint or any Restricted Subsidiary, is accorded one of the two highest long-term debt ratings by S&P or "P2" or better by Moody's or any other United States nationally recognized credit rating agency of similar standing;

(8) any fund or other pooling arrangement at least 95% of the assets of which constitute Investments described in clauses (1) through (7);

"Change of Control" means the occurrence of any of the following:

(1) the direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or more transactions, of substantially all of the properties or assets of LifePoint and its Restricted Subsidiaries taken as a whole to any "person" (as that term is defined in the Exchange Act);

(2) the adoption of a plan relating to the liquidation or dissolution of LifePoint;

(3) LifePoint becomes aware of (by way of a report or other filing pursuant to Section 13(d) of the Exchange Act, proxy, written consent or otherwise) the consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that any "person" becomes a Beneficial Owner, directly or indirectly, of more than 50% of the Voting Stock of LifePoint, measured by voting power rather than by number of shares;

(4) the first day on which a majority of the members of the Board of Directors of LifePoint are not Continuing Directors; or

(5) a change of control under our 3.25% Convertible Senior Subordinated Debentures due 2025 or our 3.5% Convertible Senior Subordinated Debentures due 2025.

"Code" means the Internal Revenue Code of 1986, as amended.

"Consolidated Assets" of any Person as of any date means the total assets of such Person and its Restricted Subsidiaries on a consolidated basis as determined in accordance with GAAP.

"Consolidated Cash Flow" means, with respect to any specified Person for any period, the Consolidated Net Income of such Person for such period.

(1) an amount equal to any extraordinary, unusual or non-recurring loss plus any net loss realized by such Person or any of its Restricted Subsidiaries with an Asset Sale (without regard to the dollar limitation in the definition thereof), to the extent such losses were deducted in computing such Person's Income; plus

e424b3

Table of Contents

(2) provision for taxes based on income or profits of such Person and its Restricted Subsidiaries for such period, to the extent that such taxes were deducted in computing such Consolidated Net Income; *plus*

(3) consolidated interest expense of such Person and its Restricted Subsidiaries for such period, whether paid or accrued and whether without limitation, amortization of debt issuance costs and original issue discount, non-cash interest payments, the interest component of obligations, the interest component of all payments associated with Capital Lease Obligations, commissions, discounts and other fees on letters of credit or bankers' acceptance financings, and net of the effect of all payments made or received pursuant to Hedging Obligations; expense was deducted in computing such Consolidated Net Income; *plus*

(4) depreciation, amortization (including amortization of goodwill and other intangibles but excluding amortization of prepaid cash expenses for such period) and other non-cash expenses (excluding any such non-cash expense to the extent that it represents an accrual of or reserve for or amortization of a prepaid cash expense that was paid in a prior period) of such Person and its Restricted Subsidiaries for such period; depreciation, amortization and other non-cash expenses were deducted in computing such Consolidated Net Income; *plus*

(5) severance payments related to management employment contracts, non-cash stock-based compensation expense, and net income of interests in LifePoint's non-wholly-owned Subsidiaries; *minus*

(6) any amortization of discounts of convertible debt instruments resulting from the application of APB 14-1 "Accounting for Convertible Securities"; *plus*

(7) non-cash items increasing such Consolidated Net Income for such period, other than the accrual of revenue in the ordinary course of operations; in each case, on a consolidated basis and determined in accordance with GAAP.

Notwithstanding the preceding, the provision for taxes based on the income or profits of, and the depreciation and amortization and depletion of, any Restricted Subsidiary will be added to Consolidated Net Income to compute Consolidated Cash Flow of LifePoint only to the extent that such taxes are permitted at the date of determination to be dividended to LifePoint by such Restricted Subsidiary without prior governmental approval pursuant to the terms of its charter and all agreements, instruments, judgments, decrees, orders, statutes, rules and governmental regulations applicable to such Subsidiary or its stockholders.

"Consolidated Net Income" means, with respect to any specified Person for any period, the aggregate of the Net Income of such Person and its Restricted Subsidiaries for such period, on a consolidated basis, determined in accordance with GAAP; *provided that*:

(1) the Net Income (but not loss) of any Person that is not a Restricted Subsidiary or that is accounted for by the equity method of accounting to the extent of the amount of dividends or distributions paid in cash to the specified Person or a Restricted Subsidiary of the Person;

(2) the Net Income of any Restricted Subsidiary will be excluded to the extent that the declaration or payment of dividends or other distributions of such Subsidiary of that Net Income is not at the date of determination permitted without any prior governmental approval (that has not been obtained indirectly, by operation of the terms of its charter or any agreement, instrument, judgment, decree, order, statute, rule or governmental regulation applicable to such Restricted Subsidiary or its stockholders;

(3) for purposes of the covenant described above under the caption "—Certain Covenants—Restricted Payments" covenant above, any Net Income acquired in a pooling of interests transaction for any period prior to the date of such acquisition will be excluded; and

e424b3

[Table of Contents](#)

(4) the cumulative effect of a change in accounting principles will be excluded.

“*Consolidated Secured Debt Ratio*” as of the date of any event for which a calculation is required (the “*date of determination*”) means the amount of all Indebtedness of LifePoint and its Restricted Subsidiaries that is secured by Liens as of the date of determination to (b) the LifePoint for the most recently ended four full fiscal quarters for which internal financial statements are available immediately preceding the date of determination, in the case with such *pro forma* adjustments as are appropriate and consistent with the *pro forma* adjustment provisions set forth in the definition of “*Leverage Ratio*”.

“*Consolidated Senior Leverage Ratio*” means, as of the date of any event for which a calculation is required (the “*date of determination*”) the amount of all Indebtedness (other than Subordinated Indebtedness) of LifePoint and its Restricted Subsidiaries and preferred stock of Restricted Subsidiaries and Guarantors as of the date of the determination to (y) the Consolidated Cash Flow of LifePoint for the most recently ended four full fiscal quarters for which financial statements are available immediately preceding the date of determination.

In addition, for purposes of calculating the Consolidated Senior Leverage Ratio, *pro forma* effect will be given to:

(1) acquisitions of any operations or businesses or assets (other than assets acquired in the ordinary course of business) that have occurred during the four quarter reference period or subsequent to such reference period and on or prior to the date of determination, as if they had occurred during the four quarter reference period; and

(2) the discontinuance of operations or businesses and dispositions of operations or businesses or assets (other than assets disposed of in the ordinary course of business) during the four quarter reference period or subsequent to such reference period and on or prior to the date of determination, as if they had occurred on the day of the four quarter reference period.

For purposes of this definition, whenever *pro forma* effect is to be given to a transaction, the *pro forma* calculations shall be determined by the chief financial or accounting officer of LifePoint.

“*Continuing Directors*” means, as of any date of determination, any member of the Board of Directors of LifePoint who:

(1) was a member of such Board of Directors immediately after the annual stockholders meeting of LifePoint following the Issuance of the Credit Agreement;

(2) was nominated for election or elected to such Board of Directors with the approval of a majority of the Continuing Directors at the time of such nomination or election.

“*Credit Agreement*” means the Credit Agreement, dated as of April 15, 2005, by and among LifePoint, as borrower, the lenders party thereto, as administrative agent, Bank of America, N.A., CIBC World Markets Corp., SunTrust Bank, UBS Securities LLC, as co-syndicator, and CIBC World Markets Inc. as sole lead arranger and sole bookrunner, including any related notes, guarantees, collateral documents, instruments and amendments therewith, and in each case as amended (including, without limitation, as to principal amount), modified, renewed, refunded, replaced or supplemented (whether or not with the original agents or lenders and whether or not contemplated under the original agreement relating thereto).

“*Credit Facilities*” means one or more debt facilities (including, without limitation, the Credit Agreement), note purchase agreements, revolving credit agreements, indentures, in each case with banks, institutional or other lenders or a trustee providing for revolving credit loans, term loans, receivable purchase agreements, sale of receivables to such lenders or to special purpose entities formed to borrow from such lenders against such receivables), letters of credit, and in each case, as amended (including, without limitation, as to principal amount), restated, modified, renewed, refunded, replaced or refinanced.

e424b3

[Table of Contents](#)

time (whether or not with the original agents or lenders or parties and whether or not contemplated under the original agreement relating to the Asset Sale).

“*Default*” means any event that is, or with the passage of time or the giving of notice or both would be, an Event of Default.

“*Designated Non-cash Consideration*” means any non-cash consideration received by LifePoint or one of its Restricted Subsidiaries that is designated as Designated Non-cash Consideration pursuant to an officers’ certificate executed by the principal financial officer or principal officers of LifePoint or such Restricted Subsidiary at the time of such Asset Sale. Any particular item of Designated Non-cash Consideration shall not be outstanding once it has been sold for cash or Cash Equivalents.

“*Disqualified Stock*” means any Capital Stock that, by its terms (or by the terms of any security into which it is convertible, or for which it is, at the option of the holder of the Capital Stock), or upon the happening of any event, matures or is mandatorily redeemable, pursuant to its terms or otherwise, or redeemable at the option of the holder of the Capital Stock, in whole or in part, on or prior to the date that is 91 days after the date of the Asset Sale. Notwithstanding the preceding sentence, any Capital Stock that would constitute Disqualified Stock solely because the holders of the Capital Stock have the right to cause LifePoint to repurchase such Capital Stock upon the occurrence of a change of control with respect to LifePoint or an asset sale by LifePoint will not constitute Disqualified Stock if the terms of such Capital Stock provide that LifePoint may not repurchase or redeem any such Capital Stock unless such repurchase or redemption complies with the covenant described above under the caption “—Certain Covenants—Repurchase or Redemption of Capital Stock.”

“*Domestic Subsidiary*” means any Restricted Subsidiary organized under the laws of the United States or any state of the United States.

“*Equity Interests*” means Capital Stock and all warrants, options or other rights to acquire Capital Stock (but excluding any debt securities that are exchangeable for, Capital Stock).

“*Equity Offering*” means any public or private sale by LifePoint for cash of its common stock or preferred stock (excluding Disqualified Stock).

“*Excess Proceeds*” has the meaning set forth in the covenant described above under the caption “—Repurchase at the Option of Holders of Capital Stock.”

“*Exchange Notes*” means the debt securities of LifePoint issued pursuant to the indenture in exchange for the notes in compliance with the terms of the Registration Rights Agreement.

“*Exchange Subsidiary Guarantees*” means the guarantees of the obligation of LifePoint under the indenture and the notes issued pursuant to the indenture for the Subsidiary Guarantees in compliance with the terms of the Registration Rights Agreement.

“*Excluded Subsidiaries*” means those Domestic Subsidiaries that are designated by LifePoint as Domestic Subsidiaries that will not be included in the consolidated financial statements of LifePoint and its Domestic Subsidiaries for any fiscal year if, as of the end of any fiscal quarter or account for more than 25% of the consolidated revenue of LifePoint and its Domestic Subsidiaries for any fiscal year period (in each case determined as of the most recent fiscal quarter for which LifePoint has internal financial statements available); provided, however, that any Domestic Subsidiary that guarantees any Indebtedness incurred pursuant to clause (1) of the second paragraph of the covenant described above under the caption “Incurrence of Indebtedness and Issuance of Preferred Stock” may not be designated as or continue to be an Excluded Subsidiary. In the event that any Domestic Subsidiary, individually or collectively, previously designated as Excluded Subsidiaries cease to meet the requirements of the previous sentence, LifePoint may, following such event, cause one or more of such Domestic Subsidiaries to become Guarantors so that the requirements of the previous sentence are satisfied.

e424b3

Table of Contents

“Existing Indebtedness” means Indebtedness of LifePoint and its Restricted Subsidiaries (other than Indebtedness under the Credit Agreement), until such amounts are repaid.

“Fixed Charges” means, with respect to any specified Person for any period, the sum, without duplication, of:

(1) the consolidated interest expense of such Person and its Restricted Subsidiaries for such period, whether paid or accrued, including amortization of debt issuance costs and original issue discount, non-cash interest payments, the interest component of any deferred payment component of all payments associated with Capital Lease Obligations, commissions, discounts and other fees and charges incurred in connection with bankers’ acceptance financings, and net of the effect of all payments made or received pursuant to Hedging Obligations; *plus*

(2) the consolidated interest of such Person and its Restricted Subsidiaries that was capitalized during such period; *plus*

(3) any interest expense on Indebtedness of another Person that is Guaranteed by such Person or one of its Restricted Subsidiaries, to the extent such Guarantee or Lien is called upon; *plus*

(4) the product of (a) all dividends, whether paid or accrued and whether or not in cash, on any series of preferred stock of such Person and its Restricted Subsidiaries, other than dividends on Equity Interests payable solely in Equity Interests of LifePoint (other than Disqualified Stock), times (b) a fraction, the numerator of which is one and the denominator of which is one minus the then current combined stock repurchase rate of such Person, expressed as a decimal, in each case, on a consolidated basis and in accordance with GAAP; *minus*

(5) any amortization of discounts of convertible debt instruments resulting from the application of APB 14-1 “Accounting for Convertible Securities”.

“Fixed Charge Coverage Ratio” means with respect to any specified Person for any period, the ratio of the Consolidated Cash Flow Available for Fixed Charges of such Person for such period. In the event that the specified Person or any of its Restricted Subsidiaries incurs, assumes, repurchases or redeems any Indebtedness (other than ordinary working capital borrowings) or issues, repurchases or redeems preferred stock subsequent to the end of the four quarter reference period for which the Fixed Charge Coverage Ratio is being calculated and on or prior to the date on which the event for which the calculation of the Fixed Charge Coverage Ratio is made (the “Calculation Date”), then the Fixed Charge Coverage Ratio will be calculated giving *pro forma* effect to such incurrence, repayment, repurchase or redemption of Indebtedness, or such issuance, repurchase or redemption of preferred stock, and the use of the rate of interest that had occurred at the beginning of the applicable four-quarter reference period.

In addition, for purposes of calculating the Fixed Charge Coverage Ratio, *pro forma* effect will be given to:

(1) acquisitions of any operations or businesses or assets (other than assets acquired in the ordinary course of business) that have occurred during the four quarter reference period or subsequent to such reference period and on or prior to the Calculation Date, as if they had occurred on the first day of the reference period; and

(2) the discontinuance of operations or businesses and dispositions of operations or businesses or assets (other than assets disposed of in the ordinary course of business) during the four quarter reference period or subsequent to such reference period and on or prior to the Calculation Date, as if they had occurred on the last day of the four quarter reference period.

If any Indebtedness bears a floating rate of interest and is being given *pro forma* effect, the interest on such Indebtedness shall be calculated as if the Calculation Date had been the applicable rate for the entire period. Interest on a Capital Lease Obligation shall be deemed to accrue at a rate determined by a responsible financial or accounting officer of LifePoint to be the rate of interest implicit in such

e424b3

Table of Contents

Capital Lease Obligation in accordance with GAAP. For purposes of making the computation referred to above, interest on any Indebtedness facility computed on a pro forma basis shall be computed based upon the average daily balance of such Indebtedness during the applicable period that may optionally be determined at an interest rate based upon a factor of a prime or similar rate, a eurocurrency interbank offered rate, or have been based upon the rate actually chosen, or, if none, then based upon such optional rate chosen as LifePoint may designate.

For purposes of this definition, whenever pro forma effect is to be given to an acquisition of assets, the amount of income or earnings before consolidated interest expense associated with any Indebtedness incurred in connection therewith, the pro forma calculations shall be determined by the responsible financial or accounting officer of LifePoint. In addition, any such pro forma calculation may include adjustments appropriate to LifePoint as set forth in an officers' certificate, to reflect operating expense reductions reasonably expected to result from any acquisition.

"GAAP" means generally accepted accounting principles in the United States as in effect as of the Issue Date, including those set forth in:

- (1) the Financial Accounting Standards Board's FASB Accounting Standards Codification; and
- (2) the rules and regulations of the SEC with respect to generally accepted accounting principles, including those governing the preparation of periodic reports required to be filed pursuant to Section 13 of the Exchange Act, including opinions and pronouncements in staff advisory opinions and statements from the accounting staff of the SEC.

"Government Securities" means securities that are:

- (1) direct obligations of the United States of America for the timely payment of which its full faith and credit is pledged; or
- (2) obligations of a Person controlled or supervised by and acting as an agency or instrumentality of the United States of America, which are unconditionally guaranteed as a full faith and credit obligation by the United States of America,

which, in either case, are not callable or redeemable at the option of the issuers thereof, and shall also include a depository receipt issued by a custodian (as defined in (a)(2) of the Securities Act), as custodian with respect to any such Government Securities or a specific payment of principal of or interest on Government Securities held by such custodian for the account of the holder of such depository receipt; provided that (except as required by law) such receipt shall not be subject to any deduction from the amount payable to the holder of such depository receipt from any amount received by the custodian in respect of such specific payment of principal of or interest on the Government Securities evidenced by such depository receipt.

"Guarantee" means a guarantee other than by endorsement of negotiable instruments for collection in the ordinary course of business, including, without limitation, by way of a pledge of assets or through letters of credit or reimbursement agreements in respect thereof, or

"Guarantors" means each of:

- (1) the Domestic Subsidiaries of LifePoint as of the Issue Date other than Excluded Subsidiaries; and
- (2) any other Subsidiary that executes a Subsidiary Guarantee in accordance with the provisions of the indenture, and their respective Guarantors, provided that upon the release and discharge of any Person from its Subsidiary Guarantee in accordance with the indenture, such Person shall not be a Guarantor.

"Hedging Obligations" means, with respect to any specified Person, the obligations of such Person under:

- (1) interest rate swap agreements, interest rate cap agreements and interest rate collar agreements; and

e424b3

Table of Contents

(2) other agreements or arrangements designed to protect such Person against fluctuations in interest rates or foreign exchange rates;

“Hospital” means a hospital, outpatient clinic, outpatient surgical center, long-term care facility, diagnostic facility, medical office building or other facility that is used or useful in or related to the provision of healthcare services.

“Indebtedness” means, with respect to any specified Person, any indebtedness of such Person, whether or not contingent:

- (1) in respect of borrowed money;
- (2) evidenced by bonds, notes, debentures or similar instruments or letters of credit (or reimbursement agreements in respect thereof);
- (3) in respect of banker’s acceptances;
- (4) representing Capital Lease Obligations of such Person and Attributable Debt in respect of Sale and Leaseback Transactions;
- (5) representing the balance deferred and unpaid of the purchase price of any property; or
- (6) representing any Hedging Obligations,

if and to the extent any of the preceding items (other than letters of credit and Hedging Obligations) would appear as a liability upon a balance sheet prepared in accordance with GAAP. In addition, the term “Indebtedness” includes all Indebtedness of others secured by a Lien on any property, whether or not such Indebtedness is assumed by the specified Person) and, to the extent not otherwise included, the Guarantee by the specified Person or other Person, in each case limited to the maximum amount of liability of the specified Person with respect to such Lien or Guarantee or the amount of such other Person’s liability. Notwithstanding anything in the foregoing to the contrary, Indebtedness shall not include trade payables or accrued expenses for proper and in the ordinary course of business, any liability for federal, state, local or other taxes or any settlements or judgments relating to governmental actions. The amount of any Indebtedness issued with original issue discount will be the accreted value of such Indebtedness.

“Insurance Subsidiary” means a Subsidiary of LifePoint or any Restricted Subsidiary established for the purpose of insuring the business of LifePoint operated by LifePoint or any of its Subsidiaries or any joint venture to which they are party or any Person employed by or on the staff of LifePoint.

“Investment Grade” means (1) with respect to S&P, any of the rating categories from and including AAA to and including BBB- and (2) with respect to the rating categories from and including Aaa to and including Baa3.

“Investments” means, with respect to any Person, all direct or indirect investments by such Person in other Persons (including Affiliates, Guarantees or other obligations), advances or capital contributions (excluding commission, travel and similar advances to directors, officers or employees in the ordinary course of business), purchases or other acquisitions for consideration of Indebtedness, Equity Interests or other securities, together with any such investments, advances or capital contributions, purchases or other acquisitions, that would be classified as investments on a balance sheet prepared in accordance with GAAP. If LifePoint or any Restricted Subsidiary sells or disposes of Equity Interests of any direct or indirect Restricted Subsidiary such that, after giving effect to any such sale or disposition, such Person is no longer a Restricted Subsidiary, LifePoint will be deemed to have made an Investment on the date of any such sale or disposition equal to the fair market value of the Equity Interests of such Restricted Subsidiary not sold or disposed of in an amount determined as provided in the final paragraph of the covenant described above under the heading “Restricted Payments”; provided that LifePoint shall not have been deemed to have made an Investment pursuant to the foregoing if LifePoint or any Restricted Subsidiary concurrently therewith been deemed to have made an Investment in connection with such Equity Interests. The acquisition by LifePoint of Equity Interests in a Person that holds an Investment in a third Person will be deemed to be an Investment by LifePoint.

e424b3

Table of Contents

LifePoint or such Restricted Subsidiary in such third Person in an amount equal to the fair market value of the Investment held by the a in an amount determined as provided in the final paragraph of the covenant described above under the caption “—Certain Covenants— LifePoint or such Restricted Subsidiary shall not have been deemed to have made an Investment pursuant to the foregoing if LifePoint have previously or concurrently therewith been deemed to have made an Investment in connection with such acquisition. “Investments” credit.

“*Issue Date*” means the original issue date for the first issuance of notes offered hereby under the indenture.

“*Lien*” means, with respect to any asset, any mortgage, lien, pledge, charge, security interest or encumbrance of any kind in respect recorded or otherwise perfected under applicable law, including any conditional sale or other title retention agreement, any lease in the agreement to sell or give a security interest in and any filing of or agreement to give any financing statement under the Uniform Comm of any jurisdiction.

“*Limited Originator Recourse*” means a reimbursement obligation of LifePoint in connection with a drawing on a letter of credit, revolving collateral account or other such credit enhancement issued to support Indebtedness of a Securitization Subsidiary that LifePoint’s board committee thereof) determines is necessary to effectuate a Qualified Securitization Transaction; *provided* that the available amount of a at any time shall not exceed 10% of the principal amount of such Indebtedness at such time; and *provided, further*, that such reimbursement incurred by LifePoint pursuant to the covenant described above under the caption “—Certain Covenants—Incurrence of Indebtedness a

“*Net Income*” means, with respect to any specified Person, the net income (loss) of such Person, determined in accordance with GA of respect of preferred stock dividends, excluding, however:

(1) any gain or loss, together with any related provision for taxes on such gain or loss, realized in connection with: (a) any Asset limitation in the definition thereof); (b) the disposition of any securities by such Person or any of its Restricted Subsidiaries or the ex such Person or any of its Restricted Subsidiaries; or (c) any acquisition, recapitalization or Permitted Investment of such Person or a

(2) any extraordinary, unusual or non-recurring gain, charge, expense or loss (together with any related provision for taxes on su recurring gain, charge, expense or loss), including, without limitation, (a) restructuring charges, reserves or other related expenses, (to facility shutdowns and discontinued operations, (c) acquisition integration costs, (d) severance or other employee termination or r (e) non-cash compensation charges recorded from grants of stock options, restricted stock, stock appreciation rights and other equity and employees and (f) litigation and investigation settlement costs and related expenses; and

(3) the net income (or loss) from disposed or discontinued operations for the four fiscal quarters preceding the date of determinin

“*Net Proceeds*” means the aggregate cash proceeds and Cash Equivalents received by LifePoint or its Restricted Subsidiaries in resp without limitation, any cash received upon the sale or other disposition of any non-cash consideration received in any Asset Sale), net o Asset Sale, including, without limitation, legal, accounting and investment banking fees, sales commissions, any relocation expenses in any taxes paid or payable as a result of the Asset Sale, in each case, after taking into account any available tax credits or deductions and amounts required to be applied to the repayment of Indebtedness, all distributions and other payments required to be made to non-major joint ventures as a result of such Asset Sale and appropriate amounts to be provided by LifePoint or any Restricted Subsidiary, as the ca accordance with GAAP against any liabilities associated with such Asset Sale and retained by LifePoint or any Restricted Subsidiary, a Sale, including, without limitation, pension and other post-employment benefit

e424b3

Table of Contents

liabilities, liabilities related to environmental matters and liabilities under any indemnification obligations associated with such Asset Sale.

“*Obligations*” means any principal, interest, penalties, fees, indemnifications, reimbursements, damages and other liabilities payable by or for LifePoint or any Restricted Subsidiary in connection with any Indebtedness.

“*Permitted Business*” means the business or businesses conducted by LifePoint and its Restricted Subsidiaries, or any of them, as of the date of the offering, and any ancillary or complementary thereto.

“*Permitted Debt*” has the meaning set forth in the covenant described above under the caption “—Certain Covenants—Incurrence of Indebtedness—Preferred Stock”.

“*Permitted Investments*” means:

- (1) any Investment in LifePoint or in a Restricted Subsidiary;
- (2) any Investment in Cash Equivalents;
- (3) any Investment by LifePoint or any Restricted Subsidiary in a Person, if as a result of such Investment:
 - (a) such Person becomes a Restricted Subsidiary; or
 - (b) such Person is merged, consolidated or amalgamated with or into, or transfers or conveys substantially all of its assets to, a Restricted Subsidiary;
- (4) any Investment made as a result of the receipt of non-cash consideration from an Asset Sale (including any Asset Swap) that complies with the covenant described above under the caption “—Repurchase at the Option of Holders—Asset Sales”;
- (5) any Investment received to the extent the consideration therefor was the issuance of Equity Interests (other than Disqualified Equity Interests);
- (6) Hedging Obligations;
- (7) intercompany Indebtedness to the extent permitted under the covenant described above under the caption the “—Certain Covenants—Incurrence of Indebtedness—Preferred Stock”;
- (8) Investments in prepaid expenses, negotiable instruments held for collection and lease, utility and workers’ compensation, performance bonuses, and other items made in the ordinary course of business and Investments to secure participation in government reimbursement programs;
- (9) loans and advances to officers, directors and employees made in the ordinary course of business;
- (10) Investments represented by accounts and notes receivable created or acquired in the ordinary course of business;
- (11) Investments existing on the Issue Date and any renewal or replacement thereof on terms and conditions not materially less favorable than the original terms and conditions, or replaced;
- (12) Investments by any qualified or nonqualified benefit plan established by LifePoint or its Restricted Subsidiaries made in accordance with the terms of the plan or any Investments made by LifePoint or any Restricted Subsidiary in connection with the funding thereof;
- (13) Investments received in settlement of debts or judgments owed to LifePoint or any Restricted Subsidiary, including, without limitation, Investments received in the perfection or enforcement of any Lien or indebtedness or in connection with any bankruptcy, liquidation, receivership or insolvency proceeding.

e424b3

e424b3

Table of Contents

(14) Investments in any Subsidiary that constitutes a special purpose entity formed for the primary purpose of issuing trust preferred securities in a transaction permitted by the covenant described above under the caption “—Certain Covenants—Incurrence of Indebtedness and Issuance of Preferred Stock”;

(15) Investments deemed to have been made as a result of the acquisition of a Person permitted under clause (3) of this definition of “Investment” if the fair market value of such Investments does not exceed 25% of the fair market value of the total consideration paid to acquire such Person;

(16) Investments by LifePoint or a Restricted Subsidiary in a Securitization Subsidiary in connection with a Qualified Securitization of Receivables that consists of a retained interest in transferred Receivables and Related Assets;

(17) Investments made within 90 days after the date of the commitment to make the Investment, that when such commitment was made, were within the terms of the indenture;

(18) Guarantees issued in accordance with the covenant described above under the caption “—Certain Covenants—Incurrence of Indebtedness and Issuance of Preferred Stock”;

(19) payroll, travel and similar advances to cover matters that are expected at the time of such advances ultimately to be treated as expenses of the business and that are made in the ordinary course of business;

(20) Investments in a Permitted Joint Venture, together with all other Investments made by LifePoint or any Restricted Subsidiary, to have an aggregate amount at the time of such Investment not to exceed \$35 million outstanding at any one time;

(21) Investments in any Insurance Subsidiary in an amount which does not at the time made exceed 125% of the minimum amount of capital required by the laws of the jurisdiction in which the Insurance Subsidiary is formed (other than any excess capital that would result in any unfavorable tax consequences to be distributed), in any self-insurance trust in an amount not to exceed 125% of the aggregate amount of the risk retained by the Insurance Subsidiaries on an annual basis and any Investment by such Insurance Subsidiary or self-insurance trust which is a legal investment under the laws of the jurisdiction in which the Insurance Subsidiary is formed or for a self-insurance trust under the applicable laws;

(22) Investments consisting of Physician Support Obligations made by LifePoint or any Restricted Subsidiary; and

(23) other Investments in any Person having an aggregate fair market value (measured on the date each such Investment was made, without regard to subsequent changes in value), when taken together with all other outstanding Investments made pursuant to this clause (23), not to exceed 5% of Total Assets in the aggregate at any one time outstanding.

“*Permitted Joint Venture*” means, with respect to any Person, (1) any corporation, association, or other business entity (other than a partnership) in which the total voting power of shares of Capital Stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors thereof is at the time of determination owned or controlled, directly or indirectly, by such Person or one or more of the Restricted Subsidiaries or a combination thereof and (2) any partnership, joint venture, limited liability company or similar entity of which 50% or less of the capital, equity and voting interests or general or limited partnership interests, as applicable, are owned or controlled, directly or indirectly, by such Person or other Restricted Subsidiaries of that Person or a combination thereof whether in the form of membership, general, special or limited partnership;

“*Permitted Liens*” means:

(1) Liens in favor of LifePoint or its Restricted Subsidiaries;

e424b3

Table of Contents

(2) Liens on property of a Person existing at the time such Person is merged with or into or consolidated with LifePoint or any Restricted Subsidiary, *provided* that such Liens were in existence prior to the contemplation of such merger or consolidation and do not extend to any assets other than those consolidated with LifePoint or the Restricted Subsidiary;

(3) Liens on property existing at the time of acquisition of the property by LifePoint or any Restricted Subsidiary, *provided* that such Liens were in existence prior to the contemplation of such acquisition;

(4) Liens to secure Indebtedness (including, without limitation, Capital Lease Obligations) permitted by clause (4) of the second set of covenants above under the caption “—Certain Covenants—Incurrence of Indebtedness and Issuance of Preferred Stock” covering only the assets of LifePoint;

(5) Liens existing on the Issue Date;

(6) Liens for taxes, assessments or governmental charges or claims that are not yet delinquent or that are being contested in good faith and promptly instituted and diligently concluded, *provided* that any reserve or other appropriate provision as is required in conformity with applicable law;

(7) Liens securing any Hedging Obligations of LifePoint or any Restricted Subsidiary;

(8) Liens securing any Indebtedness otherwise permitted to be incurred under the indenture, the proceeds of which are used to refinance any Restricted Subsidiary, *provided* that such Liens extend to or cover only the assets secured by the Indebtedness being refinanced;

(9) Liens on property of a Person existing at the time such Person becomes a Restricted Subsidiary, *provided* that such Liens were in existence prior to the contemplation of, such Person becoming a Restricted Subsidiary;

(10) statutory Liens and other Liens imposed by law incurred in the ordinary course of business for sums not yet delinquent or being contested in good faith; LifePoint or any applicable Restricted Subsidiaries shall have made any reserves or other appropriate provision required by GAAP;

(11) Liens incurred or deposits made in the ordinary course of business in connection with workers’ compensation, unemployment insurance, security, or to secure the performance of tenders, statutory obligations, surety and appeal bonds, bids, leases, government contracts, bonds, participation in government reimbursement programs and other similar obligations;

(12) judgment Liens not giving rise to an Event of Default, so long as any appropriate legal proceedings which may have been due to such judgment shall not have been finally terminated or the period within which such proceedings may be initiated shall not have expired;

(13) easements, rights-of-way, zoning restrictions and other similar charges or encumbrances in respect of real property not interfering with the conduct of the business of LifePoint or any of its Restricted Subsidiaries;

(14) any interest or title of a lessor in assets or property subject to Capital Lease Obligations or an operating lease of LifePoint or any Restricted Subsidiary;

(15) Liens incurred in connection with a financing involving the sale or other disposition of accounts receivable and related assets in connection with a securitization or similar financing;

(16) leases or subleases granted to others not interfering with the ordinary conduct of the business of LifePoint or any of the Restricted Subsidiaries;

e424b3

Table of Contents

(17) bankers' liens with respect to the right of set-off arising in the ordinary course of business against amounts maintained in bank accounts in the name of LifePoint or any Restricted Subsidiary;

(18) the interest of any issuer of a letter of credit in any cash or Cash Equivalents deposited with or for the benefit of such issuer, *provided* that the Indebtedness so collateralized is permitted to be incurred by the terms of the indenture;

(19) any Lien consisting of a right of first refusal or option to purchase an ownership interest in any Restricted Subsidiary or to purchase an ownership interest in any Restricted Subsidiary, which right of first refusal or option is entered into in the ordinary course of business or is otherwise permitted by the terms of the indenture;

(20) any Lien granted to the trustee pursuant to the terms of the indenture and any substantially equivalent Lien granted to the trustee for other debt securities of LifePoint;

(21) statutory, contractual or common law Liens of landlords and mortgagees of landlords and Liens of carriers, warehousemen, repairmen or workmen in the ordinary course of business;

(22) licenses and sublicenses of intellectual property granted to third parties in the ordinary course of business;

(23) Liens upon specific items of inventory or other goods and proceeds of any Person securing such Person's Obligations in respect of such inventory or other goods, or created for the account of such Person to facilitate the purchase, shipment or storage of such inventory or other goods;

(24) Liens securing Indebtedness of any Restricted Subsidiary (other than a Guarantor) that was permitted by the terms of this indenture, which Liens encumber only assets of such Restricted Subsidiary;

(25) Liens securing Indebtedness incurred pursuant to clause (1) or (22) of the second paragraph of the covenant described above under the caption "Covenants—Incurrence of Indebtedness and Issuance of Preferred Stock";

(26) Liens securing any Indebtedness incurred pursuant to the first paragraph of the covenant described above under the caption "Covenants—Incurrence of Indebtedness and Issuance of Preferred Stock" so long as, after giving effect to such incurrence, the Consolidated Secured Debt Ratio is not less than 1 as of the date on which such Lien is incurred;

(27) Liens with respect to obligations that do not at any one time outstanding exceed the greater of \$200 million and 5% of Total Assets;

(28) Liens on assets transferred to a Securitization Subsidiary or on assets of a Securitization Subsidiary, in either case, incurred in connection with a Securitization Transaction.

"Permitted Refinancing Indebtedness" means any Indebtedness of LifePoint or any Restricted Subsidiary issued in exchange for, or in connection with, the extension, amendment, renewal, replacement, defeasance or refund of other Indebtedness of LifePoint or any of its Restricted Subsidiaries (other than interest on such Indebtedness) that:

(1) the principal amount of such Permitted Refinancing Indebtedness does not exceed the principal amount of the Indebtedness being replaced, defeased or refunded (plus all accrued interest on the Indebtedness and the amount of all fees, expenses and premiums incurred in connection with the refinancing, replacement, defeasance or refunding);

(2) such Permitted Refinancing Indebtedness has a final maturity date not earlier than the final maturity date of, and has a Weighted Average Life to Maturity of, the Indebtedness being extended, refinanced, renewed, replaced, defeased or refunded, notwithstanding the foregoing, in the case of a refinancing, replacement, defeasance or refunding of the 3.25%

e424b3

Table of Contents

Convertible Senior Subordinated Debentures due 2025, such Permitted Refinancing Indebtedness may have a final maturity date and Maturity of no earlier than one year after the final maturity date and Weighted Average Life to Maturity of the notes;

(3) if the Indebtedness being extended, refinanced, renewed, replaced, defeased or refunded is subordinated in right of payment to the notes on terms not materially less favorable to the Holders of the notes than the terms of the Subordinated Debentures due 2025 and the 3.5% Convertible Senior Subordinated Notes due 2014, as may be permitted under the caption “—Certain Covenants—Limitation on Restricted Payments”; and

(4) if the Indebtedness being extended, refinanced, renewed, replaced, defeased or refunded was incurred by LifePoint or a Guarantor, the Refinancing Indebtedness may not be a Restricted Subsidiary that is not a Guarantor.

“*Person*” means any individual, corporation, partnership, joint venture, association, joint-stock company, trust, unincorporated organization, government or other entity.

“*Physician Support Obligation*” means:

(1) a loan to or on behalf of, or a Guarantee of Indebtedness of or income of, (x) a physician or healthcare professional providing services in the service area of a Hospital operated by LifePoint or any of its Restricted Subsidiaries or (y) any independent practice association or other entity that is majority owned by any Person or group of Persons described in clause (x), in either case made or given by LifePoint or any Restricted Subsidiary of LifePoint;

(a) in the ordinary course of its business; and

(b) pursuant to a written agreement having a period not to exceed five years; or

(2) Guarantees by LifePoint or any Restricted Subsidiary of leases and loans to acquire property (real or personal) for or on behalf of a physician or healthcare professional or any independent practice association or other entity that is majority owned by any Person or group of Persons described in clause (1), in either case made or given by LifePoint or any Restricted Subsidiary of LifePoint, for the service to patients in the service area of a Hospital operated by LifePoint or any of its Restricted Subsidiaries.

“*Principal Property*” means each Hospital (excluding personal property, office fixtures and equipment (including data processing equipment, used on, or useful with, vehicles)) owned solely by LifePoint and/or one or more of its Subsidiaries and located in the United States of America, as determined by the Directors of LifePoint determines that any such hospital is not material to LifePoint and its Subsidiaries taken as a whole.

“*Qualified Securitization Transaction*” means any transaction or series of transactions that may be entered into by LifePoint or any Restricted Subsidiary of LifePoint, in which (a) LifePoint or any Restricted Subsidiary may sell, convey or otherwise transfer to a Securitization Subsidiary its interests in Receivables and Related Assets, (b) such Securitization Subsidiary transfers to any other person, or grants a security interest in, such Receivables and Related Assets, pursuant to a transaction customarily used to achieve a transfer of financial assets under GAAP.

“*Receivables and Related Assets*” means any account receivable (whether now existing or arising thereafter) of LifePoint or any Restricted Subsidiary of LifePoint, and all related thereto including all collateral securing such accounts receivable, all contracts and contract rights and all Guarantees or other obligations in connection with asset securitization transaction involving accounts receivable.

e424b3

Table of Contents

“*Registration Rights Agreement*” means the Registration Rights Agreement to be dated September 23, 2010, among LifePoint, the GBC, and Barclays Capital Inc., as representative of the several initial purchasers.

“*Replacement Assets*” mean properties or assets substantially similar to the assets disposed of in a particular Asset Sale and acquired by LifePoint that were the subject of such Asset Sale or that are otherwise useful in a Permitted Business.

“*Restricted Investment*” means an Investment other than a Permitted Investment.

“*Restricted Subsidiary*” means any direct or indirect Subsidiary of LifePoint other than an Unrestricted Subsidiary.

“*Sale and Leaseback Transaction*” means, with respect to any Person, an arrangement whereby such Person enters into a lease of property with such Person to the lessor in contemplation of such leasing.

“*Securitization Subsidiary*” means a Subsidiary of LifePoint:

(1) that is designated a “*Securitization Subsidiary*” by the board of directors of LifePoint (or a duly authorized committee thereof);

(2) that does not engage in any activities other than Qualified Securitization Transactions and any activity necessary or incidental to such activities;

(3) no portion of the Indebtedness or any other obligation, contingent or otherwise, of which

(A) is Guaranteed by LifePoint or any Restricted Subsidiary in any way other than pursuant to Standard Securitization Undertakings or Limited Originator Recourse,

(B) is recourse to or obligates LifePoint or any other Restricted Subsidiary in any way other than pursuant to Standard Securitization Undertakings or Limited Originator Recourse, or

(C) subjects any property or asset of LifePoint or any other Restricted Subsidiary, directly or indirectly, contingently or otherwise, to any obligation other than pursuant to Standard Securitization Undertakings or Limited Originator Recourse;

(4) with respect to which neither LifePoint nor any other Restricted Subsidiary has any obligation to maintain or preserve its financial condition at certain levels of operating results; and

(5) with which neither LifePoint nor any Restricted Subsidiary has any material contract, agreement, arrangement or understanding that is more favorable to LifePoint or such Restricted Subsidiary than those that might be obtained at the time from persons that are not Affiliates of LifePoint. Securitization Undertakings and fees payable in the ordinary course of business in connection with servicing accounts receivable of LifePoint.

Any designation of a Subsidiary as a Securitization Subsidiary shall be evidenced to the trustee by filing with the trustee a certified copy of the resolution of the board of directors of LifePoint giving effect to the designation and an officers’ certificate certifying that the designation complied with the preceding paragraph.

“*Significant Subsidiary*” means any Subsidiary that would be a “*significant subsidiary*” as defined in Article 1, Rule 1-02 of Regulation S-X under the Securities Act, as such Regulation is in effect on the date hereof.

“*Standard Securitization Undertakings*” means representations, warranties, covenants and indemnities entered into by LifePoint or any Restricted Subsidiary in accounts receivable securitization transactions, as the case may be.

e424b3

Table of Contents

“*Stated Maturity*” means, with respect to any installment of interest or principal on any series of Indebtedness, the date on which the scheduled to be paid in the original documentation governing such Indebtedness, and will not include any contingent obligations to repay interest or principal prior to the date originally scheduled for the payment thereof.

“*Subordinated Indebtedness*” means any Indebtedness of LifePoint or any Guarantor which is subordinated in right of payment to the as applicable, pursuant to a written agreement to that effect.

“*Subsidiary*” means, with respect to any specified Person, (a) any corporation more than 50% of the outstanding securities having or at the time be owned or controlled, directly or indirectly, by such Person or by one or more of its Restricted Subsidiaries or by such Person Subsidiaries, or (b) any partnership, limited liability company, association, joint venture or similar business organization more than 50% ordinary voting power of which shall at the time be so owned or controlled.

“*Subsidiary Guarantee*” means a guarantee of notes pursuant to the indenture.

“*Total Assets*” means, as of any date of determination, the total assets of LifePoint and its Restricted Subsidiaries as shown on the balance sheet completed quarter for which internal financial statements are available determined in accordance with GAAP.

“*Treasury Rate*” means, as of the date the redemption notice is given to holders of the notes, the yield to maturity as of such date (as most recent Federal Reserve Statistical Release H. 15(519), which has become publicly available at least two business days prior to the date which such computation is being made (or if such Statistical Release is no longer published, as reported in any publicly available source) on United States Treasury securities with a constant maturity most nearly equal to the period from the relevant redemption date to October 1, 2013, equal to the constant maturity of the United States Treasury security for which a weekly average yield is given, the Treasury Rate shall be (calculated to the nearest one-twelfth of a year) from the weekly average yields of United States Treasury securities for which such yield is given; if the period is less than one year, the weekly average yield on actually traded United States Treasury securities adjusted to a constant maturity.

“*Unrestricted Subsidiary*” means any Subsidiary of LifePoint that is designated by the Board of Directors of LifePoint as an Unrestricted Subsidiary in a Resolution, but only to the extent that such Subsidiary:

(1) has no Indebtedness other than Indebtedness that is without recourse to LifePoint or its Restricted Subsidiaries;

(2) is not party to any agreement, contract, arrangement or understanding with LifePoint or any Restricted Subsidiary unless the terms of the contract, arrangement or understanding are not materially less favorable to LifePoint or such Restricted Subsidiary than those that would be available to Persons who are not Affiliates of LifePoint;

(3) is a Person with respect to which neither LifePoint nor any of its Restricted Subsidiaries has any (a) continuing direct or indirect ownership interest or additional Equity Interests or (b) direct or indirect obligation to maintain or preserve such Person’s financial condition or to cause such Person to maintain levels of operating results; and

(4) has not guaranteed or otherwise directly or indirectly provided credit support for any Indebtedness of LifePoint or any of its Restricted Subsidiaries.

In addition, any Subsidiary that constitutes a special purpose entity formed for the primary purpose of financing receivables or for the issuance of preferred or similar securities in connection with a transaction permitted by the covenant described above under the caption “—Certain Indebtedness and Issuance of Preferred Stock” shall be, and any Insurance Subsidiary may be, an Unrestricted Subsidiary.

e424b3

[Table of Contents](#)

Any designation of a Subsidiary of LifePoint as an Unrestricted Subsidiary after the Issue Date will be evidenced to the trustee by filing of the resolution of the Board of Directors of LifePoint giving effect to such designation and an officers' certificate certifying that such preceding conditions and was permitted by the covenant described above under the caption "—Certain Covenants—Restricted Payment." If a Subsidiary would fail to meet the preceding requirements as an Unrestricted Subsidiary, it will thereafter cease to be an Unrestricted Subsidiary and any Indebtedness of such Subsidiary will be deemed to be incurred by a Restricted Subsidiary of LifePoint as of such date as permitted to be incurred as of such date under the covenant described above under the caption "—Certain Covenants—Incurrence of Indebtedness." LifePoint will be in default of such covenant. The Board of Directors of LifePoint may at any time designate any Unrestricted Subsidiary; *provided* that such designation will be deemed to be an incurrence of Indebtedness by a Restricted Subsidiary of any outstanding Unrestricted Subsidiary and such designation will only be permitted if (1) such Indebtedness is permitted under the covenant described above under the caption "—Certain Covenants—Incurrence of Indebtedness and Issuance of Preferred Stock," calculated on a *pro forma* basis as if such designation had occurred as of the quarter reference period; and (2) no Default or Event of Default would be in existence following such designation.

"*Voting Stock*" of any Person as of any date means the Capital Stock of such Person that is at the time entitled to vote in the election of the Person.

"*Weighted Average Life to Maturity*" means, when applied to any Indebtedness at any date, the number of years obtained by dividing:

- (1) the sum of the products obtained by multiplying (a) the amount of each then remaining installment, sinking fund, serial maturity payment, or principal, including payment at final maturity, in respect of the Indebtedness, by (b) the number of years (calculated to the nearest whole number) from such date and the making of such payment; by
- (2) the then outstanding principal amount of such Indebtedness.

e424b3

[Table of Contents](#)

BOOK-ENTRY SETTLEMENT AND CLEARANCE

The Global Notes

The outstanding notes were initially issued in the form of several registered notes in global form, without interest coupons, as follows:

- notes sold to qualified institutional buyers under Rule 144A were represented by the Rule 144A global note; and
- notes sold in offshore transactions to non-U.S. persons in reliance on Regulation S were represented by the Regulation S global note.

Upon issuance, each of the outstanding notes were, and each of the exchange notes will be, deposited with the Trustee as custodian (“DTC”) and registered in the name of Cede & Co., as nominee of DTC.

Ownership of beneficial interests in each note was, and will be, limited to persons who have accounts with DTC (“DTC participants”) and interests through DTC participants. We expect that under procedures established by DTC:

- upon deposit of each global note with DTC’s custodian, DTC will credit portions of the principal amount of the global note to the accounts of DTC participants and
- ownership of beneficial interests in each global note will be shown on, and transfer of ownership of those interests will be effected through, the records of DTC (with respect to interests of DTC participants) and the records of DTC participants (with respect to other owners of beneficial interests in the global notes).

Beneficial interests in the global notes may not be exchanged for notes in physical, certificated form except in the limited circumstances set forth in the indenture.

Exchanges Among the Global Notes

After consummation of the exchange offer, beneficial interests in one old note may generally be exchanged for interests in another old note or a new note may generally be exchanged for interest in another new note. Depending on which global note the transfer is being made, the Trustee will provide certain written certifications in the form provided in the indenture.

A beneficial interest in a global note that is transferred to a person who takes delivery through another global note will, upon transfer, be subject to the restrictions and other procedures applicable to beneficial interests in the other global note.

Book-Entry Procedures for the Global Notes

All interests in the global notes will be subject to the operations and procedures of DTC. We provide the following summaries of the operations and procedures of DTC for the convenience of investors. The operations and procedures of DTC are controlled by DTC and may be changed at any time. Neither we nor the Trustee are responsible for those operations or procedures.

DTC has advised us that it is:

- a limited purpose trust company organized under the laws of the State of New York;
- a “banking organization” within the meaning of the New York State Banking Law;
- a member of the Federal Reserve System;

e424b3

e424b3

Table of Contents

- a “clearing corporation” within the meaning of the Uniform Commercial Code; and
- a “clearing agency” registered under Section 17A of the Securities Exchange Act of 1934.

DTC was created to hold securities for its participants and to facilitate the clearance and settlement of securities transactions between participants and to facilitate book-entry changes to the accounts of its participants. DTC’s participants include securities brokers and dealers, including the initial participants, clearing corporations and other organizations. Indirect access to DTC’s system is also available to others such as banks, brokers, dealers and other participants who clear through or maintain a custodial relationship with a DTC participant, either directly or indirectly. Investors who are not participants in DTC own securities held by or on behalf of DTC only through DTC participants or indirect participants in DTC.

So long as DTC’s nominee is the registered owner of a global note, that nominee will be considered the sole owner or holder of the global note for all purposes under the indenture. Except as provided below, owners of beneficial interests in a global note:

- will not be entitled to have notes represented by the global note registered in their names;
- will not receive or be entitled to receive physical, certificated notes; and
- will not be considered the owners or holders of the notes under the indenture for any purpose, including with respect to the giving of consent or approval to the Trustee under the indenture.

As a result, each investor who owns a beneficial interest in a global note must rely on the procedures of DTC to exercise any rights or remedies under the indenture (and, if the investor is not a participant or an indirect participant in DTC, on the procedures of the DTC participant through which the investor owns its interest).

Payments of principal, premium (if any) and interest with respect to the notes represented by a global note will be made by the Trustee, as the registered holder of the global note. Neither we nor the Trustee will have any responsibility or liability for the payment of amounts to or for the payment of amounts by the global note, for any aspect of the records relating to or payments made on account of those interests by DTC, or for maintaining, supervising or controlling DTC relating to those interests.

Payments by participants and indirect participants in DTC to the owners of beneficial interests in a global note will be governed by standard industry practice and will be the responsibility of those participants or indirect participants and DTC.

Transfers between participants in DTC will be effected under DTC’s procedures and will be settled in same-day funds. If the laws of a jurisdiction require persons to take physical delivery of securities in definitive form, the ability to transfer beneficial interests in a global note to such persons will be limited. Only persons who act on behalf of participants, who in turn act on behalf of indirect participants and certain banks, the ability of a person holding a beneficial interest to pledge its interest to a person or entity that does not participate in the DTC system, or otherwise take actions in respect of its interest, may be limited by physical security.

DTC has agreed to the above procedures to facilitate transfers of interests in the global notes among participants in DTC. However, DTC may discontinue or change these procedures at any time. Neither we nor the Trustee will have any responsibility for the actions of participants or indirect participants of their obligations under the rules and procedures governing its operations.

Certificated Notes

Notes in physical, certificated form will be issued and delivered to each person that DTC identifies as a beneficial owner of the related global note.

- DTC notifies us at any time that it is unwilling or unable to continue as depository for the global notes and a successor depository has not been identified.

e424b3

e424b3

[Table of Contents](#)

- DTC ceases to be registered as a clearing agency under the Securities Exchange Act of 1934 and a successor depositary is not appointed;
- we, at our option, notify the Trustee that we elect to cause the issuance of certificated notes; or
- certain other events provided in the indenture should occur.

e424b3

[Table of Contents](#)

CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS

The following is a general discussion of certain U.S. federal income tax consequences to U.S. holders and non-U.S. holders (each, a “holder”) of the exchange notes acquired pursuant to the Exchange Offer. This discussion is limited to U.S. holders and non-U.S. holders of exchange notes as capital assets (generally, property held for investment).

This discussion does not address all aspects of U.S. federal income tax that may be important to beneficial owners in light of their particular circumstances. This discussion also does not address the federal income tax consequences to beneficial owners subject to special treatment under U.S. federal tax law, including, without limitation, estates, trusts, banks, insurance companies, mutual funds, tax-exempt organizations, retirement plans, expatriates, partnerships or other pass-through entities, or persons holding the exchange notes as part of a “straddle,” “hedge,” “conversion transaction,” “synthetic security” or other transaction. It also does not address the federal income tax consequences to U.S. holders (as defined below) whose “functional currency” is not the U.S. dollar, and persons subject to the alternative minimum tax. In addition, this discussion does not address any tax considerations arising under other U.S. federal tax laws (such as estate or gift tax laws), or state, local or non-U.S. tax laws.

If an entity treated as a partnership for U.S. federal income tax purposes is the beneficial owner of an exchange note, the tax treatment of the exchange note generally depends upon the status of the partner and the activities of the partnership. A beneficial owner of exchange notes that is a partner in a partnership for U.S. federal income tax purposes and partners in such a partnership are not included in the discussions pertaining to U.S. holders and non-U.S. holders, below, and should consult their tax advisors about the U.S. federal income and other tax consequences of acquiring, owning and disposing of the exchange notes.

The following discussion is based on the Internal Revenue Code of 1986, as amended (the “Code”), Treasury regulations promulgated under the Code (“Regulations”) and administrative and judicial interpretations, all as in effect as of the date hereof, and all of which are subject to change. There can be no assurance that the IRS could not reach conclusions different from those set forth below.

This summary of certain U.S. federal income tax considerations is not intended to be, and should not be construed to be, legal advice. It is not a guarantee of the U.S. federal income tax consequences of the Exchange Offer, and it does not constitute an offer of securities. Potential investors should consult their own tax advisors as to the U.S. federal income, estate and gift tax consequences of the Exchange Offer, as well as the consequences of the Exchange Offer under the laws of any state, local, non-U.S. or other taxing jurisdiction or any applicable tax treaties, and the possible effect of the Exchange Offer on the holder's tax basis in the exchange notes.

The Exchange Offer

The exchange of outstanding notes for exchange notes pursuant to the Exchange Offer will not constitute a taxable event for U.S. federal income tax purposes. The result is:

- a holder will not recognize taxable gain or loss as a result of the exchange of its outstanding notes for exchange notes pursuant to the Exchange Offer;
- the holding period of the exchange notes will include the holding period of the outstanding notes surrendered in exchange therefor;
- a holder's adjusted tax basis in the exchange notes will be the same as the holder's adjusted tax basis in the outstanding notes surrendered in exchange therefor.

Effect of Certain Additional Payments

In certain circumstances (see “Description of the Exchange Notes—Optional Redemption” and “Description of the Exchange Notes—Change of Control”), we may be obligated to pay amounts on the exchange notes that are in excess of stated interest or principal.

e424b3

e424b3

[Table of Contents](#)

potential payments may implicate the provisions of the Treasury Regulations relating to “contingent payment debt instruments” (the “CPDI Regulations”). The CPDI Regulations provide that contingencies will not cause the exchange notes to be treated as contingent payment debt instruments if, as of the issue date, each such contingency is not more likely than not to occur. If, incidental or, in certain circumstances, it is significantly more likely that none of the contingencies will occur. We believe that the potential for such contingencies occurring on exchange notes should not cause the exchange notes to be treated as contingent payment debt instruments under the CPDI Regulations. However, the Internal Revenue Service (“IRS”) has taken a different position, which could require a holder to accrue income on its exchange notes in excess of stated interest and any other payments (“OID”), and to treat any income realized on the taxable disposition of an exchange note as ordinary income rather than capital gain. This discussion assumes that the exchange notes will not be treated as contingent payment debt instruments. Investors should consult their own tax advisors regarding the possible application of the contingent payment debt instrument rules to the exchange notes.

Tax Consequences to U.S. Holders

As used in this discussion, the term “U.S. holder” means a beneficial owner of the exchange notes that is, for U.S. federal income tax purposes,

- an individual who is a citizen or resident of the United States;
- a corporation created or organized in or under the laws of the United States, any state thereof or the District of Columbia;
- an estate the income of which is subject to U.S. federal income tax regardless of its source; or
- a trust if (1) a court within the United States is able to exercise primary supervision over the administration of the trust and the trust has a valid election under Treasury regulations to be treated as a domestic trust.

Interest on the Exchange Notes

We expect, and this discussion assumes, that the exchange notes will not be issued with more than a *de minimis* amount of OID, if any. If the exchange notes will generally be taxable to a U.S. holder as ordinary interest income at the time it accrues or is received in accordance with the accounting for U.S. federal income tax purposes.

If, contrary to such expectations, the exchange notes are issued with more than a *de minimis* amount of OID, a U.S. holder generally will include in gross income (as ordinary income) as it accrues in accordance with the constant yield method, in advance of the receipt of cash attributable to the U.S. holder’s method of tax accounting).

The rules regarding OID are complex and the rules above may not apply in all cases. Accordingly, U.S. holders should consult their own tax advisors regarding the application.

Sale or Other Taxable Disposition of the Exchange Notes

Upon the sale or other taxable disposition of an exchange note (including a retirement or a redemption), a U.S. holder generally will recognize capital gain or loss equal to the difference between the amount realized on such disposition and the holder’s adjusted tax basis in the exchange note. For these purposes, the adjusted tax basis will include any amount attributable to accrued but unpaid stated interest, which is treated as ordinary income to the extent not previously included in gross income. The adjusted tax basis in an exchange note will generally be the holder’s cost for the exchange note, increased by OID, if any, such holder has accrued on the exchange note.

Gain or loss realized on the sale or other taxable disposition of an exchange note will generally be capital gain or loss and will be long-term capital gain or loss if the exchange note has been held for more than one year at the time of such disposition.

e424b3

e424b3

[Table of Contents](#)

for more than one year. Long-term capital gains of non-corporate taxpayers are generally eligible for reduced rates of taxation. The deduction is subject to certain limitations.

Backup Withholding and Information Reporting

Information returns will be filed with the IRS in connection with interest payments on the exchange notes, accruals of OID (if any), and taxable disposition (including a retirement or redemption) of the exchange notes, unless the U.S. holder is an exempt recipient such as a foreign government. U.S. holders will be subject to backup withholding on these amounts at the applicable rate if the U.S. holder fails to provide its taxpayer identification number with certain certification procedures or otherwise establish an exemption from backup withholding. Backup withholding is not an additional tax. Backup withholding will be allowed as a credit against the holder's U.S. federal income tax liability and may entitle the holder to a refund if the information is timely furnished to the IRS.

Medicare Tax

For taxable years beginning after December 31, 2012, a U.S. holder that is an individual or estate, or a trust that does not fall into a special category, from such tax, will be subject to a 3.8% tax on the lesser of (1) the U.S. holder's "net investment income" (in the case of individuals) or "net taxable income" (in the case of estates and trusts) for the relevant taxable year and (2) the excess of the U.S. holder's "modified adjusted gross income" or "adjusted gross income" (in the case of estates and trusts) for the taxable year over a certain threshold (which in the case of individuals is \$250,000, depending on the individual's circumstances). A U.S. holder's net investment income generally will include its interest income and net gains from the disposition of the exchange notes, unless such interest income or net gains are derived in the ordinary course of the conduct of a trade or business that consists of certain passive or trading activities). U.S. holders that are individuals, estates or trusts should consult their tax advisor regarding the applicability of the Medicare tax to their income and gains in respect of the exchange notes.

Tax Consequences to Non-U.S. Holders

As used herein, the term "non-U.S. holder" means a beneficial owner of the exchange notes that is, for U.S. federal income tax purposes,

- an individual nonresident alien;
- a foreign corporation; or
- a foreign estate or trust.

Interest on the Exchange Notes

Subject to the discussion of backup withholding below, payments of interest (which, for purposes of this discussion of non-U.S. holders, includes payments on exchange notes to a non-U.S. holder will generally not be subject to the U.S. federal income tax or withholding tax under the "portfolio interest" rules if:

- (1) the non-U.S. holder does not actually or constructively own 10% or more of the total combined voting power of all classes of the issuer's equity;
- (2) the non-U.S. holder is not a controlled foreign corporation that is related to us, actually or by attribution;
- (3) the non-U.S. holder is not a bank receiving the interest pursuant to a loan agreement entered into in the ordinary course of its business;
- (4) such payments are not "effectively connected" with a trade or business of the non-U.S. holder conducted in the United States.

e424b3

e424b3

[Table of Contents](#)

(5) either:

(a) the non-U.S. holder certifies under penalties of perjury on IRS Form W-8 BEN or a suitable substitute form that it is not a U.S. person for purposes of the Code, and provides its name and address, and taxpayer identification number, if any; or

(b) a securities clearing organization, bank or other financial institution that holds customers' securities in the ordinary course of business, or the exchange notes certifies under penalties of perjury that such statement has been received from the non-U.S. holder and furnishes

Interest that does not qualify for the portfolio interest rule and that is not effectively connected income will generally be subject to withholding tax unless a non-U.S. holder is entitled to a reduced rate of withholding tax or an exemption from U.S. withholding tax under an applicable tax treaty. The non-U.S. holder must properly executed IRS Form W-8BEN or a suitable substitute form, certifying its entitlement to such reduction or exemption.

If the interest accrued on an exchange note is "effectively connected" with a trade or business of a non-U.S. holder conducted in the United States, the non-U.S. holder can obtain an exemption from withholding tax by providing a properly completed IRS Form W-8ECI or a suitable substitute form prior to the payment of interest on an exchange note exempt from the withholding tax as effectively connected income nevertheless may be subject to net income tax in the same manner as those of a U.S. holder. In addition, if such non-U.S. holder is a foreign corporation, it may be subject to a branch profits tax (or a similar tax under a tax treaty rate) of its earnings and profits for the taxable year, subject to adjustments, that are effectively connected with its conduct of a trade or business in the United States.

Sale or Other Taxable Disposition of the Exchange Notes

Except as described below under "Backup Withholding and Information Reporting," a non-U.S. holder generally will not be subject to U.S. withholding tax with respect to gain realized on a sale or other taxable disposition of an exchange note (including a retirement or redemption of an exchange note). If, however, the non-U.S. holder is an individual, the non-U.S. holder is present in the United States for 183 days or more in the taxable year of the disposition and certain other conditions are met, such recognized gain (net of certain U.S. source losses) would be subject to United States federal income tax at a 30% rate (or lower applicable rate if the non-U.S. holder is "effectively connected" with a trade or business of the non-U.S. holder conducted in the United States (and, if certain treaties apply, in the United States through an establishment maintained by the non-U.S. holder). Effectively connected gain will generally be subject to net income tax as if the non-U.S. holder were a U.S. person. In addition, if such non-U.S. holder is a foreign corporation, it may be subject to the branch profits tax described above).

Backup Withholding and Information Reporting

We must report annually to the IRS and to each non-U.S. holder the amount of interest paid to that holder and the tax, if any, withheld. Backup withholding and information reporting requirements apply regardless of whether withholding was reduced or eliminated by an applicable tax treaty. Copies of the information required to be reported on payments and withholding may also be made available to the tax authorities in the country in which the non-U.S. holder is a resident under an applicable income tax treaty or agreement.

Backup withholding and additional information reporting will generally not apply to payments of interest on the exchange notes made to a non-U.S. holder if the certification described in clause (5) under "Interest on the Exchange Notes" above is received.

Backup withholding and information reporting generally will not apply to payments of proceeds from the sale or other taxable disposition (including a redemption) of an exchange note made to a non-U.S. holder by or through the foreign office of a broker. However, information reporting will apply if the broker is, for U.S. federal income tax purposes, a U.S. person or has certain other enumerated connections with the United States, unless the broker has evidence in its records that the holder is a non-U.S. person and certain other conditions are met, or the holder otherwise establishes an exemption from the sale or

e424b3

e424b3

[Table of Contents](#)

other taxable disposition of an exchange note made to a non-U.S. holder by or through the United States office of a broker are subject to withholding at the applicable rate unless the holder certifies, under penalty of perjury, that it is a non-U.S. person and that it satisfies certain requirements that establishes an exemption. Backup withholding is not an additional tax and a non-U.S. holder may obtain a refund or a credit against such income tax liability of any amounts withheld under the backup withholding rules, provided the required information is furnished to the

Non-U.S. holders should consult their own tax advisors regarding the application of information reporting and backup withholding rules and the availability of an exemption therefrom and the procedure for obtaining such an exemption, if available.

Recently Enacted Legislation

Recently enacted legislation regarding foreign account tax compliance, effective for payments made after December 31, 2012, imposes interest and gross proceeds from the disposition of certain debt instruments paid to certain foreign entities unless various information requirements are satisfied. However, the withholding tax will not be imposed on payments pursuant to obligations outstanding as of March 31, 2012. Account information with respect to U.S. holders who hold the exchange notes through certain foreign financial institutions may be reported. Consult with their own tax advisors regarding the possible implications of this recently enacted legislation to them.

The preceding discussion is for general information purposes only and is not tax advice. Each potential investor should consult with their own tax advisors regarding the particular tax consequences with respect to the acquisition, ownership and disposition of the exchange notes acquired in the Exchange. The discussion does not address the applicability and effect of other federal or state, local and foreign tax laws, and the possible effects of changes in tax laws.

e424b3

[Table of Contents](#)

PLAN OF DISTRIBUTION

Each broker-dealer that receives exchange notes for its own account pursuant to an exchange offer must acknowledge that (i) it has no understanding with the Company or an affiliate of the Company to distribute such exchange notes and (ii) it will deliver a prospectus in connection with the exchange notes. This prospectus, as it may be amended or supplemented from time to time, may be used by a broker-dealer in connection with the exchange notes received in exchange for outstanding notes where such outstanding notes were acquired as a result of market-making activities or other transactions. That, for a period of 90 days after the consummation of the exchange offers, we will make this prospectus, as amended or supplemented, available for use in connection with any such resale. In addition, all dealers effecting transactions in the exchange notes may be required to deliver a prospectus.

We will not receive any proceeds from any sale of exchange notes by broker-dealers. Exchange notes received by broker-dealers for their own account pursuant to an exchange offer may be sold from time to time in one or more transactions in the over-the-counter market, in negotiated transactions, through the exchange notes or a combination of such methods of resale, at market prices prevailing at the time of resale, at prices related to such prices or at negotiated prices. Any such resale may be made directly to purchasers or through brokers or dealers who may receive compensation in the form of commissions or concessions from any such broker-dealer and/or the purchasers of any such exchange notes. Any broker-dealer that resells exchange notes for its own account pursuant to an exchange offer and any broker or dealer that participates in a distribution of such exchange notes may be deemed to be an underwriter within the meaning of the Securities Act, and any profit of any such resale of exchange notes and any commission or concessions received by such broker-dealer or broker or dealer may be deemed to be underwriting compensation under the Securities Act. The letter of transmittal states that, by acknowledging that it will deliver and by delivering this prospectus, the broker-dealer will not be deemed to admit that it is an “underwriter” within the meaning of the Securities Act.

For a period of 90 days after the consummation of the exchange offers, we will promptly send additional copies of this prospectus and the letter of transmittal to this prospectus to any broker-dealer that requests such documents in the letter of transmittal. We have agreed to pay all expenses incurred by the holders of the exchange notes (including the expenses of one counsel for the holders of the outstanding notes) other than commissions or concessions of any broker-dealer or broker or dealer (including any broker-dealers) against certain liabilities, including liabilities under the Securities Act.

e424b3

[Table of Contents](#)

LEGAL MATTERS

The validity of the notes offered hereby will be passed upon for us by Dewey & LeBoeuf LLP, New York, New York.

EXPERTS

The consolidated financial statements of LifePoint Hospitals, Inc. appearing in LifePoint Hospitals, Inc.'s Annual Report (Form 10-K) for the year ended December 31, 2010, and the effectiveness of LifePoint Hospitals, Inc.'s internal control over financial reporting as of December 31, 2010 have been audited by an independent registered public accounting firm, as set forth in their reports thereon, included therein, and incorporated herein by reference to such reports. The consolidated financial statements and LifePoint Hospitals, Inc.'s management's assessment of the effectiveness of internal control over financial reporting as of December 31, 2010 are incorporated herein by reference in reliance upon such reports given on the authority of such firm as experts in accounting and auditing.

WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE

We file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any report or other information that we file at the SEC's public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information about the public reference rooms. Our SEC filings are also available to the public from commercial document retrieval services and at the Internet website <http://www.sec.gov>.

This prospectus incorporates by reference the documents set forth below that LifePoint has previously filed with the SEC. These documents provide important information about LifePoint. The information incorporated by reference is deemed to be part of this prospectus, except for any information that is not incorporated by reference in this prospectus.

- Annual Report on Form 10-K for the fiscal year ended December 31, 2010;
- Quarterly Report on Form 10-Q for the three months ended March 31, 2011; and
- Current Report on Form 8-K dated January 26, 2011.

We are also incorporating by reference additional documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, from the date of this prospectus and termination or completion of this exchange offer (excluding any information furnished pursuant to Items 2.02 or 7.01 of Form S-4 (17 CFR 230.202 and 230.701)).

You can obtain any of the documents incorporated by reference through us or the SEC. Documents incorporated by reference are available to you without charge, excluding all exhibits unless we have specifically incorporated by reference an exhibit in this prospectus. You may obtain documents incorporated by reference in this prospectus by requesting them in writing or by telephone from:

LifePoint Hospitals, Inc.
Attention: Investor Relations
103 Powell Court
Brentwood, Tennessee 37027
Telephone: (615) 372-8532

You can also get more information by visiting our investor relations website at <http://www.lifepointhospitals.com>. Information contained on our website accessed through our website is not incorporated by reference in this prospectus and does not constitute a part of this prospectus and you should not rely on it.

e424b3

information.

e424b3

[Table of Contents](#)

\$400,000,000



Offer to Exchange Registered 6.625% Senior Notes due 2020 for all of our Outstanding Unregistered 6.625% Senior Notes due 2020

Prospectus

June 1, 2011
